



Clinical trial results:

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies (FIGHT-101)

Summary

| | |
|--------------------------|------------------|
| EudraCT number | 2016-002831-14 |
| Trial protocol | DK |
| Global end of trial date | 17 December 2021 |

Results information

| | |
|--------------------------------|--|
| Result version number | v2 (current) |
| This version publication date | 26 January 2023 |
| First version publication date | 15 December 2022 |
| Version creation reason | <ul style="list-style-type: none">• Correction of full data set Revisions made to align with changes made to ClinicalTrials.gov results summary. |

Trial information

Trial identification

| | |
|-----------------------|----------------|
| Sponsor protocol code | INCB 54828-101 |
|-----------------------|----------------|

Additional study identifiers

| | |
|------------------------------------|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | Incyte Corporation |
| Sponsor organisation address | 1801 Augustine Cutoff Drive, Wilmington, United States, 19803 |
| Public contact | Study Director, Incyte Corporation, 1 8554633463, medinfo@incyte.com |
| Scientific contact | Study Director, Incyte Corporation, 1 8554633463, medinfo@incyte.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 17 December 2021 |
| Is this the analysis of the primary completion data? | No |
| Global end of trial reached? | Yes |
| Global end of trial date | 17 December 2021 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

The purpose of this study was to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in participants with advanced malignancies. This study was conducted in three parts: dose escalation (Part 1), dose expansion (Part 2), and combination therapy (Part 3).

Protection of trial subjects:

This study was to be performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and conducted in adherence to the study Protocol, Good Clinical Practices as defined in Title 21 of the United States Code of Federal Regulations Parts 50, 54 56, 312, and Part 11 as well as International Council for Harmonisation Good Clinical Practice (ICH GCP) consolidated guidelines (E6) and applicable regulatory requirements.

Background therapy: -

Evidence for comparator: -

| | |
|---|------------------|
| Actual start date of recruitment | 27 February 2015 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | United States: 199 |
| Country: Number of subjects enrolled | Denmark: 2 |
| Worldwide total number of subjects | 201 |
| EEA total number of subjects | 2 |

Notes:

Subjects enrolled per age group

| | |
|---|-----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 127 |
| From 65 to 84 years | 73 |

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

This study was conducted at 15 sites: 14 in the United States; 1 in Denmark. The study was conducted in 3 parts. Participants self-administered once daily doses of pemigatinib on a 2-weeks-on/1-week-off therapy (intermittent) or continuous schedule. Participants also self-administered twice daily doses of pemigatinib on a continuous schedule.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Non-randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|-----|
| Are arms mutually exclusive? | Yes |
|------------------------------|-----|

| | |
|------------------|--|
| Arm title | Part 1: Intermittent pemigatinib 1/2/4 mg QD |
|------------------|--|

Arm description:

Participants self-administered oral pemigatinib 1/2/4 milligrams (mg) once daily (QD) on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.

| | |
|--|--------------|
| Arm type | Experimental |
| Investigational medicinal product name | pemigatinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

QD or BID intermittent or continuous dosing

| | |
|------------------|--|
| Arm title | Part 1: Intermittent pemigatinib 6 mg QD |
|------------------|--|

Arm description:

Participants self-administered oral pemigatinib 6 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.

| | |
|--|--------------|
| Arm type | Experimental |
| Investigational medicinal product name | pemigatinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

QD or BID intermittent or continuous dosing

| | |
|------------------|--|
| Arm title | Part 1: Intermittent pemigatinib 9 mg QD |
|------------------|--|

Arm description:

Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.

| | |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

| | |
|---|---|
| Investigational medicinal product name | pemigatinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| QD or BID intermittent or continuous dosing | |
| Arm title | Part 1: Intermittent pemigatinib 13.5 mg QD |
| Arm description: | |
| Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. | |
| Arm type | Experimental |
| Investigational medicinal product name | pemigatinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| QD or BID intermittent or continuous dosing | |
| Arm title | Part 1: Intermittent pemigatinib 20 mg QD |
| Arm description: | |
| Participants self-administered oral pemigatinib 20 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. | |
| Arm type | Experimental |
| Investigational medicinal product name | pemigatinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| QD or BID intermittent or continuous dosing | |
| Arm title | Part 1: Continuous pemigatinib 9 mg QD |
| Arm description: | |
| Participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle. | |
| Arm type | Experimental |
| Investigational medicinal product name | pemigatinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| QD or BID intermittent or continuous dosing | |
| Arm title | Part 1: Continuous pemigatinib 13.5 mg QD |
| Arm description: | |
| Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle. | |
| Arm type | Experimental |

| | |
|--|---|
| Investigational medicinal product name | pemigatinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: QD or BID intermittent or continuous dosing | |
| Arm title | Part 1: Continuous pemigatinib 20 mg QD |
| Arm description: Participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle. | |
| Arm type | Experimental |
| Investigational medicinal product name | pemigatinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: QD or BID intermittent or continuous dosing | |
| Arm title | Part 1: Continuous pemigatinib 7.5 mg BID |
| Arm description: Participants self-administered oral pemigatinib 7.5 mg twice daily (BID) on Days 1 through 21 of each 21-day cycle. | |
| Arm type | Experimental |
| Investigational medicinal product name | pemigatinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: QD or BID intermittent or continuous dosing | |
| Arm title | Part 1: Continuous pemigatinib 10 mg BID |
| Arm description: Participants self-administered oral pemigatinib 10 mg BID on Days 1 through 21 of each 21-day cycle. | |
| Arm type | Experimental |
| Investigational medicinal product name | pemigatinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: QD or BID intermittent or continuous dosing | |
| Arm title | Part 2: Intermittent pemigatinib 9 mg QD |
| Arm description: Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. | |
| Arm type | Experimental |

| | |
|---|---|
| Investigational medicinal product name | pemigatinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| QD or BID intermittent or continuous dosing | |
| Arm title | Part 2: Intermittent pemigatinib 13.5 mg QD |
| Arm description: | |
| Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. | |
| Arm type | Experimental |
| Investigational medicinal product name | pemigatinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| QD or BID intermittent or continuous dosing | |
| Arm title | Part 2: Continuous pemigatinib 9 mg QD |
| Arm description: | |
| Participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle. | |
| Arm type | Experimental |
| Investigational medicinal product name | pemigatinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| QD or BID intermittent or continuous dosing | |
| Arm title | Part 2: Continuous pemigatinib 13.5 mg QD |
| Arm description: | |
| Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle. | |
| Arm type | Experimental |
| Investigational medicinal product name | pemigatinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| QD or BID intermittent or continuous dosing | |
| Arm title | Part 2: Continuous pemigatinib 20 mg QD |
| Arm description: | |
| Participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle. | |
| Arm type | Experimental |
| Investigational medicinal product name | pemigatinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:
QD or BID intermittent or continuous dosing

| | |
|------------------|---|
| Arm title | Part 3: Gem/Cis/intermittent pemigatinib 9 mg |
|------------------|---|

Arm description:

Participants received gemcitabine (Gem) intravenously starting at 1000 mg/meters squared (m^2) on Days 1 and 8 of each 21-day cycle. Cisplatin (Cis) was administered intravenously starting at 70 mg/ m^2 once every 3 weeks on Day 1 of each 21-day cycle. Both gemcitabine and cisplatin doses could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued chemotherapy with medical monitor approval. Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of gemcitabine/cisplatin.

| | |
|--|----------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | gemcitabine |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Powder for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

1000 mg/ m^2 on Days 1 and 8 of each 21-day cycle

| | |
|--|----------------------------------|
| Investigational medicinal product name | cisplatin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Powder for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

70 mg/ m^2 once every 3 weeks on Day 1 of each 21-day cycle

| | |
|--|-------------|
| Investigational medicinal product name | pemigatinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

QD or BID intermittent or continuous dosing

| | |
|------------------|--|
| Arm title | Part 3: Gem/Cis/intermittent pemigatinib 13.5 mg |
|------------------|--|

Arm description:

Participants received gemcitabine intravenously starting at 1000 mg/ m^2 on Days 1 and 8 of each 21-day cycle. Cisplatin was administered intravenously starting at 70 mg/ m^2 once every 3 weeks on Day 1 of each 21-day cycle. Both gemcitabine and cisplatin doses could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued chemotherapy with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of gemcitabine/cisplatin.

| | |
|--|----------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | gemcitabine |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Powder for solution for infusion |
| Routes of administration | Intravenous use |

| | |
|--|--|
| Dosage and administration details: | |
| 1000 mg/m ² on Days 1 and 8 of each 21-day cycle | |
| Investigational medicinal product name | cisplatin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Powder for solution for infusion |
| Routes of administration | Intravenous use |
| Dosage and administration details: | |
| 70 mg/m ² once every 3 weeks on Day 1 of each 21-day cycle | |
| Investigational medicinal product name | pemigatinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| QD or BID intermittent or continuous dosing | |
| Arm title | Part 3: Tras/intermittent pemigatinib 13.5 mg |
| Arm description: | |
| <p>Trastuzumab (Tras) was administered as an open-label, commercial product at an initial intravenous dose of 8 mg/kilograms (kg), followed by 6 mg/kg intravenously once every 3 weeks. The dose could have been adjusted for toxicity management, per commercial labeling. The investigator could have interrupted, modified, or discontinued trastuzumab with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of trastuzumab.</p> | |
| Arm type | Experimental |
| Investigational medicinal product name | pemigatinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| QD or BID intermittent or continuous dosing | |
| Investigational medicinal product name | trastuzumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Powder for concentrate for solution for infusion |
| Routes of administration | Intravenous use |
| Dosage and administration details: | |
| 8 mg/kg initial dose followed by 6 mg/kg Q3W | |
| Arm title | Part 3: Doc/intermittent pemigatinib 13.5 mg |
| Arm description: | |
| <p>Participants received docetaxel (Doc) intravenously starting at 75 mg/m² once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued chemotherapy with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of docetaxel.</p> | |
| Arm type | Experimental |

| | |
|--|-------------|
| Investigational medicinal product name | pemigatinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

QD or BID intermittent or continuous dosing

| | |
|--|-----------------------|
| Investigational medicinal product name | docetaxel |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

75 mg/m² Q3W

| | |
|------------------|---|
| Arm title | Part 3: Pem/intermittent pemigatinib 9 mg |
|------------------|---|

Arm description:

Participants received pembrolizumab (Pem) intravenously at 200 mg once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued pembrolizumab with medical monitor approval. Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of pembrolizumab.

| | |
|--|--------------|
| Arm type | Experimental |
| Investigational medicinal product name | pemigatinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

QD or BID intermittent or continuous dosing

| | |
|--|--|
| Investigational medicinal product name | pembrolizumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Powder for concentrate for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

200 mg Q3W

| | |
|------------------|--|
| Arm title | Part 3: Pem/intermittent pemigatinib 13.5 mg |
|------------------|--|

Arm description:

Participants received pembrolizumab intravenously at 200 mg once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued pembrolizumab with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of pembrolizumab.

| | |
|--|--|
| Arm type | Experimental |
| Investigational medicinal product name | pembrolizumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Powder for concentrate for solution for infusion |
| Routes of administration | Intravenous use |

| | |
|---|--|
| Dosage and administration details: | |
| 200 mg Q3W | |
| Investigational medicinal product name | pemigatinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| QD or BID intermittent or continuous dosing | |
| Arm title | Part 3: Pem/continuous pemigatinib 13.5 mg |
| Arm description: | |
| Participants received pembrolizumab intravenously at 200 mg once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued pembrolizumab with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle. It was permissible to continue pemigatinib administration during the toxicity break of pembrolizumab. | |
| Arm type | Experimental |
| Investigational medicinal product name | pemigatinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| QD or BID intermittent or continuous dosing | |
| Investigational medicinal product name | pembrolizumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Powder for concentrate for solution for infusion |
| Routes of administration | Intravenous use |
| Dosage and administration details: | |
| 200 mg Q3W | |
| Arm title | Part 3: Ref/continuous pemigatinib 9 mg |
| Arm description: | |
| Retifanlimab (Ref) was administered once every 4 weeks on a 28-day cycle as an open-label product, at an initial intravenous dose of 500 mg. Participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle. | |
| Arm type | Experimental |
| Investigational medicinal product name | pemigatinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| QD or BID intermittent or continuous dosing | |
| Investigational medicinal product name | retifanlimab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |
| Dosage and administration details: | |
| 500 mg Q4W on a 28-day cycle | |
| Arm title | Part 3: Ref/continuous pemigatinib 13.5 mg |

Arm description:

Retifanlimab was administered once every 4 weeks on a 28-day cycle as an open-label product, at an initial intravenous dose of 500 mg. Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle.

| | |
|--|--------------|
| Arm type | Experimental |
| Investigational medicinal product name | pemigatinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

QD or BID intermittent or continuous dosing

| | |
|--|-----------------------|
| Investigational medicinal product name | retifanlimab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

500 mg Q4W on a 28-day cycle

| | |
|------------------|--|
| Arm title | Part 3: Ref/continuous pemigatinib 20 mg |
|------------------|--|

Arm description:

Retifanlimab was administered once every 4 weeks on a 28-day cycle as an open-label product, at an initial intravenous dose of 500 mg. Participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle.

| | |
|--|--------------|
| Arm type | Experimental |
| Investigational medicinal product name | pemigatinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

QD or BID intermittent or continuous dosing

| | |
|--|-----------------------|
| Investigational medicinal product name | retifanlimab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

500 mg Q4W on a 28-day cycle

| Number of subjects in period 1 | Part 1: Intermittent pemigatinib 1/2/4 mg QD | Part 1: Intermittent pemigatinib 6 mg QD | Part 1: Intermittent pemigatinib 9 mg QD |
|---|--|--|--|
| Started | 3 | 4 | 3 |
| Completed | 0 | 0 | 0 |
| Not completed | 3 | 4 | 3 |
| Adverse event, serious fatal | 2 | 2 | 3 |
| Placed on Hospice; Declined Further Follow-up | - | - | - |
| Consent withdrawn by subject | - | 1 | - |

| | | | |
|---|---|---|---|
| Clinical Decline; Withdrew by Physician | - | - | - |
| Adverse event, non-fatal | - | - | - |
| Rolled Over to Another Protocol | - | - | - |
| Study Terminated by Sponsor | - | - | - |
| Lost to follow-up | 1 | - | - |
| Disease Progression | - | 1 | - |

| Number of subjects in period 1 | Part 1: Intermittent pemigatinib 13.5 mg QD | Part 1: Intermittent pemigatinib 20 mg QD | Part 1: Continuous pemigatinib 9 mg QD |
|---|---|---|--|
| Started | 6 | 6 | 9 |
| Completed | 0 | 0 | 0 |
| Not completed | 6 | 6 | 9 |
| Adverse event, serious fatal | 6 | 6 | 6 |
| Placed on Hospice; Declined Further Follow-up | - | - | - |
| Consent withdrawn by subject | - | - | 1 |
| Clinical Decline; Withdrew by Physician | - | - | - |
| Adverse event, non-fatal | - | - | - |
| Rolled Over to Another Protocol | - | - | - |
| Study Terminated by Sponsor | - | - | 2 |
| Lost to follow-up | - | - | - |
| Disease Progression | - | - | - |

| Number of subjects in period 1 | Part 1: Continuous pemigatinib 13.5 mg QD | Part 1: Continuous pemigatinib 20 mg QD | Part 1: Continuous pemigatinib 7.5 mg BID |
|---|---|---|---|
| Started | 10 | 9 | 4 |
| Completed | 1 | 1 | 0 |
| Not completed | 9 | 8 | 4 |
| Adverse event, serious fatal | 5 | 8 | 4 |
| Placed on Hospice; Declined Further Follow-up | - | - | - |
| Consent withdrawn by subject | 1 | - | - |
| Clinical Decline; Withdrew by Physician | 1 | - | - |
| Adverse event, non-fatal | - | - | - |
| Rolled Over to Another Protocol | - | - | - |
| Study Terminated by Sponsor | 2 | - | - |
| Lost to follow-up | - | - | - |
| Disease Progression | - | - | - |

| Number of subjects in period 1 | Part 1: Continuous pemigatinib 10 mg BID | Part 2: Intermittent pemigatinib 9 mg QD | Part 2: Intermittent pemigatinib 13.5 mg QD |
|---------------------------------------|--|--|---|
| Started | 3 | 4 | 44 |

| | | | |
|---|---|---|----|
| Completed | 0 | 0 | 0 |
| Not completed | 3 | 4 | 44 |
| Adverse event, serious fatal | 2 | 3 | 29 |
| Placed on Hospice; Declined Further Follow-up | - | - | - |
| Consent withdrawn by subject | - | - | 13 |
| Clinical Decline; Withdrew by Physician | - | - | - |
| Adverse event, non-fatal | - | - | - |
| Rolled Over to Another Protocol | - | - | - |
| Study Terminated by Sponsor | 1 | - | 1 |
| Lost to follow-up | - | - | - |
| Disease Progression | - | 1 | 1 |

| Number of subjects in period 1 | Part 2: Continuous pemigatinib 9 mg QD | Part 2: Continuous pemigatinib 13.5 mg QD | Part 2: Continuous pemigatinib 20 mg QD |
|---|--|---|---|
| Started | 5 | 20 | 6 |
| Completed | 0 | 0 | 1 |
| Not completed | 5 | 20 | 5 |
| Adverse event, serious fatal | 4 | 15 | 2 |
| Placed on Hospice; Declined Further Follow-up | - | - | - |
| Consent withdrawn by subject | 1 | 2 | 3 |
| Clinical Decline; Withdrew by Physician | - | - | - |
| Adverse event, non-fatal | - | - | - |
| Rolled Over to Another Protocol | - | - | - |
| Study Terminated by Sponsor | - | 3 | - |
| Lost to follow-up | - | - | - |
| Disease Progression | - | - | - |

| Number of subjects in period 1 | Part 3: Gem/Cis/intermittent pemigatinib 9 mg | Part 3: Gem/Cis/intermittent pemigatinib 13.5 mg | Part 3: Tras/intermittent pemigatinib 13.5 mg |
|---|---|--|---|
| Started | 1 | 7 | 6 |
| Completed | 0 | 0 | 0 |
| Not completed | 1 | 7 | 6 |
| Adverse event, serious fatal | 1 | 7 | 5 |
| Placed on Hospice; Declined Further Follow-up | - | - | - |
| Consent withdrawn by subject | - | - | - |
| Clinical Decline; Withdrew by Physician | - | - | - |
| Adverse event, non-fatal | - | - | - |
| Rolled Over to Another Protocol | - | - | - |
| Study Terminated by Sponsor | - | - | 1 |
| Lost to follow-up | - | - | - |

| | | | |
|---------------------|---|---|---|
| Disease Progression | - | - | - |
|---------------------|---|---|---|

| Number of subjects in period 1 | Part 3: Doc/intermittent pemigatinib 13.5 mg | Part 3: Pem/intermittent pemigatinib 9 mg | Part 3: Pem/intermittent pemigatinib 13.5 mg |
|---|--|---|--|
| Started | 7 | 3 | 14 |
| Completed | 0 | 0 | 0 |
| Not completed | 7 | 3 | 14 |
| Adverse event, serious fatal | 5 | 3 | 7 |
| Placed on Hospice; Declined Further Follow-up | - | - | - |
| Consent withdrawn by subject | 1 | - | 2 |
| Clinical Decline; Withdrew by Physician | - | - | - |
| Adverse event, non-fatal | - | - | - |
| Rolled Over to Another Protocol | - | - | 1 |
| Study Terminated by Sponsor | 1 | - | 1 |
| Lost to follow-up | - | - | 1 |
| Disease Progression | - | - | 2 |

| Number of subjects in period 1 | Part 3: Pem/continuous pemigatinib 13.5 mg | Part 3: Ref/continuous pemigatinib 9 mg | Part 3: Ref/continuous pemigatinib 13.5 mg |
|---|--|---|--|
| Started | 9 | 7 | 9 |
| Completed | 0 | 0 | 1 |
| Not completed | 9 | 7 | 8 |
| Adverse event, serious fatal | 5 | 6 | 3 |
| Placed on Hospice; Declined Further Follow-up | - | - | 1 |
| Consent withdrawn by subject | 1 | - | 1 |
| Clinical Decline; Withdrew by Physician | - | - | - |
| Adverse event, non-fatal | - | - | 1 |
| Rolled Over to Another Protocol | - | - | - |
| Study Terminated by Sponsor | 1 | 1 | 2 |
| Lost to follow-up | 1 | - | - |
| Disease Progression | 1 | - | - |

| Number of subjects in period 1 | Part 3: Ref/continuous pemigatinib 20 mg |
|---|--|
| Started | 2 |
| Completed | 1 |
| Not completed | 1 |
| Adverse event, serious fatal | - |
| Placed on Hospice; Declined Further Follow-up | - |
| Consent withdrawn by subject | - |
| Clinical Decline; Withdrew by Physician | - |

| | |
|---------------------------------|---|
| Adverse event, non-fatal | - |
| Rolled Over to Another Protocol | - |
| Study Terminated by Sponsor | 1 |
| Lost to follow-up | - |
| Disease Progression | - |

Baseline characteristics

Reporting groups

| | |
|------------------------------|--|
| Reporting group title | Part 1: Intermittent pemigatinib 1/2/4 mg QD |
| Reporting group description: | Participants self-administered oral pemigatinib 1/2/4 milligrams (mg) once daily (QD) on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. |
| Reporting group title | Part 1: Intermittent pemigatinib 6 mg QD |
| Reporting group description: | Participants self-administered oral pemigatinib 6 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. |
| Reporting group title | Part 1: Intermittent pemigatinib 9 mg QD |
| Reporting group description: | Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. |
| Reporting group title | Part 1: Intermittent pemigatinib 13.5 mg QD |
| Reporting group description: | Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. |
| Reporting group title | Part 1: Intermittent pemigatinib 20 mg QD |
| Reporting group description: | Participants self-administered oral pemigatinib 20 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. |
| Reporting group title | Part 1: Continuous pemigatinib 9 mg QD |
| Reporting group description: | Participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle. |
| Reporting group title | Part 1: Continuous pemigatinib 13.5 mg QD |
| Reporting group description: | Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle. |
| Reporting group title | Part 1: Continuous pemigatinib 20 mg QD |
| Reporting group description: | Participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle. |
| Reporting group title | Part 1: Continuous pemigatinib 7.5 mg BID |
| Reporting group description: | Participants self-administered oral pemigatinib 7.5 mg twice daily (BID) on Days 1 through 21 of each 21-day cycle. |
| Reporting group title | Part 1: Continuous pemigatinib 10 mg BID |
| Reporting group description: | Participants self-administered oral pemigatinib 10 mg BID on Days 1 through 21 of each 21-day cycle. |
| Reporting group title | Part 2: Intermittent pemigatinib 9 mg QD |
| Reporting group description: | Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. |
| Reporting group title | Part 2: Intermittent pemigatinib 13.5 mg QD |
| Reporting group description: | Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. |
| Reporting group title | Part 2: Continuous pemigatinib 9 mg QD |

Reporting group description:

Participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle.

| | |
|-----------------------|---|
| Reporting group title | Part 2: Continuous pemigatinib 13.5 mg QD |
|-----------------------|---|

Reporting group description:

Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle.

| | |
|-----------------------|---|
| Reporting group title | Part 2: Continuous pemigatinib 20 mg QD |
|-----------------------|---|

Reporting group description:

Participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle.

| | |
|-----------------------|---|
| Reporting group title | Part 3: Gem/Cis/intermittent pemigatinib 9 mg |
|-----------------------|---|

Reporting group description:

Participants received gemcitabine (Gem) intravenously starting at 1000 mg/meters squared (m^2) on Days 1 and 8 of each 21-day cycle. Cisplatin (Cis) was administered intravenously starting at 70 mg/m² once every 3 weeks on Day 1 of each 21-day cycle. Both gemcitabine and cisplatin doses could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued chemotherapy with medical monitor approval. Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of gemcitabine/cisplatin.

| | |
|-----------------------|--|
| Reporting group title | Part 3: Gem/Cis/intermittent pemigatinib 13.5 mg |
|-----------------------|--|

Reporting group description:

Participants received gemcitabine intravenously starting at 1000 mg/m² on Days 1 and 8 of each 21-day cycle. Cisplatin was administered intravenously starting at 70 mg/m² once every 3 weeks on Day 1 of each 21-day cycle. Both gemcitabine and cisplatin doses could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued chemotherapy with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of gemcitabine/cisplatin.

| | |
|-----------------------|---|
| Reporting group title | Part 3: Tras/intermittent pemigatinib 13.5 mg |
|-----------------------|---|

Reporting group description:

Trastuzumab (Tras) was administered as an open-label, commercial product at an initial intravenous dose of 8 mg/kilograms (kg), followed by 6 mg/kg intravenously once every 3 weeks. The dose could have been adjusted for toxicity management, per commercial labeling. The investigator could have interrupted, modified, or discontinued trastuzumab with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of trastuzumab.

| | |
|-----------------------|--|
| Reporting group title | Part 3: Doc/intermittent pemigatinib 13.5 mg |
|-----------------------|--|

Reporting group description:

Participants received docetaxel (Doc) intravenously starting at 75 mg/m² once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued chemotherapy with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of docetaxel.

| | |
|-----------------------|---|
| Reporting group title | Part 3: Pem/intermittent pemigatinib 9 mg |
|-----------------------|---|

Reporting group description:

Participants received pembrolizumab (Pem) intravenously at 200 mg once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued pembrolizumab with medical monitor approval. Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of pembrolizumab.

| | |
|-----------------------|--|
| Reporting group title | Part 3: Pem/intermittent pemigatinib 13.5 mg |
|-----------------------|--|

Reporting group description:

Participants received pembrolizumab intravenously at 200 mg once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued pembrolizumab with medical monitor

approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of pembrolizumab.

| | |
|-----------------------|--|
| Reporting group title | Part 3: Pem/continuous pemigatinib 13.5 mg |
|-----------------------|--|

Reporting group description:

Participants received pembrolizumab intravenously at 200 mg once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued pembrolizumab with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle. It was permissible to continue pemigatinib administration during the toxicity break of pembrolizumab.

| | |
|-----------------------|---|
| Reporting group title | Part 3: Ref/continuous pemigatinib 9 mg |
|-----------------------|---|

Reporting group description:

Retifanlimab (Ref) was administered once every 4 weeks on a 28-day cycle as an open-label product, at an initial intravenous dose of 500 mg. Participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle.

| | |
|-----------------------|--|
| Reporting group title | Part 3: Ref/continuous pemigatinib 13.5 mg |
|-----------------------|--|

Reporting group description:

Retifanlimab was administered once every 4 weeks on a 28-day cycle as an open-label product, at an initial intravenous dose of 500 mg. Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle.

| | |
|-----------------------|--|
| Reporting group title | Part 3: Ref/continuous pemigatinib 20 mg |
|-----------------------|--|

Reporting group description:

Retifanlimab was administered once every 4 weeks on a 28-day cycle as an open-label product, at an initial intravenous dose of 500 mg. Participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle.

| Reporting group values | Part 1: Intermittent pemigatinib 1/2/4 mg QD | Part 1: Intermittent pemigatinib 6 mg QD | Part 1: Intermittent pemigatinib 9 mg QD |
|--|--|--|--|
| Number of subjects | 3 | 4 | 3 |
| Age categorical Units: Subjects | | | |
| Adults (18-64 years) | 2 | 4 | 3 |
| From 65-84 years | 1 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 |
| Age Continuous | | | |
| 9999=The standard deviation was not calculated for a single participant. | | | |
| Units: years | | | |
| arithmetic mean | 60.7 | 45.5 | 56.3 |
| standard deviation | ± 11.24 | ± 17.31 | ± 4.93 |
| Sex: Female, Male Units: participants | | | |
| Female | 2 | 2 | 2 |
| Male | 1 | 2 | 1 |
| Race/Ethnicity, Customized Units: Subjects | | | |
| White/Caucasian | 3 | 4 | 2 |
| Black/African-American | 0 | 0 | 1 |
| Asian | 0 | 0 | 0 |
| American-Indian/Alaska Native | 0 | 0 | 0 |
| Native Hawaiian/Pacific Islander | 0 | 0 | 0 |
| Captured as Other | 0 | 0 | 0 |
| Ethnicity (NIH/OMB) | | | |

| | | | |
|-------------------------|---|---|---|
| Units: Subjects | | | |
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 2 | 3 | 3 |
| Unknown or Not Reported | 1 | 1 | 0 |

| Reporting group values | Part 1: Intermittent pemigatinib 13.5 mg QD | Part 1: Intermittent pemigatinib 20 mg QD | Part 1: Continuous pemigatinib 9 mg QD |
|--|---|---|--|
| Number of subjects | 6 | 6 | 9 |
| Age categorical | | | |
| Units: Subjects | | | |
| Adults (18-64 years) | 4 | 5 | 5 |
| From 65-84 years | 2 | 1 | 4 |
| 85 years and over | 0 | 0 | 0 |
| Age Continuous | | | |
| 9999=The standard deviation was not calculated for a single participant. | | | |
| Units: years | | | |
| arithmetic mean | 59.0 | 56.2 | 57.9 |
| standard deviation | ± 14.79 | ± 11.89 | ± 15.70 |
| Sex: Female, Male | | | |
| Units: participants | | | |
| Female | 3 | 3 | 6 |
| Male | 3 | 3 | 3 |
| Race/Ethnicity, Customized | | | |
| Units: Subjects | | | |
| White/Caucasian | 6 | 5 | 8 |
| Black/African-American | 0 | 1 | 0 |
| Asian | 0 | 0 | 1 |
| American-Indian/Alaska Native | 0 | 0 | 0 |
| Native Hawaiian/Pacific Islander | 0 | 0 | 0 |
| Captured as Other | 0 | 0 | 0 |
| Ethnicity (NIH/OMB) | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 0 | 2 | 1 |
| Not Hispanic or Latino | 6 | 4 | 8 |
| Unknown or Not Reported | 0 | 0 | 0 |

| Reporting group values | Part 1: Continuous pemigatinib 13.5 mg QD | Part 1: Continuous pemigatinib 20 mg QD | Part 1: Continuous pemigatinib 7.5 mg BID |
|--|---|---|---|
| Number of subjects | 10 | 9 | 4 |
| Age categorical | | | |
| Units: Subjects | | | |
| Adults (18-64 years) | 6 | 6 | 1 |
| From 65-84 years | 4 | 3 | 3 |
| 85 years and over | 0 | 0 | 0 |
| Age Continuous | | | |
| 9999=The standard deviation was not calculated for a single participant. | | | |
| Units: years | | | |
| arithmetic mean | 61.2 | 56.3 | 66.8 |
| standard deviation | ± 16.88 | ± 15.19 | ± 4.57 |

| | | | |
|---|----|---|---|
| Sex: Female, Male Units: participants | | | |
| Female | 5 | 6 | 0 |
| Male | 5 | 3 | 4 |
| Race/Ethnicity, Customized Units: Subjects | | | |
| White/Caucasian | 10 | 8 | 4 |
| Black/African-American | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 |
| American-Indian/Alaska Native | 0 | 0 | 0 |
| Native Hawaiian/Pacific Islander | 0 | 0 | 0 |
| Captured as Other | 0 | 0 | 0 |
| Ethnicity (NIH/OMB) Units: Subjects | | | |
| Hispanic or Latino | 1 | 0 | 0 |
| Not Hispanic or Latino | 9 | 9 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 |

| Reporting group values | Part 1: Continuous pemigatinib 10 mg BID | Part 2: Intermittent pemigatinib 9 mg QD | Part 2: Intermittent pemigatinib 13.5 mg QD |
|--|--|--|---|
| Number of subjects | 3 | 4 | 44 |
| Age categorical Units: Subjects | | | |
| Adults (18-64 years) | 2 | 4 | 30 |
| From 65-84 years | 0 | 0 | 14 |
| 85 years and over | 1 | 0 | 0 |
| Age Continuous | | | |
| 9999=The standard deviation was not calculated for a single participant. | | | |
| Units: years | | | |
| arithmetic mean | 68.7 | 50.3 | 57.7 |
| standard deviation | ± 15.89 | ± 12.39 | ± 11.81 |
| Sex: Female, Male Units: participants | | | |
| Female | 2 | 3 | 27 |
| Male | 1 | 1 | 17 |
| Race/Ethnicity, Customized Units: Subjects | | | |
| White/Caucasian | 3 | 3 | 37 |
| Black/African-American | 0 | 0 | 7 |
| Asian | 0 | 0 | 0 |
| American-Indian/Alaska Native | 0 | 0 | 0 |
| Native Hawaiian/Pacific Islander | 0 | 0 | 0 |
| Captured as Other | 0 | 1 | 0 |
| Ethnicity (NIH/OMB) Units: Subjects | | | |
| Hispanic or Latino | 0 | 1 | 4 |
| Not Hispanic or Latino | 3 | 3 | 39 |
| Unknown or Not Reported | 0 | 0 | 1 |

| Reporting group values | Part 2: Continuous pemigatinib 9 mg QD | Part 2: Continuous pemigatinib 13.5 mg QD | Part 2: Continuous pemigatinib 20 mg QD |
|-------------------------------|--|---|---|
| | | | |

| | | | |
|--|---------|---------|--------|
| Number of subjects | 5 | 20 | 6 |
| Age categorical | | | |
| Units: Subjects | | | |
| Adults (18-64 years) | 2 | 12 | 4 |
| From 65-84 years | 3 | 8 | 2 |
| 85 years and over | 0 | 0 | 0 |
| Age Continuous | | | |
| 9999=The standard deviation was not calculated for a single participant. | | | |
| Units: years | | | |
| arithmetic mean | 63.8 | 57.4 | 58.3 |
| standard deviation | ± 10.69 | ± 13.78 | ± 8.80 |
| Sex: Female, Male | | | |
| Units: participants | | | |
| Female | 5 | 10 | 5 |
| Male | 0 | 10 | 1 |
| Race/Ethnicity, Customized | | | |
| Units: Subjects | | | |
| White/Caucasian | 5 | 18 | 6 |
| Black/African-American | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 |
| American-Indian/Alaska Native | 0 | 0 | 0 |
| Native Hawaiian/Pacific Islander | 0 | 0 | 0 |
| Captured as Other | 0 | 1 | 0 |
| Ethnicity (NIH/OMB) | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 0 | 4 | 0 |
| Not Hispanic or Latino | 5 | 16 | 6 |
| Unknown or Not Reported | 0 | 0 | 0 |

| Reporting group values | Part 3: Gem/Cis/intermittent pemigatinib 9 mg | Part 3: Gem/Cis/intermittent pemigatinib 13.5 mg | Part 3: Tras/intermittent pemigatinib 13.5 mg |
|--|--|---|--|
| Number of subjects | 1 | 7 | 6 |
| Age categorical | | | |
| Units: Subjects | | | |
| Adults (18-64 years) | 1 | 7 | 5 |
| From 65-84 years | 0 | 0 | 1 |
| 85 years and over | 0 | 0 | 0 |
| Age Continuous | | | |
| 9999=The standard deviation was not calculated for a single participant. | | | |
| Units: years | | | |
| arithmetic mean | 61.0 | 54.1 | 47.8 |
| standard deviation | ± 9999 | ± 10.43 | ± 14.44 |
| Sex: Female, Male | | | |
| Units: participants | | | |
| Female | 0 | 3 | 4 |
| Male | 1 | 4 | 2 |
| Race/Ethnicity, Customized | | | |
| Units: Subjects | | | |
| White/Caucasian | 1 | 5 | 6 |
| Black/African-American | 0 | 1 | 0 |

| | | | |
|----------------------------------|---|---|---|
| Asian | 0 | 1 | 0 |
| American-Indian/Alaska Native | 0 | 0 | 0 |
| Native Hawaiian/Pacific Islander | 0 | 0 | 0 |
| Captured as Other | 0 | 0 | 0 |
| Ethnicity (NIH/OMB) | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 1 | 7 | 6 |
| Unknown or Not Reported | 0 | 0 | 0 |

| Reporting group values | Part 3: Doc/intermittent pemigatinib 13.5 mg | Part 3: Pem/intermittent pemigatinib 9 mg | Part 3: Pem/intermittent pemigatinib 13.5 mg |
|--|--|---|--|
| Number of subjects | 7 | 3 | 14 |
| Age categorical | | | |
| Units: Subjects | | | |
| Adults (18-64 years) | 5 | 2 | 5 |
| From 65-84 years | 2 | 1 | 9 |
| 85 years and over | 0 | 0 | 0 |
| Age Continuous | | | |
| 9999=The standard deviation was not calculated for a single participant. | | | |
| Units: years | | | |
| arithmetic mean | 62.4 | 55.0 | 64.7 |
| standard deviation | ± 9.16 | ± 15.72 | ± 10.50 |
| Sex: Female, Male | | | |
| Units: participants | | | |
| Female | 3 | 1 | 5 |
| Male | 4 | 2 | 9 |
| Race/Ethnicity, Customized | | | |
| Units: Subjects | | | |
| White/Caucasian | 6 | 2 | 10 |
| Black/African-American | 1 | 1 | 2 |
| Asian | 0 | 0 | 0 |
| American-Indian/Alaska Native | 0 | 0 | 0 |
| Native Hawaiian/Pacific Islander | 0 | 0 | 0 |
| Captured as Other | 0 | 0 | 2 |
| Ethnicity (NIH/OMB) | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 0 | 0 | 1 |
| Not Hispanic or Latino | 7 | 3 | 13 |
| Unknown or Not Reported | 0 | 0 | 0 |

| Reporting group values | Part 3: Pem/continuous pemigatinib 13.5 mg | Part 3: Ref/continuous pemigatinib 9 mg | Part 3: Ref/continuous pemigatinib 13.5 mg |
|-------------------------------|--|---|--|
| Number of subjects | 9 | 7 | 9 |
| Age categorical | | | |
| Units: Subjects | | | |
| Adults (18-64 years) | 5 | 2 | 4 |
| From 65-84 years | 4 | 5 | 5 |
| 85 years and over | 0 | 0 | 0 |

| | | | |
|--|---------|---------|--------|
| Age Continuous | | | |
| 9999=The standard deviation was not calculated for a single participant. | | | |
| Units: years | | | |
| arithmetic mean | 61.8 | 63.4 | 66.9 |
| standard deviation | ± 10.89 | ± 11.43 | ± 8.80 |
| Sex: Female, Male | | | |
| Units: participants | | | |
| Female | 3 | 7 | 5 |
| Male | 6 | 0 | 4 |
| Race/Ethnicity, Customized | | | |
| Units: Subjects | | | |
| White/Caucasian | 9 | 7 | 9 |
| Black/African-American | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| American-Indian/Alaska Native | 0 | 0 | 0 |
| Native Hawaiian/Pacific Islander | 0 | 0 | 0 |
| Captured as Other | 0 | 0 | 0 |
| Ethnicity (NIH/OMB) | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 1 | 0 | 0 |
| Not Hispanic or Latino | 8 | 7 | 9 |
| Unknown or Not Reported | 0 | 0 | 0 |

| Reporting group values | Part 3: Ref/continuous pemigatinib 20 mg | Total | |
|--|--|-------|--|
| Number of subjects | 2 | 201 | |
| Age categorical | | | |
| Units: Subjects | | | |
| Adults (18-64 years) | 1 | 127 | |
| From 65-84 years | 1 | 73 | |
| 85 years and over | 0 | 1 | |
| Age Continuous | | | |
| 9999=The standard deviation was not calculated for a single participant. | | | |
| Units: years | | | |
| arithmetic mean | 68.0 | | |
| standard deviation | ± 7.07 | - | |
| Sex: Female, Male | | | |
| Units: participants | | | |
| Female | 1 | 113 | |
| Male | 1 | 88 | |
| Race/Ethnicity, Customized | | | |
| Units: Subjects | | | |
| White/Caucasian | 1 | 178 | |
| Black/African-American | 1 | 15 | |
| Asian | 0 | 4 | |
| American-Indian/Alaska Native | 0 | 0 | |
| Native Hawaiian/Pacific Islander | 0 | 0 | |
| Captured as Other | 0 | 4 | |
| Ethnicity (NIH/OMB) | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 0 | 15 | |

| | | | |
|-------------------------|---|-----|--|
| Not Hispanic or Latino | 1 | 182 | |
| Unknown or Not Reported | 1 | 4 | |

End points

End points reporting groups

| | |
|--|--|
| Reporting group title | Part 1: Intermittent pemigatinib 1/2/4 mg QD |
| Reporting group description: Participants self-administered oral pemigatinib 1/2/4 milligrams (mg) once daily (QD) on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. | |
| Reporting group title | Part 1: Intermittent pemigatinib 6 mg QD |
| Reporting group description: Participants self-administered oral pemigatinib 6 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. | |
| Reporting group title | Part 1: Intermittent pemigatinib 9 mg QD |
| Reporting group description: Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. | |
| Reporting group title | Part 1: Intermittent pemigatinib 13.5 mg QD |
| Reporting group description: Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. | |
| Reporting group title | Part 1: Intermittent pemigatinib 20 mg QD |
| Reporting group description: Participants self-administered oral pemigatinib 20 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. | |
| Reporting group title | Part 1: Continuous pemigatinib 9 mg QD |
| Reporting group description: Participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle. | |
| Reporting group title | Part 1: Continuous pemigatinib 13.5 mg QD |
| Reporting group description: Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle. | |
| Reporting group title | Part 1: Continuous pemigatinib 20 mg QD |
| Reporting group description: Participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle. | |
| Reporting group title | Part 1: Continuous pemigatinib 7.5 mg BID |
| Reporting group description: Participants self-administered oral pemigatinib 7.5 mg twice daily (BID) on Days 1 through 21 of each 21-day cycle. | |
| Reporting group title | Part 1: Continuous pemigatinib 10 mg BID |
| Reporting group description: Participants self-administered oral pemigatinib 10 mg BID on Days 1 through 21 of each 21-day cycle. | |
| Reporting group title | Part 2: Intermittent pemigatinib 9 mg QD |
| Reporting group description: Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. | |
| Reporting group title | Part 2: Intermittent pemigatinib 13.5 mg QD |
| Reporting group description: Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. | |
| Reporting group title | Part 2: Continuous pemigatinib 9 mg QD |

Reporting group description:

Participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle.

| | |
|-----------------------|---|
| Reporting group title | Part 2: Continuous pemigatinib 13.5 mg QD |
|-----------------------|---|

Reporting group description:

Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle.

| | |
|-----------------------|---|
| Reporting group title | Part 2: Continuous pemigatinib 20 mg QD |
|-----------------------|---|

Reporting group description:

Participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle.

| | |
|-----------------------|---|
| Reporting group title | Part 3: Gem/Cis/intermittent pemigatinib 9 mg |
|-----------------------|---|

Reporting group description:

Participants received gemcitabine (Gem) intravenously starting at 1000 mg/meters squared (m^2) on Days 1 and 8 of each 21-day cycle. Cisplatin (Cis) was administered intravenously starting at 70 mg/m² once every 3 weeks on Day 1 of each 21-day cycle. Both gemcitabine and cisplatin doses could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued chemotherapy with medical monitor approval. Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of gemcitabine/cisplatin.

| | |
|-----------------------|--|
| Reporting group title | Part 3: Gem/Cis/intermittent pemigatinib 13.5 mg |
|-----------------------|--|

Reporting group description:

Participants received gemcitabine intravenously starting at 1000 mg/m² on Days 1 and 8 of each 21-day cycle. Cisplatin was administered intravenously starting at 70 mg/m² once every 3 weeks on Day 1 of each 21-day cycle. Both gemcitabine and cisplatin doses could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued chemotherapy with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of gemcitabine/cisplatin.

| | |
|-----------------------|---|
| Reporting group title | Part 3: Tras/intermittent pemigatinib 13.5 mg |
|-----------------------|---|

Reporting group description:

Trastuzumab (Tras) was administered as an open-label, commercial product at an initial intravenous dose of 8 mg/kilograms (kg), followed by 6 mg/kg intravenously once every 3 weeks. The dose could have been adjusted for toxicity management, per commercial labeling. The investigator could have interrupted, modified, or discontinued trastuzumab with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of trastuzumab.

| | |
|-----------------------|--|
| Reporting group title | Part 3: Doc/intermittent pemigatinib 13.5 mg |
|-----------------------|--|

Reporting group description:

Participants received docetaxel (Doc) intravenously starting at 75 mg/m² once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued chemotherapy with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of docetaxel.

| | |
|-----------------------|---|
| Reporting group title | Part 3: Pem/intermittent pemigatinib 9 mg |
|-----------------------|---|

Reporting group description:

Participants received pembrolizumab (Pem) intravenously at 200 mg once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued pembrolizumab with medical monitor approval. Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of pembrolizumab.

| | |
|-----------------------|--|
| Reporting group title | Part 3: Pem/intermittent pemigatinib 13.5 mg |
|-----------------------|--|

Reporting group description:

Participants received pembrolizumab intravenously at 200 mg once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued pembrolizumab with medical monitor

approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of pembrolizumab.

| | |
|-----------------------|--|
| Reporting group title | Part 3: Pem/continuous pemigatinib 13.5 mg |
|-----------------------|--|

Reporting group description:

Participants received pembrolizumab intravenously at 200 mg once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued pembrolizumab with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle. It was permissible to continue pemigatinib administration during the toxicity break of pembrolizumab.

| | |
|-----------------------|---|
| Reporting group title | Part 3: Ref/continuous pemigatinib 9 mg |
|-----------------------|---|

Reporting group description:

Retifanlimab (Ref) was administered once every 4 weeks on a 28-day cycle as an open-label product, at an initial intravenous dose of 500 mg. Participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle.

| | |
|-----------------------|--|
| Reporting group title | Part 3: Ref/continuous pemigatinib 13.5 mg |
|-----------------------|--|

Reporting group description:

Retifanlimab was administered once every 4 weeks on a 28-day cycle as an open-label product, at an initial intravenous dose of 500 mg. Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle.

| | |
|-----------------------|--|
| Reporting group title | Part 3: Ref/continuous pemigatinib 20 mg |
|-----------------------|--|

Reporting group description:

Retifanlimab was administered once every 4 weeks on a 28-day cycle as an open-label product, at an initial intravenous dose of 500 mg. Participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle.

| | |
|----------------------------|---|
| Subject analysis set title | Parts 1 and 2: Intermittent pemigatinib 9 mg QD |
|----------------------------|---|

| | |
|---------------------------|-----------------|
| Subject analysis set type | Safety analysis |
|---------------------------|-----------------|

Subject analysis set description:

Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in either Part 1 or Part 2. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.

| | |
|----------------------------|--|
| Subject analysis set title | Parts 1 and 2: Intermittent pemigatinib 13.5 mg QD |
|----------------------------|--|

| | |
|---------------------------|-----------------|
| Subject analysis set type | Safety analysis |
|---------------------------|-----------------|

Subject analysis set description:

Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in either Part 1 or Part 2. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.

| | |
|----------------------------|---|
| Subject analysis set title | Parts 1 and 2: Continuous pemigatinib 9 mg QD |
|----------------------------|---|

| | |
|---------------------------|-----------------|
| Subject analysis set type | Safety analysis |
|---------------------------|-----------------|

Subject analysis set description:

Participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle in either Part 1 or Part 2.

| | |
|----------------------------|--|
| Subject analysis set title | Parts 1 and 2: Continuous pemigatinib 13.5 mg QD |
|----------------------------|--|

| | |
|---------------------------|-----------------|
| Subject analysis set type | Safety analysis |
|---------------------------|-----------------|

Subject analysis set description:

Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle in either Part 1 or Part 2.

| | |
|----------------------------|--|
| Subject analysis set title | Parts 1 and 2: Continuous pemigatinib 20 mg QD |
|----------------------------|--|

| | |
|---------------------------|-----------------|
| Subject analysis set type | Safety analysis |
|---------------------------|-----------------|

Subject analysis set description:

Participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle in either Part 1 or Part 2.

| | |
|----------------------------|---|
| Subject analysis set title | Parts 1 and 2: intermittent or continuous pemigatinib |
|----------------------------|---|

| | |
|---------------------------|---------------|
| Subject analysis set type | Full analysis |
|---------------------------|---------------|

Subject analysis set description:

Participant self-administered intermittent pemigatinib once daily (QD) or continuous pemigatinib QD or

twice daily (BID). Intermittent dosing: participants self-administered oral pemigatinib 1/2/4 milligrams (mg), 6 mg, 9 mg, 13.5 mg, or 20 mg once daily (QD) on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1 or Part 2. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. Continuous dosing: participants self-administered oral pemigatinib 9 mg, 13.5 mg, or 20 mg QD on Days 1 through 21 of each 21-day cycle in Part 1 or Part 2. Participants self-administered oral pemigatinib 7.5 mg or 10 mg BID on Days 1 through 21 of each 21-day cycle in Part 1.

| | |
|----------------------------|--|
| Subject analysis set title | Part 1: Intermittent pemigatinib 1 mg QD |
| Subject analysis set type | Full analysis |

Subject analysis set description:

Participants self-administered oral pemigatinib 1 milligram (mg) once daily (QD) on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.

| | |
|----------------------------|--|
| Subject analysis set title | Part 1: Intermittent pemigatinib 2 mg QD |
| Subject analysis set type | Full analysis |

Subject analysis set description:

Participants self-administered oral pemigatinib 2 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.

| | |
|----------------------------|--|
| Subject analysis set title | Part 1: Intermittent pemigatinib 4 mg QD |
| Subject analysis set type | Full analysis |

Subject analysis set description:

Participants self-administered oral pemigatinib 4 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.

| | |
|----------------------------|--|
| Subject analysis set title | Parts 1 and 2: Intermittent/continuous pemigatinib 9 mg QD |
| Subject analysis set type | Full analysis |

Subject analysis set description:

Participants self-administered intermittent or continuous oral pemigatinib 9 mg QD in either Part 1 or Part 2. Intermittent dosing: participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in either Part 1 or Part 2. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. Continuous dosing: participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle in either Part 1 or Part 2.

| | |
|----------------------------|---|
| Subject analysis set title | Parts 1 and 2: Intermittent/continuous pemigatinib 13.5 mg QD |
| Subject analysis set type | Full analysis |

Subject analysis set description:

Participants self-administered intermittent or continuous oral pemigatinib 13.5 mg QD in either Part 1 or Part 2. Intermittent dosing: participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in either Part 1 or Part 2. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. Continuous dosing: participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle in either Part 1 or Part 2.

| | |
|----------------------------|---|
| Subject analysis set title | Parts 1 and 2: Intermittent/continuous pemigatinib 20 mg QD |
| Subject analysis set type | Full analysis |

Subject analysis set description:

Participants self-administered intermittent or continuous oral pemigatinib 20 mg QD in either Part 1 or Part 2. Intermittent dosing: participants self-administered oral pemigatinib 20 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. Continuous dosing: participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle in either Part 1 or Part 2.

| | |
|----------------------------|--|
| Subject analysis set title | Parts 1 and 2: Intermittent/continuous pemigatinib 9 mg QD |
| Subject analysis set type | Full analysis |

Subject analysis set description:

Participants self-administered intermittent or continuous oral pemigatinib 9 mg QD in either Part 1 or Part 2. Intermittent dosing: participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in either Part 1 or Part 2. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. Continuous dosing: participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle in

either Part 1 or Part 2.

| | |
|----------------------------|---|
| Subject analysis set title | Parts 1 and 2: Intermittent/continuous pemigatinib 13.5 mg QD |
|----------------------------|---|

| | |
|---------------------------|---------------|
| Subject analysis set type | Full analysis |
|---------------------------|---------------|

Subject analysis set description:

Participants self-administered intermittent or continuous oral pemigatinib 13.5 mg QD in either Part 1 or Part 2. Intermittent dosing: participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in either Part 1 or Part 2. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. Continuous dosing: participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle in either Part 1 or Part 2.

| | |
|----------------------------|---|
| Subject analysis set title | Parts 1 and 2: Intermittent/continuous pemigatinib 20 mg QD |
|----------------------------|---|

| | |
|---------------------------|---------------|
| Subject analysis set type | Full analysis |
|---------------------------|---------------|

Subject analysis set description:

Participants self-administered intermittent or continuous oral pemigatinib 20 mg QD in either Part 1 or Part 2. Intermittent dosing: participants self-administered oral pemigatinib 20 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. Continuous dosing: participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle in either Part 1 or Part 2.

| | |
|----------------------------|--|
| Subject analysis set title | Part 2: intermittent/continuous pemigatinib 13.5 mg QD, fasted |
|----------------------------|--|

| | |
|---------------------------|---------------|
| Subject analysis set type | Full analysis |
|---------------------------|---------------|

Subject analysis set description:

Participants self-administered intermittent or continuous pemigatinib 13.5 mg QD in the fasted state in Part 2. Intermittent dosing: participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. Continuous dosing: participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle.

| | |
|----------------------------|---|
| Subject analysis set title | Part 2: intermittent/continuous pemigatinib 13.5 mg QD, fed |
|----------------------------|---|

| | |
|---------------------------|---------------|
| Subject analysis set type | Full analysis |
|---------------------------|---------------|

Subject analysis set description:

Participants self-administered intermittent or continuous pemigatinib 13.5 mg QD in the fed state in Part 2. Intermittent dosing: participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. Continuous dosing: participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle.

| | |
|----------------------------|--|
| Subject analysis set title | Part 3: Pem/intermittent pemigatinib 13.5 mg |
|----------------------------|--|

| | |
|---------------------------|---------------|
| Subject analysis set type | Full analysis |
|---------------------------|---------------|

Subject analysis set description:

Participants received pembrolizumab intravenously at 200 mg once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued pembrolizumab with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of pembrolizumab.

Primary: Parts 1 and 2 Combined: Number of participants with any treatment-emergent adverse event (TEAE)

| | |
|-----------------|---|
| End point title | Parts 1 and 2 Combined: Number of participants with any treatment-emergent adverse event (TEAE) ^{[1][2]} |
|-----------------|---|

End point description:

Adverse events were defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occurred after a participant provided informed consent. Abnormal laboratory values or test results that occurred after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy (e.g., hematologic abnormality that required transfusion), or required changes in the study drug(s). TEAEs were defined as adverse events either reported for the first time or the worsening of pre-existing events after the first dose of study drug and within 30 days of the last dose of study drug.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

up to 763 days

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not conducted.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted.

| End point values | Part 1: Intermittent pemigatinib 1/2/4 mg QD | Part 1: Intermittent pemigatinib 6 mg QD | Part 1: Intermittent pemigatinib 20 mg QD | Part 1: Continuous pemigatinib 7.5 mg BID |
|-----------------------------|---|---|--|--|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 4 | 6 | 4 |
| Units: participants | 3 | 3 | 6 | 4 |

| End point values | Part 1: Continuous pemigatinib 10 mg BID | Parts 1 and 2: Intermittent pemigatinib 9 mg QD | Parts 1 and 2: Intermittent pemigatinib 13.5 mg QD | Parts 1 and 2: Continuous pemigatinib 9 mg QD |
|-----------------------------|---|--|---|--|
| Subject group type | Reporting group | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 3 | 7 | 50 | 14 |
| Units: participants | 3 | 7 | 50 | 14 |

| End point values | Parts 1 and 2: Continuous pemigatinib 13.5 mg QD | Parts 1 and 2: Continuous pemigatinib 20 mg QD | | |
|-----------------------------|---|---|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 30 | 15 | | |
| Units: participants | 30 | 15 | | |

Statistical analyses

No statistical analyses for this end point

Primary: Part 3: Number of participants with any TEAE

End point title | Part 3: Number of participants with any TEAE^{[3][4]}

End point description:

Adverse events were defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occurred after a participant provided informed consent. Abnormal laboratory values or test results that occurred after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy (e.g., hematologic abnormality that required transfusion), or required changes in the study drug(s). TEAEs were defined as adverse events either reported for the first time or the worsening of pre-existing events after the first dose of study drug and within 30 days of the last dose of study drug.

End point type | Primary

End point timeframe:

up to 869 days

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not conducted.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted.

| End point values | Part 3: Gem/Cis/intermittent pemigatinib 9 mg | Part 3: Gem/Cis/intermittent pemigatinib 13.5 mg | Part 3: Tras/intermittent pemigatinib 13.5 mg | Part 3: Doc/intermittent pemigatinib 13.5 mg |
|-----------------------------|--|---|--|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 1 | 7 | 6 | 7 |
| Units: participants | 1 | 7 | 6 | 7 |

| End point values | Part 3: Pem/intermittent pemigatinib 9 mg | Part 3: Pem/intermittent pemigatinib 13.5 mg | Part 3: Pem/continuous pemigatinib 13.5 mg | Part 3: Ref/continuous pemigatinib 9 mg |
|-----------------------------|--|---|---|--|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 14 | 9 | 7 |
| Units: participants | 3 | 14 | 9 | 7 |

| End point values | Part 3: Ref/continuous pemigatinib 13.5 mg | Part 3: Ref/continuous pemigatinib 20 mg | | |
|-----------------------------|---|---|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 9 | 2 | | |
| Units: participants | 9 | 2 | | |

Statistical analyses

No statistical analyses for this end point

Primary: E0 following once daily dosing of pemigatinib as monotherapy in Parts 1 and 2

| | |
|-----------------|--|
| End point title | E0 following once daily dosing of pemigatinib as monotherapy in Parts 1 and 2 ^[5] |
|-----------------|--|

End point description:

E0 was defined as the Baseline serum concentration of phosphate. The average serum concentration of phosphate on Cycle 1 Days 8 and 15 was chosen as a dependent variable for E-R analysis, which was independent of the intermittent dosing and continuous dosing regimens. Therefore, the intermittent dosing and continuous dosing groups from Parts 1 and 2 were combined into a single analysis group for E-R analysis.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not conducted.

| | | | | |
|---|---|--|--|--|
| End point values | Parts 1 and 2: intermittent or continuous pemigatinib | | | |
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 93 | | | |
| Units: milligrams per deciliter (mg/dL) | | | | |
| geometric mean (geometric coefficient of variation) | 3.66 (\pm 1.91) | | | |

Statistical analyses

No statistical analyses for this end point

Primary: EC50 following once daily dosing of pemigatinib as monotherapy in Parts 1 and 2

| | |
|-----------------|--|
| End point title | EC50 following once daily dosing of pemigatinib as monotherapy in Parts 1 and 2 ^[6] |
|-----------------|--|

End point description:

EC50 was defined as the pemigatinib steady-state area under the plasma or serum concentration-time curve that increases 50% of serum phosphate. The average serum concentration of phosphate on Cycle 1 Days 8 and 15 was chosen as a dependent variable for E-R analysis, which was independent of the intermittent dosing and continuous dosing regimens. Therefore, the intermittent dosing and continuous dosing groups from Parts 1 and 2 were combined into a single analysis group for E-R analysis.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not conducted.

| | | | | |
|---|---|--|--|--|
| End point values | Parts 1 and 2: intermittent or continuous pemigatinib | | | |
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 93 | | | |
| Units: hours*nanomoles | | | | |
| geometric mean (geometric coefficient of variation) | 1573 (\pm 21.6) | | | |

Statistical analyses

No statistical analyses for this end point

Primary: Emax following once daily dosing of pemigatinib as monotherapy in Parts 1 and 2

| | |
|-----------------|--|
| End point title | Emax following once daily dosing of pemigatinib as monotherapy in Parts 1 and 2 ^[7] |
|-----------------|--|

End point description:

Emax was defined as the maximum degree of increasing of serum phosphate by pemigatinib. The average serum concentration of phosphate on Cycle 1 Days 8 and 15 was chosen as a dependent variable for E-R analysis, which was independent of the intermittent dosing and continuous dosing regimens. Therefore, the intermittent dosing and continuous dosing groups from Parts 1 and 2 were combined into a single analysis group for E-R analysis.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not conducted.

| | | | | |
|---|---|--|--|--|
| End point values | Parts 1 and 2: intermittent or continuous pemigatinib | | | |
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 93 | | | |
| Units: mg/dL | | | | |
| geometric mean (geometric coefficient of variation) | 5.76 (\pm 7.76) | | | |

Statistical analyses

No statistical analyses for this end point

Primary: Highest serum phosphate concentration following pemigatinib as monotherapy in Parts 1 and 2

| | |
|-----------------|--|
| End point title | Highest serum phosphate concentration following pemigatinib as monotherapy in Parts 1 and 2 ^[8] |
|-----------------|--|

End point description:

Serum phosphate concentration was assessed throughout Parts 1 and 2. The average serum concentration of phosphate on Cycle 1 Days 8 and 15 was chosen as a dependent variable for E-R analysis, which was independent of the intermittent dosing and continuous dosing regimens. Therefore, the intermittent dosing and continuous dosing groups from Parts 1 and 2 were combined into a single analysis group for E-R analysis.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not conducted.

| | | | | |
|--|--|--|--|--|
| End point values | Parts 1 and 2: intermittent or continuous pemigatinib | | | |
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 93 | | | |
| Units: mg/dL | | | | |
| number (not applicable) | | | | |
| Minimum value in range of highest values | 3.5 | | | |
| Maximum value in range of highest values | 11.2 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Overall response rate (ORR)

| | |
|-----------------|--|
| End point title | Part 2: Overall response rate (ORR) ^[9] |
|-----------------|--|

End point description:

ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR), per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as determined by the investigator. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to <10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

up to 126 days

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted.

| End point values | Part 2: Intermittent pemigatinib 9 mg QD | Part 2: Intermittent pemigatinib 13.5 mg QD | Part 2: Continuous pemigatinib 9 mg QD | Part 2: Continuous pemigatinib 13.5 mg QD |
|-----------------------------------|---|--|---|--|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 4 | 44 | 5 | 20 |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 25.0 (0.6 to 80.6) | 4.5 (0.6 to 15.5) | 0.0 (0.0 to 52.2) | 30.0 (11.9 to 54.3) |

| End point values | Part 2: Continuous pemigatinib 20 mg QD | | | |
|-----------------------------------|--|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 6 | | | |
| Units: percentage of participants | | | | |

| | | | | |
|----------------------------------|-------------------|--|--|--|
| number (confidence interval 95%) | 0.0 (0.0 to 45.9) | | | |
|----------------------------------|-------------------|--|--|--|

Statistical analyses

No statistical analyses for this end point

Secondary: Part 3: ORR

| | |
|-----------------|-----------------------------|
| End point title | Part 3: ORR ^[10] |
|-----------------|-----------------------------|

End point description:

ORR was defined as the percentage of participants with a best overall response of CR or PR, per RECIST version 1.1, as determined by the investigator. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to <10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

up to 203 days

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted.

| End point values | Part 3: Gem/Cis/intermittent pemigatinib 9 mg | Part 3: Gem/Cis/intermittent pemigatinib 13.5 mg | Part 3: Tras/intermittent pemigatinib 13.5 mg | Part 3: Doc/intermittent pemigatinib 13.5 mg |
|-----------------------------------|---|--|---|--|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 1 | 7 | 6 | 7 |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 0.0 (0.0 to 97.5) | 42.9 (9.9 to 81.6) | 0.0 (0.0 to 45.9) | 14.3 (0.4 to 57.9) |

| End point values | Part 3: Pem/intermittent pemigatinib 9 mg | Part 3: Pem/intermittent pemigatinib 13.5 mg | Part 3: Pem/continuous pemigatinib 13.5 mg | Part 3: Ref/continuous pemigatinib 9 mg |
|-----------------------------------|---|--|--|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 14 | 9 | 7 |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 0.0 (0.0 to 70.8) | 28.6 (8.4 to 58.1) | 33.3 (7.5 to 70.1) | 0.0 (0.0 to 41.0) |

| End point values | Part 3: Ref/continuous | Part 3: Ref/continuous | | |
|------------------|---------------------------|---------------------------|--|--|
|------------------|---------------------------|---------------------------|--|--|

| | pemigatinib 13.5 mg | pemigatinib 20 mg | | |
|-----------------------------------|------------------------|----------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 9 | 2 | | |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 22.2 (2.8 to 60.0) | 0.0 (0.0 to 84.2) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Parts 1 and 2: Cmax after once daily dosing of pemigatinib as monotherapy on Cycle 1 Day 1

| | |
|-----------------|--|
| End point title | Parts 1 and 2: Cmax after once daily dosing of pemigatinib as monotherapy on Cycle 1 Day 1 ^[11] |
|-----------------|--|

End point description:

Cmax was defined as the maximum observed plasma concentration. 9999 denotes that a standard deviation was not calculated for a single participant.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Part 1: predose; 0.5, 1, 2, 4, 6, and 8 hours post-dose post-dose on Cycle 1 Day 1. Part 2: predose on Cycle 1 Day 1

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted.

| End point values | Part 1: Intermittent pemigatinib 6 mg QD | Part 1: Intermittent pemigatinib 1 mg QD | Part 1: Intermittent pemigatinib 2 mg QD | Part 1: Intermittent pemigatinib 4 mg QD |
|---|---|---|---|---|
| Subject group type | Reporting group | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 4 | 1 | 1 | 1 |
| Units: nanograms per milliliter (ng/mL) | | | | |
| arithmetic mean (standard deviation) | 64.6 (± 9.16) | 25.3 (± 9999) | 13.6 (± 9999) | 109 (± 9999) |

| End point values | Parts 1 and 2: Intermittent/co ntinuous pemigatinib 9 mg QD | Parts 1 and 2: Intermittent/co ntinuous pemigatinib 13.5 mg QD | Parts 1 and 2: Intermittent/co ntinuous pemigatinib 20 mg QD | |
|---|---|--|--|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 21 | 69 | 69 | |
| Units: nanograms per milliliter (ng/mL) | | | | |
| arithmetic mean (standard deviation) | 139 (± 79.8) | 196 (± 121) | 300 (± 135) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Parts 1 and 2: t_{max} after once daily dosing of pemigatinib as monotherapy on Cycle 1 Day 1

| | |
|-----------------|--|
| End point title | Parts 1 and 2: t _{max} after once daily dosing of pemigatinib as monotherapy on Cycle 1 Day 1 ^[12] |
|-----------------|--|

End point description:

t_{max} was defined as the time to the maximum observed plasma concentration. -9999 and 9999 denote that a range was not calculated for a single participant.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Part 1: predose; 0.5, 1, 2, 4, 6, and 8 hours post-dose post-dose on Cycle 1 Day 1. Part 2: predose on Cycle 1 Day 1

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted.

| End point values | Part 1: Intermittent pemigatinib 6 mg QD | Part 1: Intermittent pemigatinib 1 mg QD | Part 1: Intermittent pemigatinib 2 mg QD | Part 1: Intermittent pemigatinib 4 mg QD |
|-------------------------------|---|---|---|---|
| Subject group type | Reporting group | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 4 | 1 | 1 | 1 |
| Units: hours (hr) | | | | |
| median (full range (min-max)) | 1.14 (1.00 to 2.08) | 1 (-9999 to 9999) | 5.92 (-9999 to 9999) | 2.02 (-9999 to 9999) |

| End point values | Parts 1 and 2: Intermittent/co ntinuous pemigatinib 9 mg QD | Parts 1 and 2: Intermittent/co ntinuous pemigatinib 13.5 mg QD | Parts 1 and 2: Intermittent/co ntinuous pemigatinib 20 mg QD | |
|-------------------------------|---|--|--|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 21 | 69 | 69 | |
| Units: hours (hr) | | | | |
| median (full range (min-max)) | 1.17 (0.500 to 2.13) | 1.20 (0.400 to 26.1) | 1.98 (0.500 to 22.9) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Parts 1 and 2: AUC_{last} after once daily dosing of pemigatinib as monotherapy on Cycle 1 Day 1

| | |
|-----------------|---|
| End point title | Parts 1 and 2: AUC _{last} after once daily dosing of pemigatinib as monotherapy on Cycle 1 Day 1 ^[13] |
|-----------------|---|

End point description:

AUC_{last} was defined as the area under the plasma or serum concentration-time curve from the time of

dosing to the last measurable concentration. 9999 denotes that a standard deviation was not calculated for a single participant.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Part 1: predose; 0.5, 1, 2, 4, 6, and 8 hours post-dose post-dose on Cycle 1 Day 1. Part 2: predose on Cycle 1 Day 1

Notes:

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted.

| End point values | Part 1: Intermittent pemigatinib 6 mg QD | Part 1: Intermittent pemigatinib 1 mg QD | Part 1: Intermittent pemigatinib 2 mg QD | Part 1: Intermittent pemigatinib 4 mg QD |
|--------------------------------------|---|---|---|---|
| Subject group type | Reporting group | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 4 | 1 | 1 | 1 |
| Units: hr*ng/mL | | | | |
| arithmetic mean (standard deviation) | 641 (± 116) | 190 (± 9999) | 68.8 (± 9999) | 1010 (± 9999) |

| End point values | Parts 1 and 2: Intermittent/co ntinuous pemigatinib 9 mg QD | Parts 1 and 2: Intermittent/co ntinuous pemigatinib 13.5 mg QD | Parts 1 and 2: Intermittent/co ntinuous pemigatinib 20 mg QD | |
|--------------------------------------|---|--|--|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 21 | 69 | 69 | |
| Units: hr*ng/mL | | | | |
| arithmetic mean (standard deviation) | 1140 (± 498) | 1820 (± 1210) | 2510 (± 935) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Parts 1 and 2: AUC0-24 after once daily dosing of pemigatinib as monotherapy on Cycle 1 Day 1

| | |
|-----------------|---|
| End point title | Parts 1 and 2: AUC0-24 after once daily dosing of pemigatinib as monotherapy on Cycle 1 Day 1 ^[14] |
|-----------------|---|

End point description:

AUC0-24 was defined as the area under the plasma or serum concentration-time curve from time 0 to 24 hours post-dose. 9999 denotes that a standard deviation was not calculated for a single participant.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Part 1: predose; 0.5, 1, 2, 4, 6, and 8 hours post-dose post-dose on Cycle 1 Day 1. Part 2: predose on Cycle 1 Day 1

Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted.

| End point values | Part 1: Intermittent pemigatinib 6 mg QD | Part 1: Intermittent pemigatinib 1 mg QD | Part 1: Intermittent pemigatinib 2 mg QD | Part 1: Intermittent pemigatinib 4 mg QD |
|--------------------------------------|---|---|---|---|
| Subject group type | Reporting group | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 4 | 1 | 1 | 1 |
| Units: hr*ng/mL | | | | |
| arithmetic mean (standard deviation) | 644 (± 115) | 191 (± 9999) | 9999 (± 9999) | 1010 (± 9999) |

| End point values | Parts 1 and 2: Intermittent/co ntinuous pemigatinib 9 mg QD | Parts 1 and 2: Intermittent/co ntinuous pemigatinib 13.5 mg QD | Parts 1 and 2: Intermittent/co ntinuous pemigatinib 20 mg QD | |
|--------------------------------------|---|--|--|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 21 | 69 | 69 | |
| Units: hr*ng/mL | | | | |
| arithmetic mean (standard deviation) | 1150 (± 497) | 1840 (± 1080) | 2850 (± 1050) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Parts 1 and 2: Cmax after once daily dosing of pemigatinib as monotherapy on Cycle 1 Days 8 and 14 (steady state)

| | |
|-----------------|---|
| End point title | Parts 1 and 2: Cmax after once daily dosing of pemigatinib as monotherapy on Cycle 1 Days 8 and 14 (steady state) ^[15] |
|-----------------|---|

End point description:

Cmax was defined as the maximum observed plasma concentration. 9999 denotes that a standard deviation was not calculated for a single participant.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14.
Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted for all treatment group comparisons

| End point values | Part 1: Intermittent pemigatinib 6 mg QD | Part 1: Intermittent pemigatinib 1 mg QD | Part 1: Intermittent pemigatinib 2 mg QD | Part 1: Intermittent pemigatinib 4 mg QD |
|--------------------------------------|---|---|---|---|
| Subject group type | Reporting group | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 4 | 1 | 1 | 1 |
| Units: ng/mL | | | | |
| arithmetic mean (standard deviation) | 86.1 (± 38.0) | 26.2 (± 9999) | 22.9 (± 9999) | 103 (± 9999) |

| End point values | Parts 1 and 2: Intermittent/continuous pemigatinib 9 mg QD | Parts 1 and 2: Intermittent/continuous pemigatinib 13.5 mg QD | Parts 1 and 2: Intermittent/continuous pemigatinib 20 mg QD | |
|--------------------------------------|--|---|---|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 18 | 57 | 13 | |
| Units: ng/mL | | | | |
| arithmetic mean (standard deviation) | 196 (± 123) | 271 (± 151) | 449 (± 172) | |

Statistical analyses

| Statistical analysis title | ANOVA of log-transformed, dose-normalized data |
|---|---|
| Statistical analysis description: pairwise p-values from a 1-factor ANOVA of log-transformed, dose-normalized data (factor = dose) | |
| Comparison groups | Part 1: Intermittent pemigatinib 6 mg QD v Parts 1 and 2: Intermittent/continuous pemigatinib 9 mg QD |
| Number of subjects included in analysis | 22 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.2841 |
| Method | ANOVA |

| Statistical analysis title | ANOVA of log-transformed, dose-normalized data |
|---|--|
| Statistical analysis description: pairwise p-values from a 1-factor ANOVA of log-transformed, dose-normalized data (factor = dose) | |
| Comparison groups | Part 1: Intermittent pemigatinib 6 mg QD v Parts 1 and 2: Intermittent/continuous pemigatinib 13.5 mg QD |
| Number of subjects included in analysis | 61 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.3042 |
| Method | ANOVA |

| Statistical analysis title | ANOVA of log-transformed, dose-normalized data |
|---|--|
| Statistical analysis description: pairwise p-values from a 1-factor ANOVA of log-transformed, dose-normalized data (factor = dose) | |
| Comparison groups | Parts 1 and 2: Intermittent/continuous pemigatinib 9 mg QD v Parts 1 and 2: Intermittent/continuous pemigatinib 20 mg QD |
| Number of subjects included in analysis | 31 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.4315 |
| Method | ANOVA |

| | |
|---|--|
| Statistical analysis title | ANOVA of log-transformed, dose-normalized data |
| Statistical analysis description: pairwise p-values from a 1-factor ANOVA of log-transformed, dose-normalized data (factor = dose) | |
| Comparison groups | Parts 1 and 2: Intermittent/continuous pemigatinib 9 mg QD v Parts 1 and 2: Intermittent/continuous pemigatinib 13.5 mg QD |
| Number of subjects included in analysis | 75 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.8214 |
| Method | ANOVA |

| | |
|---|---|
| Statistical analysis title | ANOVA of log-transformed, dose-normalized data |
| Statistical analysis description: pairwise p-values from a 1-factor ANOVA of log-transformed, dose-normalized data (factor = dose) | |
| Comparison groups | Parts 1 and 2: Intermittent/continuous pemigatinib 13.5 mg QD v Parts 1 and 2: Intermittent/continuous pemigatinib 20 mg QD |
| Number of subjects included in analysis | 70 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.2595 |
| Method | ANOVA |

| | |
|---|--|
| Statistical analysis title | ANOVA of log-transformed, dose-normalized data |
| Statistical analysis description: pairwise p-values from a 1-factor ANOVA of log-transformed, dose-normalized data (factor = dose) | |
| Comparison groups | Part 1: Intermittent pemigatinib 6 mg QD v Parts 1 and 2: Intermittent/continuous pemigatinib 20 mg QD |
| Number of subjects included in analysis | 17 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.1259 |
| Method | ANOVA |

Secondary: Parts 1 and 2: t_{max} after once daily dosing of pemigatinib as monotherapy on Cycle 1 Days 8 and 14 (steady state)

| | |
|-----------------|---|
| End point title | Parts 1 and 2: t _{max} after once daily dosing of pemigatinib as monotherapy on Cycle 1 Days 8 and 14 (steady state) ^[16] |
|-----------------|---|

End point description:

t_{max} was defined as the time to the maximum observed plasma concentration. -9999 and 9999 denote that a range was not calculated for a single participant.

| | | | | |
|--|---|---|---|---|
| End point type | Secondary | | | |
| End point timeframe: | | | | |
| Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. | | | | |
| Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14 | | | | |
| Notes: | | | | |
| [16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. | | | | |
| Justification: Statistical analysis was not conducted. | | | | |
| End point values | Part 1: Intermittent pemigatinib 6 mg QD | Part 1: Intermittent pemigatinib 1 mg QD | Part 1: Intermittent pemigatinib 2 mg QD | Part 1: Intermittent pemigatinib 4 mg QD |
| Subject group type | Reporting group | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 4 | 1 | 1 | 1 |
| Units: hr | | | | |
| median (full range (min-max)) | 1.58 (0.983 to 23.7) | 1.07 (-9999 to 9999) | 3.98 (-9999 to 9999) | 2.02 (-9999 to 9999) |

| | | | | |
|-------------------------------|---|--|--|--|
| End point values | Parts 1 and 2: Intermittent/co ntinuous pemigatinib 9 mg QD | Parts 1 and 2: Intermittent/co ntinuous pemigatinib 13.5 mg QD | Parts 1 and 2: Intermittent/co ntinuous pemigatinib 20 mg QD | |
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 18 | 57 | 13 | |
| Units: hr | | | | |
| median (full range (min-max)) | 1.00 (0.500 to 6.10) | 1.13 (0.500 to 6.00) | 1.12 (0.517 to 5.90) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Parts 1 and 2: t_{1/2} after once daily dosing of pemigatinib as monotherapy on Cycle 1 Days 8 and 14 (steady state)

| | |
|--|---|
| End point title | Parts 1 and 2: t _{1/2} after once daily dosing of pemigatinib as monotherapy on Cycle 1 Days 8 and 14 (steady state) ^[17] |
| End point description: | |
| t _{1/2} was defined as the apparent plasma terminal phase disposition half-life. 9999 denotes that a standard deviation was not calculated for a single participant. | |
| End point type | Secondary |
| End point timeframe: | |
| Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. | |
| Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14 | |
| Notes: | |
| [17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. | |
| Justification: Statistical analysis was not conducted. | |

| End point values | Part 1: Intermittent pemigatinib 6 mg QD | Part 1: Intermittent pemigatinib 1 mg QD | Part 1: Intermittent pemigatinib 2 mg QD | Part 1: Intermittent pemigatinib 4 mg QD |
|--------------------------------------|---|---|---|---|
| Subject group type | Reporting group | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 4 | 1 | 1 | 1 |
| Units: hr | | | | |
| arithmetic mean (standard deviation) | 21.0 (± 22.8) | 10.9 (± 9999) | 18.1 (± 9999) | 30.4 (± 9999) |

| End point values | Parts 1 and 2: Intermittent/co ntinuous pemigatinib 9 mg QD | Parts 1 and 2: Intermittent/co ntinuous pemigatinib 13.5 mg QD | Parts 1 and 2: Intermittent/co ntinuous pemigatinib 20 mg QD | |
|--------------------------------------|---|--|--|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 18 | 57 | 13 | |
| Units: hr | | | | |
| arithmetic mean (standard deviation) | 17.2 (± 9.70) | 17.4 (± 9.64) | 13.1 (± 6.01) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Parts 1 and 2: Cmin after once daily dosing of pemigatinib as monotherapy on Cycle 1 Days 8 and 14 (steady state)

| | |
|-----------------|---|
| End point title | Parts 1 and 2: Cmin after once daily dosing of pemigatinib as monotherapy on Cycle 1 Days 8 and 14 (steady state) ^[18] |
|-----------------|---|

End point description:

Cmin was defined as the minimum observed plasma concentration over the dose interval. 9999 denotes that a standard deviation was not calculated for a single participant.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14.
Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

Notes:

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted.

| End point values | Part 1: Intermittent pemigatinib 6 mg QD | Part 1: Intermittent pemigatinib 1 mg QD | Part 1: Intermittent pemigatinib 2 mg QD | Part 1: Intermittent pemigatinib 4 mg QD |
|--------------------------------------|---|---|---|---|
| Subject group type | Reporting group | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 4 | 1 | 1 | 1 |
| Units: ng/mL | | | | |
| arithmetic mean (standard deviation) | 30.0 (± 15.1) | 3.24 (± 9999) | 7.87 (± 9999) | 23.9 (± 9999) |

| | | | | |
|--------------------------------------|--|---|---|--|
| End point values | Parts 1 and 2: Intermittent/continuous pemigatinib 9 mg QD | Parts 1 and 2: Intermittent/continuous pemigatinib 13.5 mg QD | Parts 1 and 2: Intermittent/continuous pemigatinib 20 mg QD | |
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 18 | 57 | 13 | |
| Units: ng/mL | | | | |
| arithmetic mean (standard deviation) | 49.9 (± 49.6) | 71.7 (± 56.7) | 104 (± 93.3) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Parts 1 and 2: AUC0-24 after once daily dosing of pemigatinib as monotherapy on Cycle 1 Days 8 and 14 (steady state)

| | |
|-----------------|--|
| End point title | Parts 1 and 2: AUC0-24 after once daily dosing of pemigatinib as monotherapy on Cycle 1 Days 8 and 14 (steady state) ^[19] |
|-----------------|--|

End point description:

AUC0-24 was defined as the area under the plasma or serum concentration-time curve from time 0 to 24 hours post-dose. 9999 denotes that a standard deviation was not calculated for a single participant.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14.
Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

Notes:

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted for all treatment group comparisons

| | | | | |
|--------------------------------------|--|--|--|--|
| End point values | Part 1: Intermittent pemigatinib 6 mg QD | Part 1: Intermittent pemigatinib 1 mg QD | Part 1: Intermittent pemigatinib 2 mg QD | Part 1: Intermittent pemigatinib 4 mg QD |
| Subject group type | Reporting group | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 4 | 1 | 1 | 1 |
| Units: hr*ng/mL | | | | |
| arithmetic mean (standard deviation) | 1080 (± 301) | 208 (± 9999) | 322 (± 9999) | 1380 (± 9999) |

| | | | | |
|--------------------------------------|--|---|---|--|
| End point values | Parts 1 and 2: Intermittent/continuous pemigatinib 9 mg QD | Parts 1 and 2: Intermittent/continuous pemigatinib 13.5 mg QD | Parts 1 and 2: Intermittent/continuous pemigatinib 20 mg QD | |
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 18 | 57 | 13 | |
| Units: hr*ng/mL | | | | |
| arithmetic mean (standard deviation) | 2180 (± 1630) | 3010 (± 1890) | 4350 (± 1480) | |

Statistical analyses

| | |
|---|--|
| Statistical analysis title | ANOVA of log-transformed, dose-normalized data |
| Statistical analysis description: pairwise p-values from a 1-factor ANOVA of log-transformed, dose-normalized data (factor = dose) | |
| Comparison groups | Part 1: Intermittent pemigatinib 6 mg QD v Parts 1 and 2: Intermittent/continuous pemigatinib 9 mg QD |
| Number of subjects included in analysis | 22 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.8577 |
| Method | ANOVA |

| | |
|---|---|
| Statistical analysis title | ANOVA of log-transformed, dose-normalized data |
| Statistical analysis description: pairwise p-values from a 1-factor ANOVA of log-transformed, dose-normalized data (factor = dose) | |
| Comparison groups | Part 1: Intermittent pemigatinib 6 mg QD v Parts 1 and 2: Intermittent/continuous pemigatinib 13.5 mg QD |
| Number of subjects included in analysis | 61 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.7238 |
| Method | ANOVA |

| | |
|---|---|
| Statistical analysis title | ANOVA of log-transformed, dose-normalized data |
| Statistical analysis description: pairwise p-values from a 1-factor ANOVA of log-transformed, dose-normalized data (factor = dose) | |
| Comparison groups | Part 1: Intermittent pemigatinib 6 mg QD v Parts 1 and 2: Intermittent/continuous pemigatinib 20 mg QD |
| Number of subjects included in analysis | 17 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.5923 |
| Method | ANOVA |

| | |
|---|--|
| Statistical analysis title | ANOVA of log-transformed, dose-normalized data |
| Statistical analysis description: pairwise p-values from a 1-factor ANOVA of log-transformed, dose-normalized data (factor = dose) | |

| | |
|---|--|
| Comparison groups | Parts 1 and 2: Intermittent/continuous pemigatinib 9 mg QD v Parts 1 and 2: Intermittent/continuous pemigatinib 13.5 mg QD |
| Number of subjects included in analysis | 75 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.7634 |
| Method | ANOVA |

| | |
|---|---|
| Statistical analysis title | ANOVA of log-transformed, dose-normalized data |
| Statistical analysis description: pairwise p-values from a 1-factor ANOVA of log-transformed, dose-normalized data (factor = dose) | |
| Comparison groups | Parts 1 and 2: Intermittent/continuous pemigatinib 9 mg QD v Parts 1 and 2: Intermittent/continuous pemigatinib 20 mg QD |
| Number of subjects included in analysis | 31 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.5749 |
| Method | ANOVA |

| | |
|---|---|
| Statistical analysis title | ANOVA of log-transformed, dose-normalized data |
| Statistical analysis description: pairwise p-values from a 1-factor ANOVA of log-transformed, dose-normalized data (factor = dose) | |
| Comparison groups | Parts 1 and 2: Intermittent/continuous pemigatinib 13.5 mg QD v Parts 1 and 2: Intermittent/continuous pemigatinib 20 mg QD |
| Number of subjects included in analysis | 70 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.6877 |
| Method | ANOVA |

Secondary: Parts 1 and 2: CL/F after once daily dosing of pemigatinib as monotherapy on Cycle 1 Days 8 and 14 (steady state)

| | |
|--|--|
| End point title | Parts 1 and 2: CL/F after once daily dosing of pemigatinib as monotherapy on Cycle 1 Days 8 and 14 (steady state) ^[20] |
| End point description: CL/F was defined as the apparent oral dose clearance. 9999 denotes that a standard deviation was not calculated for a single participant. | |
| End point type | Secondary |

End point timeframe:

Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14.
Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

Notes:

[20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all
the baseline period arms will be reported on when providing values for an end point on the baseline
period.

Justification: Statistical analysis was not conducted.

| End point values | Part 1: Intermittent pemigatinib 6 mg QD | Part 1: Intermittent pemigatinib 1 mg QD | Part 1: Intermittent pemigatinib 2 mg QD | Part 1: Intermittent pemigatinib 4 mg QD |
|--------------------------------------|---|---|---|---|
| Subject group type | Reporting group | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 4 | 1 | 1 | 1 |
| Units: Liters per hr (L/hr) | | | | |
| arithmetic mean (standard deviation) | 12.0 (± 3.14) | 9.86 (± 9999) | 12.8 (± 9999) | 5.93 (± 9999) |

| End point values | Parts 1 and 2: Intermittent/co ntinuous pemigatinib 9 mg QD | Parts 1 and 2: Intermittent/co ntinuous pemigatinib 13.5 mg QD | Parts 1 and 2: Intermittent/co ntinuous pemigatinib 20 mg QD | |
|--------------------------------------|---|--|--|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 18 | 57 | 13 | |
| Units: Liters per hr (L/hr) | | | | |
| arithmetic mean (standard deviation) | 15.7 (± 17.7) | 11.9 (± 5.72) | 10.3 (± 3.01) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Parts 1 and 2: Vz/F after once daily dosing of pemigatinib as monotherapy on Cycle 1 Days 8 and 14 (steady state)

| | |
|-----------------|---|
| End point title | Parts 1 and 2: Vz/F after once daily dosing of pemigatinib as monotherapy on Cycle 1 Days 8 and 14 (steady state) ^[21] |
|-----------------|---|

End point description:

Vz/F was defined as the apparent volume of distribution. 9999 denotes that a standard deviation was not calculated for a single participant.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14.
Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

Notes:

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted.

| End point values | Part 1: Intermittent pemigatinib 6 mg QD | Part 1: Intermittent pemigatinib 1 mg QD | Part 1: Intermittent pemigatinib 2 mg QD | Part 1: Intermittent pemigatinib 4 mg QD |
|-----------------------------|---|---|---|---|
| Subject group type | Reporting group | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 4 | 1 | 1 | 1 |
| Units: Liters | | | | |

| | | | | |
|--------------------------------------|------------------|-------------------|-------------------|-------------------|
| arithmetic mean (standard deviation) | 301 (\pm 241) | 156 (\pm 9999) | 334 (\pm 9999) | 260 (\pm 9999) |
|--------------------------------------|------------------|-------------------|-------------------|-------------------|

| | | | | |
|--------------------------------------|--|---|---|--|
| End point values | Parts 1 and 2: Intermittent/continuous pemigatinib 9 mg QD | Parts 1 and 2: Intermittent/continuous pemigatinib 13.5 mg QD | Parts 1 and 2: Intermittent/continuous pemigatinib 20 mg QD | |
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 18 | 57 | 13 | |
| Units: Liters | | | | |
| arithmetic mean (standard deviation) | 246 (\pm 76.1) | 274 (\pm 165) | 180 (\pm 49.1) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Parts 1 and 2: Accumulation ratio after once daily dosing of pemigatinib as monotherapy on Cycle 1 Days 8 and 14 (steady state)

| | |
|-----------------|---|
| End point title | Parts 1 and 2: Accumulation ratio after once daily dosing of pemigatinib as monotherapy on Cycle 1 Days 8 and 14 (steady state) ^[22] |
|-----------------|---|

End point description:

The accumulation ratio was defined as the ratio of the accumulation of a drug under steady-state conditions as compared to a single dose. 9999 denotes that a standard deviation was not calculated for a single participant.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14.
Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

Notes:

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted.

| | | | | |
|--------------------------------------|--|--|--|--|
| End point values | Part 1: Intermittent pemigatinib 6 mg QD | Part 1: Intermittent pemigatinib 1 mg QD | Part 1: Intermittent pemigatinib 2 mg QD | Part 1: Intermittent pemigatinib 4 mg QD |
| Subject group type | Reporting group | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 4 | 1 | 1 | 1 |
| Units: ratio | | | | |
| arithmetic mean (standard deviation) | 1.67 (\pm 0.264) | 1.09 (\pm 9999) | 1.64 (\pm 9999) | 1.36 (\pm 9999) |

| | | | | |
|-------------------------|--|---|---|--|
| End point values | Parts 1 and 2: Intermittent/continuous pemigatinib 9 mg QD | Parts 1 and 2: Intermittent/continuous pemigatinib 13.5 mg QD | Parts 1 and 2: Intermittent/continuous pemigatinib 20 mg QD | |
|-------------------------|--|---|---|--|

| | | | | |
|--------------------------------------|----------------------|----------------------|----------------------|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 18 | 57 | 13 | |
| Units: ratio | | | | |
| arithmetic mean (standard deviation) | 1.71 (\pm 0.534) | 1.69 (\pm 0.538) | 1.76 (\pm 0.476) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Parts 1 and 2: Cmax steady state following administration of pemigatinib in the fasted (Cycle 1 Day 14) and fed (Cycle 2 Day 14) states

| | |
|------------------------|---|
| End point title | Parts 1 and 2: Cmax steady state following administration of pemigatinib in the fasted (Cycle 1 Day 14) and fed (Cycle 2 Day 14) states |
| End point description: | Cmax was defined as the maximum observed plasma concentration. |
| End point type | Secondary |
| End point timeframe: | Cycles 1 and 2: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Day 14 |

| | | | | |
|--------------------------------------|--|---|--|--|
| End point values | Part 2: intermittent/continuous pemigatinib 13.5 mg QD, fasted | Part 2: intermittent/continuous pemigatinib 13.5 mg QD, fed | | |
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 12 | 12 | | |
| Units: ng/mL | | | | |
| arithmetic mean (standard deviation) | 215 (\pm 86.5) | 179 (\pm 82.8) | | |

Statistical analyses

| | |
|---|--|
| Statistical analysis title | crossover ANOVA of log-transformed data |
| Comparison groups | Part 2: intermittent/continuous pemigatinib 13.5 mg QD, fasted v Part 2: intermittent/continuous pemigatinib 13.5 mg QD, fed |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.143 |
| Method | ANOVA |

Secondary: Parts 1 and 2: tmax steady state following administration of pemigatinib

in the fasted (Cycle 1 Day 14) and fed (Cycle 2 Day 14) states

| | |
|------------------------|---|
| End point title | Parts 1 and 2: tmax steady state following administration of pemigatinib in the fasted (Cycle 1 Day 14) and fed (Cycle 2 Day 14) states |
| End point description: | tmax was defined as the time to the maximum observed plasma concentration. |
| End point type | Secondary |
| End point timeframe: | Cycles 1 and 2: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Day 14 |

| | | | | |
|-------------------------------|--|---|--|--|
| End point values | Part 2: intermittent/continuous pemigatinib 13.5 mg QD, fasted | Part 2: intermittent/continuous pemigatinib 13.5 mg QD, fed | | |
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 12 | 12 | | |
| Units: hr | | | | |
| median (full range (min-max)) | 1.58 (0.500 to 5.78) | 4.02 (1.00 to 7.58) | | |

Statistical analyses

| | |
|---|--|
| Statistical analysis title | crossover ANOVA of log-transformed data |
| Comparison groups | Part 2: intermittent/continuous pemigatinib 13.5 mg QD, fasted v Part 2: intermittent/continuous pemigatinib 13.5 mg QD, fed |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.0013 |
| Method | ANOVA |

Secondary: Parts 1 and 2: t1/2 steady state following administration of pemigatinib in the fasted (Cycle 1 Day 14) and fed (Cycle 2 Day 14) states

| | |
|------------------------|---|
| End point title | Parts 1 and 2: t1/2 steady state following administration of pemigatinib in the fasted (Cycle 1 Day 14) and fed (Cycle 2 Day 14) states |
| End point description: | t1/2 was defined as the apparent plasma terminal phase disposition half-life. |
| End point type | Secondary |
| End point timeframe: | Cycles 1 and 2: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Day 14 |

| | | | | |
|--------------------------------------|--|---|--|--|
| End point values | Part 2: intermittent/continuous pemigatinib 13.5 mg QD, fasted | Part 2: intermittent/continuous pemigatinib 13.5 mg QD, fed | | |
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 12 | 12 | | |
| Units: hr | | | | |
| arithmetic mean (standard deviation) | 19.2 (± 10.5) | 23.8 (± 17.5) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | crossover ANOVA of log-transformed data |
| Comparison groups | Part 2: intermittent/continuous pemigatinib 13.5 mg QD, fasted v Part 2: intermittent/continuous pemigatinib 13.5 mg QD, fed |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.319 |
| Method | ANOVA |

Secondary: Parts 1 and 2: Cmin steady state following administration of pemigatinib in the fasted (Cycle 1 Day 14) and fed (Cycle 2 Day 14) states

| | |
|------------------------|---|
| End point title | Parts 1 and 2: Cmin steady state following administration of pemigatinib in the fasted (Cycle 1 Day 14) and fed (Cycle 2 Day 14) states |
| End point description: | Cmin was defined as the minimum observed plasma concentration over the dose interval. |
| End point type | Secondary |
| End point timeframe: | Cycles 1 and 2: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Day 14 |

| | | | | |
|--------------------------------------|--|---|--|--|
| End point values | Part 2: intermittent/continuous pemigatinib 13.5 mg QD, fasted | Part 2: intermittent/continuous pemigatinib 13.5 mg QD, fed | | |
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 12 | 12 | | |
| Units: ng/mL | | | | |
| arithmetic mean (standard deviation) | 61.1 (± 33.5) | 65.7 (± 34.7) | | |

Statistical analyses

| | |
|---|--|
| Statistical analysis title | crossover ANOVA of log-transformed data |
| Comparison groups | Part 2: intermittent/continuous pemigatinib 13.5 mg QD, fasted v Part 2: intermittent/continuous pemigatinib 13.5 mg QD, fed |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.128 |
| Method | ANOVA |

Secondary: Parts 1 and 2: AUC0-24 steady state following administration of pemigatinib in the fasted (Cycle 1 Day 14) and fed (Cycle 2 Day 14) states

| | |
|------------------------|--|
| End point title | Parts 1 and 2: AUC0-24 steady state following administration of pemigatinib in the fasted (Cycle 1 Day 14) and fed (Cycle 2 Day 14) states |
| End point description: | AUC0-24 was defined as the area under the plasma or serum concentration-time curve from time 0 to 24 hours post-dose. |
| End point type | Secondary |
| End point timeframe: | Cycles 1 and 2: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Day 14 |

| End point values | Part 2: intermittent/co ntinuous pemigatinib 13.5 mg QD, fasted | Part 2: intermittent/co ntinuous pemigatinib 13.5 mg QD, fed | | |
|--------------------------------------|--|---|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 12 | 12 | | |
| Units: hr*ng/mL | | | | |
| arithmetic mean (standard deviation) | 2580 (± 999) | 2910 (± 1310) | | |

Statistical analyses

| | |
|-----------------------------------|--|
| Statistical analysis title | crossover ANOVA of log-transformed data |
| Comparison groups | Part 2: intermittent/continuous pemigatinib 13.5 mg QD, fasted v Part 2: intermittent/continuous pemigatinib 13.5 mg QD, fed |

| | |
|---|---------------|
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.305 |
| Method | ANOVA |

Secondary: Parts 1 and 2: CL/F steady state following administration of pemigatinib in the fasted (Cycle 1 Day 14) and fed (Cycle 2 Day 14) states

| | |
|------------------------|---|
| End point title | Parts 1 and 2: CL/F steady state following administration of pemigatinib in the fasted (Cycle 1 Day 14) and fed (Cycle 2 Day 14) states |
| End point description: | CL/F was defined as the apparent oral dose clearance. |
| End point type | Secondary |
| End point timeframe: | Cycles 1 and 2: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Day 14 |

| End point values | Part 2: intermittent/co ntinuous pemigatinib 13.5 mg QD, fasted | Part 2: intermittent/co ntinuous pemigatinib 13.5 mg QD, fed | | |
|--------------------------------------|--|---|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 12 | 12 | | |
| Units: L/hr | | | | |
| arithmetic mean (standard deviation) | 12.4 (± 4.94) | 11.3 (± 4.87) | | |

Statistical analyses

| | |
|---|--|
| Statistical analysis title | crossover ANOVA of log-transformed data |
| Comparison groups | Part 2: intermittent/continuous pemigatinib 13.5 mg QD, fasted v Part 2: intermittent/continuous pemigatinib 13.5 mg QD, fed |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.305 |
| Method | ANOVA |

Secondary: Parts 1 and 2: Vz/F steady state following administration of pemigatinib in the fasted (Cycle 1 Day 14) and fed (Cycle 2 Day 14) states

| | |
|-----------------|---|
| End point title | Parts 1 and 2: Vz/F steady state following administration of pemigatinib in the fasted (Cycle 1 Day 14) and fed (Cycle 2 Day 14) states |
|-----------------|---|

End point description:

V_z/F was defined as the apparent volume of distribution.

End point type Secondary

End point timeframe:

Cycles 1 and 2: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Day 14

| End point values | Part 2: intermittent/continuous pemigatinib 13.5 mg QD, fasted | Part 2: intermittent/continuous pemigatinib 13.5 mg QD, fed | | |
|--------------------------------------|--|---|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 12 | 12 | | |
| Units: Liters | | | | |
| arithmetic mean (standard deviation) | 307 (± 139) | 364 (± 262) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | crossover ANOVA of log-transformed data |
| Comparison groups | Part 2: intermittent/continuous pemigatinib 13.5 mg QD, fasted v Part 2: intermittent/continuous pemigatinib 13.5 mg QD, fed |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.772 |
| Method | ANOVA |

Secondary: Part 3: C_{max} of pemigatinib as part of combination therapy on Cycle 1 Day 1

End point title Part 3: C_{max} of pemigatinib as part of combination therapy on Cycle 1 Day 1^[23]

End point description:

C_{max} was defined as the maximum observed plasma concentration.

End point type Secondary

End point timeframe:

predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 1

Notes:

[23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted.

| End point values | Part 3: Gem/Cis/intermittent pemigatinib 13.5 mg | Part 3: Tras/intermittent pemigatinib 13.5 mg | Part 3: Doc/intermittent pemigatinib 13.5 mg | Part 3: Pem/intermittent pemigatinib 9 mg |
|--------------------------------------|---|--|---|--|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 7 | 6 | 7 | 3 |
| Units: ng/mL | | | | |
| arithmetic mean (standard deviation) | 234 (± 84.1) | 259 (± 55.4) | 214 (± 98.2) | 137 (± 65.7) |

| End point values | Part 3: Pem/intermittent pemigatinib 13.5 mg | | | |
|--------------------------------------|---|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 19 | | | |
| Units: ng/mL | | | | |
| arithmetic mean (standard deviation) | 199 (± 99.6) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Part 3: tmax of pemigatinib as part of combination therapy on Cycle 1 Day 1

| | |
|-----------------|---|
| End point title | Part 3: tmax of pemigatinib as part of combination therapy on Cycle 1 Day 1 ^[24] |
|-----------------|---|

End point description:

tmax was defined as the time to the maximum observed plasma concentration.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 1

Notes:

[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted.

| End point values | Part 3: Gem/Cis/intermittent pemigatinib 13.5 mg | Part 3: Tras/intermittent pemigatinib 13.5 mg | Part 3: Doc/intermittent pemigatinib 13.5 mg | Part 3: Pem/intermittent pemigatinib 9 mg |
|-------------------------------|---|--|---|--|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 7 | 6 | 7 | 3 |
| Units: hr | | | | |
| median (full range (min-max)) | 2.00 (0.500 to 22.6) | 0.783 (0.500 to 18.6) | 1.00 (0.500 to 3.98) | 1.98 (1.00 to 4.00) |

| | | | | |
|-------------------------------|--|--|--|--|
| End point values | Part 3: Pem/intermittent pemigatinib 13.5 mg | | | |
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 19 | | | |
| Units: hr | | | | |
| median (full range (min-max)) | 1.05 (0.500 to 23.4) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Part 3: AUClast of pemigatinib as part of combination therapy on Cycle 1 Day 1

| | |
|------------------------|--|
| End point title | Part 3: AUClast of pemigatinib as part of combination therapy on Cycle 1 Day 1 ^[25] |
| End point description: | AUClast was defined as the area under the plasma or serum concentration-time curve from the time of dosing to the last measurable concentration. |
| End point type | Secondary |
| End point timeframe: | predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 1 |

Notes:

[25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted.

| | | | | |
|--------------------------------------|--|---|--|---|
| End point values | Part 3: Gem/Cis/intermittent pemigatinib 13.5 mg | Part 3: Tras/intermittent pemigatinib 13.5 mg | Part 3: Doc/intermittent pemigatinib 13.5 mg | Part 3: Pem/intermittent pemigatinib 9 mg |
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 7 | 6 | 7 | 3 |
| Units: hr*ng/mL | | | | |
| arithmetic mean (standard deviation) | 2890 (± 1010) | 2040 (± 513) | 1890 (± 491) | 1480 (± 587) |

| | | | | |
|--------------------------------------|--|--|--|--|
| End point values | Part 3: Pem/intermittent pemigatinib 13.5 mg | | | |
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 19 | | | |
| Units: hr*ng/mL | | | | |
| arithmetic mean (standard deviation) | 1880 (± 821) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Part 3: AUC0-24 of pemigatinib as part of combination therapy on Cycle 1 Day 1

| | |
|-----------------|--|
| End point title | Part 3: AUC0-24 of pemigatinib as part of combination therapy on Cycle 1 Day 1 ^[26] |
|-----------------|--|

End point description:

AUC0-24 was defined as the area under the plasma or serum concentration-time curve from time 0 to 24 hours post-dose.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 1

Notes:

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted.

| End point values | Part 3: Gem/Cis/intermittent pemigatinib 13.5 mg | Part 3: Tras/intermittent pemigatinib 13.5 mg | Part 3: Doc/intermittent pemigatinib 13.5 mg | Part 3: Pem/intermittent pemigatinib 9 mg |
|--------------------------------------|--|---|--|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 7 | 6 | 7 | 3 |
| Units: hr*ng/mL | | | | |
| arithmetic mean (standard deviation) | 2920 (± 1070) | 1890 (± 269) | 1890 (± 471) | 1550 (± 552) |

| End point values | Part 3: Pem/intermittent pemigatinib 13.5 mg | | | |
|--------------------------------------|--|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 19 | | | |
| Units: hr*ng/mL | | | | |
| arithmetic mean (standard deviation) | 1910 (± 838) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Part 3: Cmax of pemigatinib as part of combination therapy on Cycle 1 Day 14 (steady state)

| | |
|-----------------|---|
| End point title | Part 3: Cmax of pemigatinib as part of combination therapy on Cycle 1 Day 14 (steady state) ^[27] |
|-----------------|---|

End point description:

Cmax was defined as the maximum observed plasma concentration.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

Notes:

[27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted.

| End point values | Part 3: Gem/Cis/intermittent pemigatinib 13.5 mg | Part 3: Tras/intermittent pemigatinib 13.5 mg | Part 3: Doc/intermittent pemigatinib 13.5 mg | Part 3: Pem/intermittent pemigatinib 9 mg |
|--------------------------------------|---|--|---|--|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 4 | 5 | 5 | 3 |
| Units: ng/mL | | | | |
| arithmetic mean (standard deviation) | 214 (± 203) | 404 (± 41.7) | 231 (± 99.4) | 166 (± 52.1) |

| End point values | Part 3: Pem/intermittent pemigatinib 13.5 mg | | | |
|--------------------------------------|---|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 14 | | | |
| Units: ng/mL | | | | |
| arithmetic mean (standard deviation) | 255 (± 119) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Part 3: tmax of pemigatinib as part of combination therapy on Cycle 1 Day 14 (steady state)

| | |
|-----------------|---|
| End point title | Part 3: tmax of pemigatinib as part of combination therapy on Cycle 1 Day 14 (steady state) ^[28] |
|-----------------|---|

End point description:

tmax was defined as the time to the maximum observed plasma concentration.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

Notes:

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted.

| End point values | Part 3: Gem/Cis/intermittent pemigatinib 13.5 mg | Part 3: Tras/intermittent pemigatinib 13.5 mg | Part 3: Doc/intermittent pemigatinib 13.5 mg | Part 3: Pem/intermittent pemigatinib 9 mg |
|-------------------------------|---|--|---|--|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 4 | 5 | 5 | 3 |
| Units: hr | | | | |
| median (full range (min-max)) | 1.50 (0.950 to 4.00) | 0.583 (0.500 to 1.07) | 1.90 (0.500 to 2.08) | 5.78 (1.25 to 6.08) |

| End point values | Part 3: Pem/intermittent pemigatinib 13.5 mg | | | |
|-------------------------------|---|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 14 | | | |
| Units: hr | | | | |
| median (full range (min-max)) | 1.08 (0.500 to 7.98) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Part 3: t_{1/2} of pemigatinib as part of combination therapy on Cycle 1 Day 14 (steady state)

| | |
|-----------------|---|
| End point title | Part 3: t _{1/2} of pemigatinib as part of combination therapy on Cycle 1 Day 14 (steady state) ^[29] |
|-----------------|---|

End point description:

t_{1/2} was defined as the apparent plasma terminal phase disposition half-life. 9999 denotes that a standard deviation was not calculated for a single participant.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

Notes:

[29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted.

| End point values | Part 3: Gem/Cis/intermittent pemigatinib 13.5 mg | Part 3: Tras/intermittent pemigatinib 13.5 mg | Part 3: Doc/intermittent pemigatinib 13.5 mg | Part 3: Pem/intermittent pemigatinib 9 mg |
|--------------------------------------|---|--|---|--|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 4 | 5 | 5 | 3 |
| Units: hr | | | | |
| arithmetic mean (standard deviation) | 10.6 (± 3.29) | 15.3 (± 2.64) | 14.7 (± 6.43) | 15.3 (± 0.207) |

| | | | | |
|--------------------------------------|--|--|--|--|
| End point values | Part 3: Pem/intermittent pemigatinib 13.5 mg | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 14 | | | |
| Units: hr | | | | |
| arithmetic mean (standard deviation) | 17.0 (± 6.90) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Part 3: Cmin of pemigatinib as part of combination therapy on Cycle 1 Day 14 (steady state)

| | |
|-----------------|---|
| End point title | Part 3: Cmin of pemigatinib as part of combination therapy on Cycle 1 Day 14 (steady state) ^[30] |
|-----------------|---|

End point description:

Cmin was defined as the minimum observed plasma concentration over the dose interval.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

Notes:

[30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted.

| | | | | |
|--------------------------------------|--|---|--|---|
| End point values | Part 3: Gem/Cis/intermittent pemigatinib 13.5 mg | Part 3: Tras/intermittent pemigatinib 13.5 mg | Part 3: Doc/intermittent pemigatinib 13.5 mg | Part 3: Pem/intermittent pemigatinib 9 mg |
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 4 | 5 | 5 | 3 |
| Units: ng/mL | | | | |
| arithmetic mean (standard deviation) | 48.5 (± 57.8) | 64.2 (± 25.8) | 63.1 (± 32.4) | 58.0 (± 31.6) |

| | | | | |
|--------------------------------------|--|--|--|--|
| End point values | Part 3: Pem/intermittent pemigatinib 13.5 mg | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 14 | | | |
| Units: ng/mL | | | | |
| arithmetic mean (standard deviation) | 56.6 (± 31.3) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Part 3: AUC0-24 of pemigatinib as part of combination therapy on Cycle 1 Day 14 (steady state)

| | |
|-----------------|--|
| End point title | Part 3: AUC0-24 of pemigatinib as part of combination therapy on Cycle 1 Day 14 (steady state) ^[31] |
|-----------------|--|

End point description:

AUC0-24 was defined as the area under the plasma or serum concentration-time curve from time 0 to 24 hours post-dose.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

Notes:

[31] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted.

| End point values | Part 3: Gem/Cis/intermittent pemigatinib 13.5 mg | Part 3: Tras/intermittent pemigatinib 13.5 mg | Part 3: Doc/intermittent pemigatinib 13.5 mg | Part 3: Pem/intermittent pemigatinib 9 mg |
|--------------------------------------|--|---|--|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 4 | 5 | 5 | 3 |
| Units: hr*ng/mL | | | | |
| arithmetic mean (standard deviation) | 1650 (± 1060) | 3440 (± 672) | 2910 (± 1390) | 2400 (± 628) |

| End point values | Part 3: Pem/intermittent pemigatinib 13.5 mg | | | |
|--------------------------------------|--|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 14 | | | |
| Units: hr*ng/mL | | | | |
| arithmetic mean (standard deviation) | 2400 (± 967) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Part 3: CL/F of pemigatinib as part of combination therapy on Cycle 1 Day 14 (steady state)

| | |
|-----------------|---|
| End point title | Part 3: CL/F of pemigatinib as part of combination therapy on Cycle 1 Day 14 (steady state) ^[32] |
|-----------------|---|

End point description:

CL/F was defined as the apparent oral dose clearance.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

Notes:

[32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted.

| End point values | Part 3: Gem/Cis/intermittent pemigatinib 13.5 mg | Part 3: Tras/intermittent pemigatinib 13.5 mg | Part 3: Doc/intermittent pemigatinib 13.5 mg | Part 3: Pem/intermittent pemigatinib 9 mg |
|--------------------------------------|--|---|--|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 4 | 5 | 5 | 3 |
| Units: L/hr | | | | |
| arithmetic mean (standard deviation) | 24.5 (± 17.7) | 8.26 (± 1.39) | 12.7 (± 9.03) | 8.03 (± 1.89) |

| End point values | Part 3: Pem/intermittent pemigatinib 13.5 mg | | | |
|--------------------------------------|--|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 14 | | | |
| Units: L/hr | | | | |
| arithmetic mean (standard deviation) | 13.4 (± 5.46) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Part 3: Vz/F of pemigatinib as part of combination therapy on Cycle 1 Day 14 (steady state)

| | |
|-----------------|---|
| End point title | Part 3: Vz/F of pemigatinib as part of combination therapy on Cycle 1 Day 14 (steady state) ^[33] |
|-----------------|---|

End point description:

Vz/F was defined as the apparent volume of distribution.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

Notes:

[33] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted.

| End point values | Part 3: Gem/Cis/intermittent pemigatinib 13.5 mg | Part 3: Tras/intermittent pemigatinib 13.5 mg | Part 3: Doc/intermittent pemigatinib 13.5 mg | Part 3: Pem/intermittent pemigatinib 9 mg |
|--------------------------------------|---|--|---|--|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 4 | 5 | 5 | 3 |
| Units: Liters | | | | |
| arithmetic mean (standard deviation) | 376 (± 261) | 182 (± 43.2) | 227 (± 82.2) | 177 (± 39.8) |

| End point values | Part 3: Pem/intermittent pemigatinib 13.5 mg | | | |
|--------------------------------------|---|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 14 | | | |
| Units: Liters | | | | |
| arithmetic mean (standard deviation) | 303 (± 136) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Part 3: Accumulation ratio of pemigatinib as part of combination therapy on Cycle 1 Day 14 (steady state)

| | |
|-----------------|---|
| End point title | Part 3: Accumulation ratio of pemigatinib as part of combination therapy on Cycle 1 Day 14 (steady state) ^[34] |
|-----------------|---|

End point description:

The accumulation ratio was defined as the ratio of the accumulation of a drug under steady-state conditions as compared to a single dose.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

Notes:

[34] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted.

| End point values | Part 3: Gem/Cis/intermittent pemigatinib 13.5 mg | Part 3: Tras/intermittent pemigatinib 13.5 mg | Part 3: Doc/intermittent pemigatinib 13.5 mg | Part 3: Pem/intermittent pemigatinib 9 mg |
|--------------------------------------|---|--|---|--|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 4 | 5 | 5 | 3 |
| Units: ratio | | | | |
| arithmetic mean (standard deviation) | 0.604 (± 0.265) | 1.90 (± 0.432) | 1.52 (± 0.772) | 1.65 (± 0.501) |

| End point values | Part 3: Pem/intermittent pemigatinib 13.5 mg | | | |
|--------------------------------------|---|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 14 | | | |
| Units: ratio | | | | |
| arithmetic mean (standard deviation) | 1.53 (± 0.381) | | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

up to 869 days

Adverse event reporting additional description:

Treatment-emergent adverse events (TEAEs), defined as adverse events either reported for the first time or the worsening of pre-existing events after the first dose of study drug and within 30 days of the last dose of study drug, are reported for all enrolled participants who received at least 1 dose of study drug (Safety Population).

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|----|
| Dictionary version | 24 |
|--------------------|----|

Reporting groups

| | |
|-----------------------|--|
| Reporting group title | Part 1: Intermittent pemigatinib 1/2/4 mg QD |
|-----------------------|--|

Reporting group description:

Participants self-administered oral pemigatinib 1/2/4 milligrams (mg) once daily (QD) on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.

| | |
|-----------------------|--|
| Reporting group title | Part 1: Intermittent pemigatinib 6 mg QD |
|-----------------------|--|

Reporting group description:

Participants self-administered oral pemigatinib 6 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.

| | |
|-----------------------|---|
| Reporting group title | Parts 1 and 2: Intermittent pemigatinib 9 mg QD |
|-----------------------|---|

Reporting group description:

Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in either Part 1 or Part 2. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.

| | |
|-----------------------|--|
| Reporting group title | Parts 1 and 2: Intermittent pemigatinib 13.5 mg QD |
|-----------------------|--|

Reporting group description:

Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in either Part 1 or Part 2. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.

| | |
|-----------------------|---|
| Reporting group title | Part 1: Intermittent pemigatinib 20 mg QD |
|-----------------------|---|

Reporting group description:

Participants self-administered oral pemigatinib 20 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.

| | |
|-----------------------|---|
| Reporting group title | Parts 1 and 2: Continuous pemigatinib 9 mg QD |
|-----------------------|---|

Reporting group description:

Participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle in either Part 1 or Part 2.

| | |
|-----------------------|--|
| Reporting group title | Parts 1 and 2: Continuous pemigatinib 13.5 mg QD |
|-----------------------|--|

Reporting group description:

Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle in either Part 1 or Part 2.

| | |
|-----------------------|--|
| Reporting group title | Parts 1 and 2: Continuous pemigatinib 20 mg QD |
|-----------------------|--|

Reporting group description:

Participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle in either Part 1 or Part 2.

| | |
|-----------------------|---|
| Reporting group title | Part 1: Continuous pemigatinib 7.5 mg BID |
|-----------------------|---|

Reporting group description:

Participants self-administered oral pemigatinib 7.5 mg twice daily (BID) on Days 1 through 21 of each

21-day cycle.

| | |
|-----------------------|--|
| Reporting group title | Part 1: Continuous pemigatinib 10 mg BID |
|-----------------------|--|

Reporting group description:

Participants self-administered oral pemigatinib 10 mg BID on Days 1 through 21 of each 21-day cycle.

| | |
|-----------------------|---|
| Reporting group title | Part 3: Gem/Cis/intermittent pemigatinib 9 mg |
|-----------------------|---|

Reporting group description:

Participants received gemcitabine (Gem) intravenously starting at 1000 mg/meters squared (m^2) on Days 1 and 8 of each 21-day cycle. Cisplatin (Cis) was administered intravenously starting at 70 mg/ m^2 once every 3 weeks on Day 1 of each 21-day cycle. Both gemcitabine and cisplatin doses could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued chemotherapy with medical monitor approval. Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of gemcitabine/cisplatin

| | |
|-----------------------|--|
| Reporting group title | Part 3: Gem/Cis/intermittent pemigatinib 13.5 mg |
|-----------------------|--|

Reporting group description:

Participants received gemcitabine intravenously starting at 1000 mg/ m^2 on Days 1 and 8 of each 21-day cycle. Cisplatin was administered intravenously starting at 70 mg/ m^2 once every 3 weeks on Day 1 of each 21-day cycle. Both gemcitabine and cisplatin doses could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued chemotherapy with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of gemcitabine/cisplatin.

| | |
|-----------------------|---|
| Reporting group title | Part 3: Tras/intermittent pemigatinib 13.5 mg |
|-----------------------|---|

Reporting group description:

Trastuzumab (Tras) was administered as an open-label, commercial product at an initial intravenous dose of 8 mg/kilograms (kg), followed by 6 mg/kg intravenously once every 3 weeks. The dose could have been adjusted for toxicity management, per commercial labeling. The investigator could have interrupted, modified, or discontinued trastuzumab with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of trastuzumab.

| | |
|-----------------------|--|
| Reporting group title | Part 3: Doc/intermittent pemigatinib 13.5 mg |
|-----------------------|--|

Reporting group description:

Participants received docetaxel (Doc) intravenously starting at 75 mg/ m^2 once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued chemotherapy with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of docetaxel.

| | |
|-----------------------|---|
| Reporting group title | Part 3: Pem/intermittent pemigatinib 9 mg |
|-----------------------|---|

Reporting group description:

Participants received pembrolizumab (Pem) intravenously at 200 mg once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued pembrolizumab with medical monitor approval. Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of pembrolizumab.

| | |
|-----------------------|--|
| Reporting group title | Part 3: Pem/intermittent pemigatinib 13.5 mg |
|-----------------------|--|

Reporting group description:

Participants received pembrolizumab intravenously at 200 mg once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued pembrolizumab with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of pembrolizumab.

| | |
|-----------------------|--|
| Reporting group title | Part 3: Pem/continuous pemigatinib 13.5 mg |
|-----------------------|--|

Reporting group description:

Participants received pembrolizumab intravenously at 200 mg once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued pembrolizumab with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle. It was permissible to continue pemigatinib administration during the toxicity break of pembrolizumab.

| | |
|-----------------------|---|
| Reporting group title | Part 3: Ref/continuous pemigatinib 9 mg |
|-----------------------|---|

Reporting group description:

Retifanlimab (Ref) was administered once every 4 weeks on a 28-day cycle as an open-label product, at an initial intravenous dose of 500 mg. Participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle.

| | |
|-----------------------|--|
| Reporting group title | Part 3: Ref/continuous pemigatinib 13.5 mg |
|-----------------------|--|

Reporting group description:

Retifanlimab was administered once every 4 weeks on a 28-day cycle as an open-label product, at an initial intravenous dose of 500 mg. Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle.

| | |
|-----------------------|--|
| Reporting group title | Part 3: Ref/continuous pemigatinib 20 mg |
|-----------------------|--|

Reporting group description:

Retifanlimab was administered once every 4 weeks on a 28-day cycle as an open-label product, at an initial intravenous dose of 500 mg. Participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle.

| Serious adverse events | Part 1: Intermittent pemigatinib 1/2/4 mg QD | Part 1: Intermittent pemigatinib 6 mg QD | Parts 1 and 2: Intermittent pemigatinib 9 mg QD |
|---|--|--|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 4 (0.00%) | 3 / 7 (42.86%) |
| number of deaths (all causes) | 3 | 2 | 6 |
| number of deaths resulting from adverse events | 1 | 0 | 0 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Metastases to central nervous system | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastases to spine | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastatic neoplasm | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|----------------|---------------|---------------|
| Vascular disorders | | | |
| Haemorrhage | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypertension | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypotension | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Shock | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Disease progression | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Facial pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fatigue | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---------------|---------------|---------------|
| Hypothermia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mucosal inflammation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Multiple organ dysfunction syndrome | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oedema | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Systemic inflammatory response syndrome | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |

| | | | |
|---|---------------|---------------|---------------|
| Acute respiratory failure | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic obstructive pulmonary disease | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypoxia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumothorax | | | |

| | | | |
|---|---------------|---------------|---------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory failure | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Completed suicide | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mental status changes | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Product issues | | | |
| Device occlusion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---------------|---------------|---------------|
| Blood creatinine increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood osmolarity decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Clostridium test positive | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Troponin I | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Alcohol poisoning | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fall | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Femur fracture | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Procedural pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|----------------|---------------|---------------|
| Spinal compression fracture subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Atrial fibrillation subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrial flutter subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrial thrombosis subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac arrest subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac tamponade subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Cerebrovascular accident subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Depressed level of consciousness subjects affected / exposed | 1 / 3 (33.33%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---------------|---------------|---------------|
| Dizziness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dysarthria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemorrhage intracranial | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hydrocephalus | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myoclonus | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Seizure | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Febrile neutropenia | | | |

| | | | |
|---|---------------|---------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neutropenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Constipation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dysphagia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Enterocolitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal haemorrhage | | | |

| | | | |
|---|---------------|---------------|---------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Large intestinal obstruction | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oesophagitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal obstruction | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Upper gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Varices oesophageal | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting | | | |

| | | | |
|---|---------------|---------------|---------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Cholangitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperbilirubinaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Erythema | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal failure | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Endocrine disorders | | | |
| Hypothyroidism | | | |

| | | | |
|---|---------------|---------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Inappropriate antidiuretic hormone secretion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fistula | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Flank pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pathological fracture | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vertebral osteophyte | | | |

| | | | |
|---|---------------|---------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic sinusitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Clostridium difficile infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Device related infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Escherichia bacteraemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Meningitis bacterial | | | |

| | | | |
|---|---------------|---------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oesophageal candidiasis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Paronychia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 2 / 7 (28.57%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sepsis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urosepsis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |

| | | | |
|---|---------------|---------------|---------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Electrolyte imbalance | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypophagia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolic alkalosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Parts 1 and 2: Intermittent pemigatinib 13.5 mg QD | Part 1: Intermittent pemigatinib 20 mg QD | Parts 1 and 2: Continuous pemigatinib 9 mg QD |
|--|---|---|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 21 / 50 (42.00%) | 3 / 6 (50.00%) | 6 / 14 (42.86%) |
| number of deaths (all causes) | 37 | 6 | 10 |
| number of deaths resulting from adverse events | 4 | 1 | 1 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Metastases to central nervous system | | | |

| | | | |
|---|----------------|---------------|----------------|
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastases to spine | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastatic neoplasm | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Haemorrhage | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypertension | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypotension | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Shock | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Disease progression | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |

| | | | |
|---|----------------|---------------|----------------|
| Facial pain | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fatigue | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypothermia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mucosal inflammation | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Multiple organ dysfunction syndrome | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oedema | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oedema peripheral | | | |

| | | | |
|--|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyrexia | | | |
| subjects affected / exposed | 2 / 50 (4.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Systemic inflammatory response syndrome | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Acute respiratory failure | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Chronic obstructive pulmonary disease | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypoxia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|----------------|----------------|----------------|
| Pleural effusion | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory failure | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Psychiatric disorders | | | |
| Completed suicide | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mental status changes | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Product issues | | | |

| | | | |
|---|----------------|---------------|----------------|
| Device occlusion subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Blood alkaline phosphatase increased subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood bilirubin increased subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood creatinine increased subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood osmolarity decreased subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Clostridium test positive subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Troponin I subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Alcohol poisoning subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|----------------|---------------|----------------|
| Fall | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Femur fracture | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Procedural pain | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal compression fracture | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Atrial fibrillation | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrial flutter | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrial thrombosis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac arrest | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac tamponade | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Depressed level of consciousness | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dizziness | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dysarthria | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemorrhage intracranial | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Hydrocephalus | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myoclonus | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Seizure | | | |

| | | | |
|---|----------------|---------------|----------------|
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Febrile neutropenia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neutropenia | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 2 / 50 (4.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Constipation | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea | | | |

| | | | |
|---|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dysphagia | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Enterocolitis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Large intestinal obstruction | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oesophagitis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal obstruction | | | |

| | | | |
|---|----------------|---------------|----------------|
| subjects affected / exposed | 2 / 50 (4.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Upper gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Varices oesophageal | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Vomiting | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Cholangitis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperbilirubinaemia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Erythema | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|----------------|---------------|----------------|
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal failure | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Endocrine disorders | | | |
| Hypothyroidism | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Inappropriate antidiuretic hormone secretion | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fistula | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Flank pain | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal chest pain | | | |

| | | | |
|---|----------------|---------------|----------------|
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pathological fracture | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vertebral osteophyte | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic sinusitis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Clostridium difficile infection | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Device related infection | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Escherichia bacteraemia | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Meningitis bacterial | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oesophageal candidiasis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Paronychia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 2 / 50 (4.00%) | 1 / 6 (16.67%) | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Sepsis | | | |

| | | | |
|---|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urosepsis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Electrolyte imbalance | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 2 / 50 (4.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypophagia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolic alkalosis | | | |

| | | | |
|---|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Parts 1 and 2: Continuous pemigatinib 13.5 mg QD | Parts 1 and 2: Continuous pemigatinib 20 mg QD | Part 1: Continuous pemigatinib 7.5 mg BID |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 14 / 30 (46.67%) | 7 / 15 (46.67%) | 2 / 4 (50.00%) |
| number of deaths (all causes) | 21 | 10 | 4 |
| number of deaths resulting from adverse events | 2 | 1 | 0 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Metastases to central nervous system | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastases to spine | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastatic neoplasm | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Haemorrhage | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypertension | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypotension | | | |

| | | | |
|--|-----------------|----------------|---------------|
| subjects affected / exposed | 2 / 30 (6.67%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Shock | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Disease progression | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| Facial pain | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fatigue | | | |
| subjects affected / exposed | 3 / 30 (10.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 1 / 3 | 2 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypothermia | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mucosal inflammation | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Multiple organ dysfunction syndrome | | | |

| | | | |
|--|----------------|----------------|---------------|
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oedema | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Systemic inflammatory response syndrome | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Acute respiratory failure | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic obstructive pulmonary disease | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|----------------|----------------|---------------|
| Dyspnoea | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemoptysis | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypoxia | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory failure | | | |

| | | | |
|---|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Completed suicide | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mental status changes | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Product issues | | | |
| Device occlusion | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood osmolarity decreased | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|----------------|----------------|---------------|
| Clostridium test positive | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Troponin I | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Alcohol poisoning | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fall | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Femur fracture | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Procedural pain | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal compression fracture | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Atrial fibrillation | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|----------------|----------------|---------------|
| Atrial flutter | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrial thrombosis | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac arrest | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac tamponade | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Depressed level of consciousness | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dizziness | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dysarthria | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemorrhage intracranial | | | |

| | | | |
|---|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hydrocephalus | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myoclonus | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Seizure | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Febrile neutropenia | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neutropenia | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |

| | | | |
|---|----------------|----------------|----------------|
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Constipation | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dysphagia | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Enterocolitis | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 1 / 4 (25.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Large intestinal obstruction | | | |

| | | | |
|---|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oesophagitis | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal obstruction | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Upper gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Varices oesophageal | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Cholangitis | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperbilirubinaemia | | | |

| | | | |
|--|-----------------|----------------|---------------|
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Erythema | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 3 / 30 (10.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hydronephrosis | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal failure | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Endocrine disorders | | | |
| Hypothyroidism | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Inappropriate antidiuretic hormone secretion | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |

| | | | |
|---|----------------|----------------|---------------|
| subjects affected / exposed | 2 / 30 (6.67%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fistula | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Flank pain | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pain in extremity | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pathological fracture | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vertebral osteophyte | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Bronchitis | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic sinusitis | | | |

| | | | |
|---|----------------|----------------|---------------|
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Clostridium difficile infection | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Device related infection | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Escherichia bacteraemia | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Meningitis bacterial | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oesophageal candidiasis | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Paronychia | | | |

| | | | |
|---|-----------------|----------------|----------------|
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 1 / 15 (6.67%) | 2 / 4 (50.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sepsis | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 3 / 30 (10.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urosepsis | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Electrolyte imbalance | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypercalcaemia | | | |

| | | | |
|---|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypophagia | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolic alkalosis | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Part 1: Continuous pemigatinib 10 mg BID | Part 3: Gem/Cis/intermittent pemigatinib 9 mg | Part 3: Gem/Cis/intermittent pemigatinib 13.5 mg |
|--|--|---|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 2 / 3 (66.67%) | 1 / 1 (100.00%) | 3 / 7 (42.86%) |
| number of deaths (all causes) | 2 | 1 | 7 |
| number of deaths resulting from adverse events | 0 | 0 | 1 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Metastases to central nervous system | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastases to spine | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastatic neoplasm | | | |

| | | | |
|---|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Haemorrhage | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypertension | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypotension | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Shock | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Disease progression | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Facial pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fatigue | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|----------------|---------------|----------------|
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypothermia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mucosal inflammation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Multiple organ dysfunction syndrome | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oedema | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Systemic inflammatory response syndrome | | | |

| | | | |
|--|---------------|---------------|---------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Acute respiratory failure | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic obstructive pulmonary disease | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypoxia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonitis | | | |

| | | | |
|---|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory failure | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Completed suicide | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mental status changes | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 2 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Product issues | | | |
| Device occlusion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---------------|---------------|---------------|
| Blood bilirubin increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood osmolarity decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Clostridium test positive | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Troponin I | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Alcohol poisoning | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fall | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Femur fracture | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---------------|---------------|---------------|
| Procedural pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal compression fracture | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Atrial fibrillation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrial flutter | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrial thrombosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac arrest | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac tamponade | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|----------------|---------------|---------------|
| Depressed level of consciousness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dizziness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dysarthria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemorrhage intracranial | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hydrocephalus | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myoclonus | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Seizure | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |

| | | | |
|---|---------------|-----------------|---------------|
| Anaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Febrile neutropenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 1 (100.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neutropenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Constipation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 1 (100.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dysphagia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Enterocolitis | | | |

| | | | |
|---|---------------|---------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Large intestinal obstruction | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oesophagitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal obstruction | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Upper gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Varices oesophageal | | | |

| | | | |
|---|---------------|---------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Cholangitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperbilirubinaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Erythema | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal failure | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|----------------|---------------|---------------|
| Endocrine disorders | | | |
| Hypothyroidism | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Inappropriate antidiuretic hormone secretion | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fistula | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Flank pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pathological fracture | | | |

| | | | |
|---|---------------|---------------|---------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vertebral osteophyte | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic sinusitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Clostridium difficile infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Device related infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Escherichia bacteraemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Influenza | | | |

| | | | |
|---|---------------|---------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Meningitis bacterial | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oesophageal candidiasis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Paronychia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sepsis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urosepsis | | | |

| | | | |
|---|---------------|---------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Electrolyte imbalance | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 2 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypophagia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolic alkalosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Part 3: Tras/intermittent pemigatinib 13.5 mg | Part 3: Doc/intermittent pemigatinib 13.5 mg | Part 3: Pem/intermittent pemigatinib 9 mg |
|--|---|--|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 6 / 7 (85.71%) | 1 / 3 (33.33%) |
| number of deaths (all causes) | 5 | 5 | 3 |
| number of deaths resulting from | 0 | 1 | 1 |

| adverse events | | | |
|---|---------------|----------------|---------------|
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Metastases to central nervous system | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastases to spine | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastatic neoplasm | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Haemorrhage | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypertension | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypotension | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Shock | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Disease progression | | | |

| | | | |
|---|---------------|----------------|---------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Facial pain | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fatigue | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypothermia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mucosal inflammation | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Multiple organ dysfunction syndrome | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oedema | | | |

| | | | |
|--|---------------|---------------|---------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Systemic inflammatory response syndrome | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Acute respiratory failure | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic obstructive pulmonary disease | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---------------|----------------|----------------|
| Hypoxia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory failure | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Completed suicide | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 1 / 3 (33.33%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Mental status changes | | | |

| | | | |
|---|---------------|---------------|---------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Product issues | | | |
| Device occlusion | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood osmolarity decreased | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Clostridium test positive | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Troponin I | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural | | | |

| | | | |
|---|---------------|---------------|---------------|
| complications | | | |
| Alcohol poisoning | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fall | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Femur fracture | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Procedural pain | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal compression fracture | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Atrial fibrillation | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrial flutter | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrial thrombosis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---------------|----------------|---------------|
| Cardiac arrest | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac tamponade | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Depressed level of consciousness | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dizziness | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dysarthria | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemorrhage intracranial | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hydrocephalus | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myoclonus | | | |

| | | | |
|---|---------------|----------------|---------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Seizure | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Febrile neutropenia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neutropenia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Constipation | | | |

| | | | |
|---|---------------|----------------|---------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dysphagia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Enterocolitis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Large intestinal obstruction | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oesophagitis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectal haemorrhage | | | |

| | | | |
|---|---------------|---------------|---------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal obstruction | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Upper gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Varices oesophageal | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Cholangitis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperbilirubinaemia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Erythema | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |

| | | | |
|---|---------------|----------------|---------------|
| Acute kidney injury | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal failure | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Endocrine disorders | | | |
| Hypothyroidism | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Inappropriate antidiuretic hormone secretion | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fistula | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Flank pain | | | |

| | | | |
|---|---------------|---------------|---------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pathological fracture | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vertebral osteophyte | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic sinusitis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Clostridium difficile infection | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Device related infection | | | |

| | | | |
|---|---------------|----------------|---------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Escherichia bacteraemia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Meningitis bacterial | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Oesophageal candidiasis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Paronychia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |

| | | | |
|---|---------------|----------------|---------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sepsis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urosepsis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 2 / 7 (28.57%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Electrolyte imbalance | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypophagia | | | |

| | | | |
|---|---------------|---------------|---------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolic alkalosis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Part 3: Pem/intermittent pemigatinib 13.5 mg | Part 3: Pem/continuous pemigatinib 13.5 mg | Part 3: Ref/continuous pemigatinib 9 mg |
|---|--|--|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 7 / 14 (50.00%) | 3 / 9 (33.33%) | 4 / 7 (57.14%) |
| number of deaths (all causes) | 9 | 6 | 6 |
| number of deaths resulting from adverse events | 0 | 1 | 0 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Metastases to central nervous system | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastases to spine | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastatic neoplasm | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Haemorrhage | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypertension | | | |

| | | | |
|--|----------------|---------------|----------------|
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypotension | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Shock | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Disease progression | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Facial pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fatigue | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 1 / 7 (14.29%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypothermia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mucosal inflammation | | | |

| | | | |
|--|----------------|---------------|---------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Multiple organ dysfunction syndrome | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oedema | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Systemic inflammatory response syndrome | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Acute respiratory failure | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic obstructive pulmonary | | | |

| | | | |
|---|----------------|---------------|---------------|
| disease | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypoxia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary embolism | | | |

| | | | |
|---|----------------|---------------|---------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory failure | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Completed suicide | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mental status changes | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Product issues | | | |
| Device occlusion | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|----------------|----------------|---------------|
| Blood osmolarity decreased subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Clostridium test positive subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Troponin I subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Alcohol poisoning subjects affected / exposed | 0 / 14 (0.00%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Fall subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Femur fracture subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Procedural pain subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal compression fracture subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|----------------|---------------|---------------|
| Cardiac disorders | | | |
| Atrial fibrillation | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrial flutter | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrial thrombosis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac arrest | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac tamponade | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Depressed level of consciousness | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dizziness | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|----------------|---------------|---------------|
| Dysarthria | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemorrhage intracranial | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hydrocephalus | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myoclonus | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Seizure | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Febrile neutropenia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neutropenia | | | |

| | | | |
|---|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Constipation | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dysphagia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Enterocolitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrooesophageal reflux disease | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Large intestinal obstruction | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oesophagitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal obstruction | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 1 / 7 (14.29%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Upper gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Varices oesophageal | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Cholangitis | | | |

| | | | |
|---|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperbilirubinaemia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Erythema | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 1 / 7 (14.29%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal failure | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Endocrine disorders | | | |
| Hypothyroidism | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 1 / 7 (14.29%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Inappropriate antidiuretic hormone secretion | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 1 / 7 (14.29%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|----------------|----------------|---------------|
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fistula | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Flank pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pathological fracture | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vertebral osteophyte | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|----------------|----------------|---------------|
| Chronic sinusitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Clostridium difficile infection | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Device related infection | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Escherichia bacteraemia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Meningitis bacterial | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oesophageal candidiasis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Paronychia | | | |

| | | | |
|---|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sepsis | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urosepsis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Electrolyte imbalance | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypercalcaemia | | | |

| | | | |
|---|----------------|---------------|---------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypophagia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolic alkalosis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Part 3: Ref/continuous pemigatinib 13.5 mg | Part 3: Ref/continuous pemigatinib 20 mg | |
|--|--|--|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 5 / 9 (55.56%) | 2 / 2 (100.00%) | |
| number of deaths (all causes) | 3 | 0 | |
| number of deaths resulting from adverse events | 1 | 0 | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Metastases to central nervous system | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metastases to spine | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metastatic neoplasm | | | |

| | | | |
|---|----------------|----------------|--|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular disorders | | | |
| Haemorrhage | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypertension | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypotension | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Shock | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General disorders and administration site conditions | | | |
| Disease progression | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Facial pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fatigue | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 2 (50.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|---------------|---------------|--|
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypothermia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mucosal inflammation | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Multiple organ dysfunction syndrome | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oedema | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Systemic inflammatory response syndrome | | | |

| | | | |
|--|---------------|---------------|--|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Acute respiratory failure | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chronic obstructive pulmonary disease | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dyspnoea | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypoxia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonitis | | | |

| | | | |
|---|----------------|---------------|--|
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory failure | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Psychiatric disorders | | | |
| Completed suicide | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mental status changes | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Product issues | | | |
| Device occlusion | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Investigations | | | |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|----------------|---------------|--|
| Blood bilirubin increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood creatinine increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood osmolarity decreased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Clostridium test positive | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Troponin I | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Injury, poisoning and procedural complications | | | |
| Alcohol poisoning | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fall | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Femur fracture | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|----------------|---------------|--|
| Procedural pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Spinal compression fracture | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac disorders | | | |
| Atrial fibrillation | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atrial flutter | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atrial thrombosis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac arrest | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac tamponade | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nervous system disorders | | | |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|---------------|---------------|--|
| Depressed level of consciousness subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dizziness subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dysarthria subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemorrhage intracranial subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hydrocephalus subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myoclonus subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Seizure subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Syncope subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood and lymphatic system disorders | | | |

| | | | |
|---|----------------|----------------|--|
| Anaemia | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 1 / 2 (50.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Febrile neutropenia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neutropenia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Constipation | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diarrhoea | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dysphagia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Enterocolitis | | | |

| | | | |
|---|----------------|---------------|--|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Large intestinal obstruction | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oesophagitis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Small intestinal obstruction | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Upper gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Varices oesophageal | | | |

| | | | |
|---|---------------|-----------------|--|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vomiting | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatobiliary disorders | | | |
| Cholangitis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyperbilirubinaemia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skin and subcutaneous tissue disorders | | | |
| Erythema | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 2 / 2 (100.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 2 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal failure | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|---------------|---------------|--|
| Endocrine disorders | | | |
| Hypothyroidism | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Inappropriate antidiuretic hormone secretion | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fistula | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Flank pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pathological fracture | | | |

| | | | |
|---|---------------|---------------|--|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vertebral osteophyte | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chronic sinusitis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Clostridium difficile infection | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Device related infection | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Escherichia bacteraemia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Influenza | | | |

| | | | |
|---|----------------|---------------|--|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Meningitis bacterial | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oesophageal candidiasis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Paronychia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sepsis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary tract infection | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urosepsis | | | |

| | | | |
|---|----------------|---------------|--|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Electrolyte imbalance | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypophagia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metabolic alkalosis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Part 1: Intermittent pemigatinib 1/2/4 mg QD | Part 1: Intermittent pemigatinib 6 mg QD | Parts 1 and 2: Intermittent pemigatinib 9 mg QD |
|---|--|--|---|
| Total subjects affected by non-serious adverse events subjects affected / exposed | 3 / 3 (100.00%) | 3 / 4 (75.00%) | 7 / 7 (100.00%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) Benign neoplasm of thyroid gland subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Cancer pain subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Melanocytic naevus subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Metastases to central nervous system subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Pyogenic granuloma subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Seborrhoeic keratosis subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Skin papilloma subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 1 / 7 (14.29%) 1 |
| Vascular disorders Diastolic hypertension subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Hot flush subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Hypertension | | | |

| | | | |
|--|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypotension | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Systolic hypertension | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thrombophlebitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Venous thrombosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Catheter site pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Chest discomfort | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chills | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fatigue | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 1 / 4 (25.00%) | 4 / 7 (57.14%) |
| occurrences (all) | 1 | 1 | 4 |
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Generalised oedema | | | |

| | | | |
|------------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza like illness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mucosal inflammation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Performance status decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Peripheral swelling | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Swelling face | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tenderness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Immune system disorders | | | |
| Allergy to animal | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |

| | | | |
|--|---------------------|---------------------|---------------------|
| Drug hypersensitivity subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Hypersensitivity subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Reproductive system and breast disorders | | | |
| Breast fibrosis subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Postmenopausal haemorrhage subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Aspiration subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Cough subjects affected / exposed occurrences (all) | 1 / 3 (33.33%) 1 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Dysphonia subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 1 / 7 (14.29%) 1 |
| Dyspnoea subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 4 (25.00%) 1 | 0 / 7 (0.00%) 0 |
| Dyspnoea exertional subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Epistaxis subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 1 / 7 (14.29%) 1 |
| Haemoptysis subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Hiccups | | | |

| | | | |
|-----------------------------|---------------|---------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoxia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal congestion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal discomfort | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal dryness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 2 |
| Nasal septum deviation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paranasal sinus discomfort | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pharyngeal inflammation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Productive cough | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Pulmonary embolism | | | |

| | | | |
|--|--------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Rales | | | |
| subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Respiratory tract congestion | | | |
| subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Rhinitis allergic | | | |
| subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Rhinorrhoea | | | |
| subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 1 / 7 (14.29%) 1 |
| Rhonchi | | | |
| subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Sinus disorder | | | |
| subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Sinus pain | | | |
| subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Sneezing | | | |
| subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Upper-airway cough syndrome | | | |
| subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Wheezing | | | |
| subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 4 (25.00%) 1 | 0 / 7 (0.00%) 0 |
| Psychiatric disorders | | | |
| Adjustment disorder with depressed mood | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anxiety | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Confusional state | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Depression | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Disorientation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Insomnia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Restlessness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Investigations | | | |
| Activated partial thromboplastin time prolonged | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 1 | 0 | 1 |
| Amylase increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 2 | 0 | 1 |
| Blood 1,25-dihydroxycholecalciferol decreased | | | |

| | | | |
|---|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 2 |
| Blood 1,25-dihydroxycholecalciferol increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 2 |
| Blood 25-hydroxycholecalciferol decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 4 (0.00%) | 2 / 7 (28.57%) |
| occurrences (all) | 1 | 0 | 3 |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Blood folate decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood glucose increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 2 |
| Blood phosphorus increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood thyroid stimulating hormone decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood uric acid increased | | | |

| | | | |
|-------------------------------------|---------------|---------------|---------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Computerised tomogram abnormal | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gamma-glutamyltransferase increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lipase increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Liver function test increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Platelet count decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urine analysis abnormal | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitamin B12 decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitamin D decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitamin D increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|--|---------------------|--------------------|---------------------|
| Weight decreased subjects affected / exposed occurrences (all) | 2 / 3 (66.67%) 2 | 0 / 4 (0.00%) 0 | 1 / 7 (14.29%) 1 |
| Weight increased subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 1 / 7 (14.29%) 1 |
| White blood cell count decreased subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| White blood cell count increased subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Injury, poisoning and procedural complications | | | |
| Contusion subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Fall subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Infusion related reaction subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Limb injury subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Lip injury subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Nail avulsion subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Procedural pain subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Skin abrasion | | | |

| | | | |
|--|--------------------|--------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Tooth fracture subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Wound complication subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Congenital, familial and genetic disorders | | | |
| Corneal dystrophy subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Cardiac disorders | | | |
| Atrial thrombosis subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Bradycardia subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 1 / 7 (14.29%) 1 |
| Nodal rhythm subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Palpitations subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Sinus tachycardia subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Tachycardia subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Nervous system disorders | | | |
| Ataxia subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Dizziness | | | |

| | | | |
|-------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 3 (33.33%) | 1 / 4 (25.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Dysarthria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysgeusia | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 1 | 0 | 1 |
| Headache | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperaesthesia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoaesthesia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 1 | 1 |
| Memory impairment | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Presyncope | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Restless legs syndrome | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Seizure | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Somnolence | | | |

| | | | |
|---|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Taste disorder | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 2 |
| Tremor | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vocal cord paralysis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 1 | 0 | 1 |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Leukopenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymph node pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphadenopathy | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphopenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Microcytic anaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|------------------------------|---------------|---------------|----------------|
| Neutropenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thrombocytopenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 2 / 7 (28.57%) |
| occurrences (all) | 0 | 0 | 3 |
| Ear and labyrinth disorders | | | |
| Cerumen impaction | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Deafness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear congestion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Excessive cerumen production | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tinnitus | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vertigo | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye disorders | | | |
| Blepharitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blepharospasm | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cataract | | | |

| | | | |
|--|---------------|---------------|---------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cataract cortical | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cataract nuclear | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cataract subcapsular | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chorioretinopathy | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctival haemorrhage | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Corneal epithelium defect | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Detachment of macular retinal pigment epithelium | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diplopia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry age-related macular degeneration | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry eye | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Entropion | | | |

| | | | |
|-----------------------------|---------------|---------------|---------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye discharge | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye irritation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye pruritus | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eyelid function disorder | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eyelid pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eyelid ptosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Growth of eyelashes | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Iridocyclitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Keratitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Keratopathy | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lacrimation decreased | | | |

| | | | |
|-----------------------------|---------------|---------------|---------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lacrimation increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Macular fibrosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Meibomian gland dysfunction | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ocular discomfort | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ocular hyperaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ocular hypertension | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ocular surface disease | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Periorbital oedema | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Photophobia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Photopsia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pterygium | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Punctate keratitis | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Retinal degeneration | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Retinal detachment | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Retinal disorder | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Retinal fovea disorder | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Retinal oedema | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Scleral discolouration | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Scleral hyperaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Subretinal fluid | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Trichiasis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ulcerative keratitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vision blurred | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 1 / 4 (25.00%) | 2 / 7 (28.57%) |
| occurrences (all) | 1 | 1 | 2 |
| Visual acuity reduced | | | |

| | | | |
|---------------------------------|---------------|---------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Visual impairment | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitreoretinal traction syndrome | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitreous detachment | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitreous floaters | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal disorders | | | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal distension | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Abdominal pain lower | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal tenderness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Angular cheilitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|------------------------------|---------------|----------------|----------------|
| Ascites | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chapped lips | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Colitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Constipation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 2 / 7 (28.57%) |
| occurrences (all) | 0 | 0 | 2 |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 1 | 3 |
| Diarrhoea haemorrhagic | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry mouth | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 3 / 7 (42.86%) |
| occurrences (all) | 0 | 1 | 5 |
| Dyspepsia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Dysphagia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eructation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flatulence | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|--|--------------------|--------------------|---------------------|
| Gastrooesophageal reflux disease subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Gingival pain subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Glossodynia subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Haematochezia subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Haemorrhoidal haemorrhage subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Haemorrhoids subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Hiatus hernia subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Hyperaesthesia teeth subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Hypoaesthesia oral subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 1 / 7 (14.29%) 1 |
| Lip ulceration subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Loose tooth subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Mouth ulceration subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| Nausea | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 1 / 4 (25.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 1 | 1 | 1 |
| Oesophageal hypomotility | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oesophageal stenosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oesophageal ulcer | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral dysaesthesia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paraesthesia oral | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rectal tenesmus | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Stomatitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 2 / 7 (28.57%) |
| occurrences (all) | 0 | 0 | 2 |
| Tongue erythema | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Tooth disorder | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---------------------|--------------------|---------------------|
| Vomiting subjects affected / exposed occurrences (all) | 1 / 3 (33.33%) 2 | 0 / 4 (0.00%) 0 | 1 / 7 (14.29%) 1 |
| Hepatobiliary disorders Hyperbilirubinaemia subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Portal vein thrombosis subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Skin and subcutaneous tissue disorders Actinic keratosis subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Alopecia subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 3 / 7 (42.86%) 3 |
| Decubitus ulcer subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Dry skin subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Ecchymosis subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Eczema subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Eczema asteatotic subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Erythema subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Hyperhidrosis | | | |

| | | | |
|-----------------------------|---------------|----------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hyperkeratosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypertrichosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lichenoid keratosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Madarosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nail bed bleeding | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nail bed tenderness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nail discolouration | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Nail hypertrophy | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nail ridging | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Onychoclasis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Onycholysis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Onychomadesis | | | |

| | | | |
|--|---------------|---------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain of skin | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Palmar-plantar erythrodysesthesia syndrome | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 4 |
| Paraneoplastic pemphigus | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Psoriasis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash papular | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash pruritic | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin fissures | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin induration | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|---------------|----------------|----------------|
| Skin irritation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin lesion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Skin ulcer | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urticaria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitiligo | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Autoimmune nephritis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bladder pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bladder spasm | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysuria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 1 | 1 |
| Haematuria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hydronephrosis | | | |

| | | | |
|-------------------------------|---------------|---------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lower urinary tract symptoms | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Micturition urgency | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nephrolithiasis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nocturia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pollakiuria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary retention | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary tract obstruction | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary tract pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Endocrine disorders | | | |
| Adrenal insufficiency | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperparathyroidism | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Hyperparathyroidism secondary | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|----------------|----------------|----------------|
| Hyperthyroidism | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoparathyroidism | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypothyroidism | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Steroid withdrawal syndrome | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thyroiditis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 1 | 1 |
| Arthritis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Back pain | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 4 (0.00%) | 2 / 7 (28.57%) |
| occurrences (all) | 1 | 0 | 2 |
| Bone pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flank pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Joint swelling | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscle spasms | | | |

| | | | |
|-----------------------------|---------------|----------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscle tightness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscular weakness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Myalgia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neck pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Osteoarthritis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Osteonecrosis of jaw | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 2 / 7 (28.57%) |
| occurrences (all) | 0 | 2 | 2 |
| Trismus | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infections and infestations | | | |
| Acute sinusitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|---------------|----------------|----------------|
| Body tinea | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Candida infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 2 |
| Catheter site cellulitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 2 |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Diverticulitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Ear infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastroenteritis viral | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Herpes ophthalmic | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Herpes simplex | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|---------------|---------------|----------------|
| Influenza | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nail infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral candidiasis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral herpes | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paronychia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Tinea pedis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tinea versicolour | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|------------------------------------|----------------|----------------|----------------|
| Tooth infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 2 | 1 |
| Urinary tract infection bacterial | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vaginal infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metabolism and nutrition disorders | | | |
| Cachexia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Decreased appetite | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 4 (50.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 2 | 1 |
| Dehydration | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 1 / 4 (25.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Fluid overload | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fluid retention | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glucose tolerance impaired | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypercalcaemia | | | |

| | | | |
|------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 1 | 0 | 1 |
| Hypercholesterolaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Hyperkalaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperphosphataemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 4 / 7 (57.14%) |
| occurrences (all) | 0 | 2 | 13 |
| Hypertriglyceridaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Hyperuricaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Hypoalbuminaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypocalcaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Hypoglycaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypokalaemia | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 1 / 4 (25.00%) | 2 / 7 (28.57%) |
| occurrences (all) | 1 | 1 | 2 |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Hyponatraemia | | | |

| | | | |
|-----------------------------|---------------|---------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Hypophosphataemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 2 / 7 (28.57%) |
| occurrences (all) | 0 | 0 | 4 |
| Malnutrition | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metabolic acidosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitamin D deficiency | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |

| Non-serious adverse events | Parts 1 and 2: Intermittent pemigatinib 13.5 mg QD | Part 1: Intermittent pemigatinib 20 mg QD | Parts 1 and 2: Continuous pemigatinib 9 mg QD |
|---|---|---|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 50 / 50 (100.00%) | 6 / 6 (100.00%) | 14 / 14 (100.00%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Benign neoplasm of thyroid gland | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cancer pain | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Melanocytic naevus | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metastases to central nervous system | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Pyogenic granuloma | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |

| | | | |
|--|----------------------|--------------------|---------------------|
| Seborrhoeic keratosis subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Skin papilloma subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Vascular disorders | | | |
| Diastolic hypertension subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Hot flush subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Hypertension subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Hypotension subjects affected / exposed occurrences (all) | 5 / 50 (10.00%) 5 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Systolic hypertension subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Thrombophlebitis subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Venous thrombosis subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| General disorders and administration site conditions | | | |
| Asthenia subjects affected / exposed occurrences (all) | 1 / 50 (2.00%) 1 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Catheter site pain subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Chest discomfort | | | |

| | | | |
|-------------------------------------|------------------|----------------|-----------------|
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chills | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fatigue | | | |
| subjects affected / exposed | 18 / 50 (36.00%) | 2 / 6 (33.33%) | 8 / 14 (57.14%) |
| occurrences (all) | 21 | 2 | 8 |
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Generalised oedema | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Influenza like illness | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Mucosal inflammation | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 2 / 50 (4.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 2 / 50 (4.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 2 | 0 | 1 |
| Pain | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Performance status decreased | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Peripheral swelling | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 1 | 0 | 1 |
| Pyrexia | | | |

| | | | |
|---|----------------------|---------------------|----------------------|
| subjects affected / exposed occurrences (all) | 1 / 50 (2.00%) 1 | 0 / 6 (0.00%) 0 | 2 / 14 (14.29%) 3 |
| Swelling face subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Tenderness subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Immune system disorders Allergy to animal subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Drug hypersensitivity subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Hypersensitivity subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 2 / 14 (14.29%) 2 |
| Reproductive system and breast disorders Breast fibrosis subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Postmenopausal haemorrhage subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Respiratory, thoracic and mediastinal disorders Aspiration subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Cough subjects affected / exposed occurrences (all) | 6 / 50 (12.00%) 6 | 2 / 6 (33.33%) 2 | 2 / 14 (14.29%) 2 |
| Dysphonia subjects affected / exposed occurrences (all) | 1 / 50 (2.00%) 1 | 1 / 6 (16.67%) 1 | 0 / 14 (0.00%) 0 |
| Dyspnoea | | | |

| | | | |
|-----------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 2 / 50 (4.00%) | 1 / 6 (16.67%) | 1 / 14 (7.14%) |
| occurrences (all) | 2 | 1 | 1 |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Epistaxis | | | |
| subjects affected / exposed | 6 / 50 (12.00%) | 1 / 6 (16.67%) | 1 / 14 (7.14%) |
| occurrences (all) | 7 | 1 | 2 |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hiccups | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoxia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal congestion | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nasal discomfort | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal dryness | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Nasal septum deviation | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 5 / 50 (10.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 9 | 0 | 0 |
| Paranasal sinus discomfort | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pharyngeal inflammation | | | |

| | | | |
|------------------------------|----------------|----------------|-----------------|
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 2 / 14 (14.29%) |
| occurrences (all) | 1 | 0 | 2 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Productive cough | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rales | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Respiratory tract congestion | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Rhinitis allergic | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 1 | 0 | 1 |
| Rhinorrhoea | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rhonchi | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus disorder | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus pain | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sneezing | | | |

| | | | |
|--|---------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Upper-airway cough syndrome subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Wheezing subjects affected / exposed occurrences (all) | 1 / 50 (2.00%) 1 | 1 / 6 (16.67%) 2 | 1 / 14 (7.14%) 1 |
| Psychiatric disorders | | | |
| Adjustment disorder with depressed mood subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Anxiety subjects affected / exposed occurrences (all) | 4 / 50 (8.00%) 4 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Confusional state subjects affected / exposed occurrences (all) | 1 / 50 (2.00%) 1 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Depression subjects affected / exposed occurrences (all) | 2 / 50 (4.00%) 2 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Disorientation subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Insomnia subjects affected / exposed occurrences (all) | 1 / 50 (2.00%) 1 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Restlessness subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Investigations | | | |
| Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Alanine aminotransferase increased | | | |

| | | | |
|---|-----------------|---------------|-----------------|
| subjects affected / exposed | 4 / 50 (8.00%) | 0 / 6 (0.00%) | 5 / 14 (35.71%) |
| occurrences (all) | 6 | 0 | 5 |
| Amylase increased | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 7 / 50 (14.00%) | 0 / 6 (0.00%) | 5 / 14 (35.71%) |
| occurrences (all) | 8 | 0 | 5 |
| Blood 1,25-dihydroxycholecalciferol decreased | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood 1,25-dihydroxycholecalciferol increased | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood 25-hydroxycholecalciferol decreased | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 5 / 50 (10.00%) | 0 / 6 (0.00%) | 3 / 14 (21.43%) |
| occurrences (all) | 7 | 0 | 3 |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine increased | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 2 / 50 (4.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Blood folate decreased | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Blood glucose increased | | | |

| | | | |
|---|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood phosphorus increased | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood thyroid stimulating hormone decreased | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood uric acid increased | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Computerised tomogram abnormal | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Gamma-glutamyltransferase increased | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lipase increased | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Liver function test increased | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count increased | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Platelet count decreased | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urine analysis abnormal | | | |

| | | | |
|--|----------------------|---------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Vitamin B12 decreased subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Vitamin D decreased subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Vitamin D increased subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Weight decreased subjects affected / exposed occurrences (all) | 5 / 50 (10.00%) 5 | 2 / 6 (33.33%) 2 | 3 / 14 (21.43%) 3 |
| Weight increased subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 4 |
| White blood cell count decreased subjects affected / exposed occurrences (all) | 1 / 50 (2.00%) 1 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| White blood cell count increased subjects affected / exposed occurrences (all) | 1 / 50 (2.00%) 1 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Injury, poisoning and procedural complications | | | |
| Contusion subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Fall subjects affected / exposed occurrences (all) | 3 / 50 (6.00%) 3 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 3 |
| Infusion related reaction subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Limb injury | | | |

| | | | |
|--|---------------------|--------------------|----------------------|
| subjects affected / exposed occurrences (all) | 1 / 50 (2.00%) 1 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Lip injury subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Nail avulsion subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Procedural pain subjects affected / exposed occurrences (all) | 1 / 50 (2.00%) 2 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Skin abrasion subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 2 / 14 (14.29%) 2 |
| Tooth fracture subjects affected / exposed occurrences (all) | 1 / 50 (2.00%) 1 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Wound complication subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Congenital, familial and genetic disorders | | | |
| Corneal dystrophy subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Cardiac disorders | | | |
| Atrial thrombosis subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Bradycardia subjects affected / exposed occurrences (all) | 2 / 50 (4.00%) 2 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Nodal rhythm subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Palpitations | | | |

| | | | |
|---|----------------------|---------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Sinus tachycardia subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Tachycardia subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 2 / 14 (14.29%) 2 |
| Nervous system disorders | | | |
| Ataxia subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Dizziness subjects affected / exposed occurrences (all) | 1 / 50 (2.00%) 1 | 0 / 6 (0.00%) 0 | 2 / 14 (14.29%) 2 |
| Dysarthria subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Dysgeusia subjects affected / exposed occurrences (all) | 5 / 50 (10.00%) 5 | 1 / 6 (16.67%) 1 | 2 / 14 (14.29%) 2 |
| Headache subjects affected / exposed occurrences (all) | 2 / 50 (4.00%) 2 | 1 / 6 (16.67%) 2 | 0 / 14 (0.00%) 0 |
| Hyperaesthesia subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Hypoaesthesia subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 1 / 6 (16.67%) 1 | 0 / 14 (0.00%) 0 |
| Memory impairment subjects affected / exposed occurrences (all) | 1 / 50 (2.00%) 1 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Neuropathy peripheral subjects affected / exposed occurrences (all) | 1 / 50 (2.00%) 1 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |

| | | | |
|--------------------------------------|------------------|----------------|-----------------|
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Presyncope | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Restless legs syndrome | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Seizure | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Somnolence | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Taste disorder | | | |
| subjects affected / exposed | 4 / 50 (8.00%) | 1 / 6 (16.67%) | 2 / 14 (14.29%) |
| occurrences (all) | 4 | 1 | 2 |
| Tremor | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vocal cord paralysis | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 10 / 50 (20.00%) | 2 / 6 (33.33%) | 6 / 14 (42.86%) |
| occurrences (all) | 14 | 2 | 8 |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Leukopenia | | | |

| | | | |
|------------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymph node pain | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphadenopathy | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphopenia | | | |
| subjects affected / exposed | 2 / 50 (4.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Microcytic anaemia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutropenia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thrombocytopenia | | | |
| subjects affected / exposed | 4 / 50 (8.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 6 | 0 | 1 |
| Ear and labyrinth disorders | | | |
| Cerumen impaction | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Deafness | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear congestion | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear pain | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Excessive cerumen production | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|--|----------------|----------------|----------------|
| Tinnitus | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vertigo | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye disorders | | | |
| Blepharitis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Blepharospasm | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cataract | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cataract cortical | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cataract nuclear | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cataract subcapsular | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chorioretinopathy | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctival haemorrhage | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Corneal epithelium defect | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Detachment of macular retinal pigment epithelium | | | |

| | | | |
|--------------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diplopia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry age-related macular degeneration | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Dry eye | | | |
| subjects affected / exposed | 8 / 50 (16.00%) | 1 / 6 (16.67%) | 1 / 14 (7.14%) |
| occurrences (all) | 9 | 1 | 2 |
| Entropion | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye discharge | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye irritation | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye pain | | | |
| subjects affected / exposed | 2 / 50 (4.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Eye pruritus | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eyelid function disorder | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eyelid pain | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Eyelid ptosis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |

| | | | |
|-----------------------------|-----------------|----------------|----------------|
| Growth of eyelashes | | | |
| subjects affected / exposed | 6 / 50 (12.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 6 | 0 | 0 |
| Iridocyclitis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Keratitis | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Keratopathy | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Lacrimation decreased | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Lacrimation increased | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Macular fibrosis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Meibomian gland dysfunction | | | |
| subjects affected / exposed | 2 / 50 (4.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 2 | 0 | 1 |
| Ocular discomfort | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ocular hyperaemia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 6 (16.67%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 1 | 1 |
| Ocular hypertension | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ocular surface disease | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| Periorbital oedema | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 1 | 0 | 1 |
| Photophobia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Photopsia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pterygium | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Punctate keratitis | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Retinal degeneration | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Retinal detachment | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Retinal disorder | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Retinal fovea disorder | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Retinal oedema | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Scleral discolouration | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Scleral hyperaemia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |

| | | | |
|---------------------------------|----------------|----------------|----------------|
| Subretinal fluid | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Trichiasis | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Ulcerative keratitis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vision blurred | | | |
| subjects affected / exposed | 4 / 50 (8.00%) | 2 / 6 (33.33%) | 0 / 14 (0.00%) |
| occurrences (all) | 4 | 2 | 0 |
| Visual acuity reduced | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Visual impairment | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitreoretinal traction syndrome | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitreous detachment | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitreous floaters | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal disorders | | | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal distension | | | |
| subjects affected / exposed | 4 / 50 (8.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 4 | 0 | 1 |
| Abdominal pain | | | |

| | | | |
|-----------------------------|------------------|----------------|-----------------|
| subjects affected / exposed | 10 / 50 (20.00%) | 1 / 6 (16.67%) | 2 / 14 (14.29%) |
| occurrences (all) | 10 | 1 | 2 |
| Abdominal pain lower | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 6 (16.67%) | 2 / 14 (14.29%) |
| occurrences (all) | 0 | 1 | 2 |
| Abdominal tenderness | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Angular cheilitis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Ascites | | | |
| subjects affected / exposed | 4 / 50 (8.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 4 | 1 | 0 |
| Chapped lips | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Colitis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Constipation | | | |
| subjects affected / exposed | 14 / 50 (28.00%) | 2 / 6 (33.33%) | 4 / 14 (28.57%) |
| occurrences (all) | 14 | 2 | 4 |
| Diarrhoea | | | |
| subjects affected / exposed | 12 / 50 (24.00%) | 2 / 6 (33.33%) | 3 / 14 (21.43%) |
| occurrences (all) | 12 | 2 | 3 |
| Diarrhoea haemorrhagic | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry mouth | | | |
| subjects affected / exposed | 17 / 50 (34.00%) | 2 / 6 (33.33%) | 5 / 14 (35.71%) |
| occurrences (all) | 19 | 2 | 5 |
| Dyspepsia | | | |

| | | | |
|----------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 2 / 50 (4.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Dysphagia | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 2 / 6 (33.33%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Eructation | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flatulence | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 2 / 50 (4.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 2 | 0 | 1 |
| Gingival pain | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glossodynia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Haematochezia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemorrhoidal haemorrhage | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemorrhoids | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 1 | 0 | 1 |
| Hiatus hernia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperaesthesia teeth | | | |

| | | | |
|-----------------------------|-----------------|----------------|-----------------|
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hypoaesthesia oral | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lip ulceration | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Loose tooth | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Mouth ulceration | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Nausea | | | |
| subjects affected / exposed | 8 / 50 (16.00%) | 2 / 6 (33.33%) | 6 / 14 (42.86%) |
| occurrences (all) | 8 | 2 | 6 |
| Oesophageal hypomotility | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oesophageal stenosis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oesophageal ulcer | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral dysaesthesia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral pain | | | |
| subjects affected / exposed | 3 / 50 (6.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 4 | 0 | 1 |
| Paraesthesia oral | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rectal haemorrhage | | | |

| | | | |
|--|------------------|----------------|-----------------|
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Rectal tenesmus | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Stomatitis | | | |
| subjects affected / exposed | 11 / 50 (22.00%) | 3 / 6 (50.00%) | 6 / 14 (42.86%) |
| occurrences (all) | 13 | 3 | 8 |
| Tongue erythema | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth disorder | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vomiting | | | |
| subjects affected / exposed | 7 / 50 (14.00%) | 1 / 6 (16.67%) | 4 / 14 (28.57%) |
| occurrences (all) | 7 | 1 | 4 |
| Hepatobiliary disorders | | | |
| Hyperbilirubinaemia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Portal vein thrombosis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| Actinic keratosis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Alopecia | | | |
| subjects affected / exposed | 15 / 50 (30.00%) | 1 / 6 (16.67%) | 6 / 14 (42.86%) |
| occurrences (all) | 15 | 1 | 7 |
| Decubitus ulcer | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry skin | | | |

| | | | |
|-----------------------------|-----------------|---------------|----------------|
| subjects affected / exposed | 5 / 50 (10.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 5 | 0 | 0 |
| Ecchymosis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Eczema | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eczema asteatotic | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erythema | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperhidrosis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperkeratosis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Hypertrichosis | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Lichenoid keratosis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Madarosis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nail bed bleeding | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nail bed tenderness | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nail discolouration | | | |

| | | | |
|--|-----------------|----------------|-----------------|
| subjects affected / exposed | 5 / 50 (10.00%) | 0 / 6 (0.00%) | 2 / 14 (14.29%) |
| occurrences (all) | 5 | 0 | 2 |
| Nail hypertrophy | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Nail ridging | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Onychoclasia | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Onycholysis | | | |
| subjects affected / exposed | 5 / 50 (10.00%) | 0 / 6 (0.00%) | 2 / 14 (14.29%) |
| occurrences (all) | 5 | 0 | 2 |
| Onychomadesis | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 2 | 0 | 1 |
| Pain of skin | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 6 (16.67%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 1 | 1 |
| Palmar-plantar erythrodysesthesia syndrome | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 6 (16.67%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 1 | 1 |
| Paraneoplastic pemphigus | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Psoriasis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |

| | | | |
|--|---------------------|---------------------|---------------------|
| Rash maculo-papular subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Rash papular subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Rash pruritic subjects affected / exposed occurrences (all) | 1 / 50 (2.00%) 1 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Skin fissures subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Skin induration subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Skin irritation subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Skin lesion subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Skin ulcer subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Urticaria subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Vitiligo subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 1 / 6 (16.67%) 1 | 0 / 14 (0.00%) 0 |
| Renal and urinary disorders Acute kidney injury subjects affected / exposed occurrences (all) | 1 / 50 (2.00%) 1 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Autoimmune nephritis | | | |

| | | | |
|-------------------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bladder pain | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bladder spasm | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysuria | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haematuria | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Lower urinary tract symptoms | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Micturition urgency | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nephrolithiasis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nocturia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pollakiuria | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary retention | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 1 | 0 | 2 |
| Urinary tract obstruction | | | |

| | | | |
|---|---------------------|---------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Urinary tract pain subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Endocrine disorders | | | |
| Adrenal insufficiency subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Hyperparathyroidism subjects affected / exposed occurrences (all) | 1 / 50 (2.00%) 1 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Hyperparathyroidism secondary subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Hyperthyroidism subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Hypoparathyroidism subjects affected / exposed occurrences (all) | 1 / 50 (2.00%) 1 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Hypothyroidism subjects affected / exposed occurrences (all) | 2 / 50 (4.00%) 2 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Steroid withdrawal syndrome subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Thyroiditis subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia subjects affected / exposed occurrences (all) | 4 / 50 (8.00%) 4 | 2 / 6 (33.33%) 2 | 4 / 14 (28.57%) 5 |
| Arthritis | | | |

| | | | |
|-----------------------------------|-----------------|----------------|-----------------|
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Back pain | | | |
| subjects affected / exposed | 3 / 50 (6.00%) | 0 / 6 (0.00%) | 2 / 14 (14.29%) |
| occurrences (all) | 3 | 0 | 2 |
| Bone pain | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flank pain | | | |
| subjects affected / exposed | 2 / 50 (4.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Joint swelling | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Muscle spasms | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscle tightness | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Muscular weakness | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Myalgia | | | |
| subjects affected / exposed | 5 / 50 (10.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 5 | 0 | 0 |
| Neck pain | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Osteoarthritis | | | |

| | | | |
|--|---------------------|---------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Osteonecrosis of jaw subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Pain in extremity subjects affected / exposed occurrences (all) | 3 / 50 (6.00%) 3 | 1 / 6 (16.67%) 1 | 3 / 14 (21.43%) 3 |
| Trismus subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Infections and infestations | | | |
| Acute sinusitis subjects affected / exposed occurrences (all) | 1 / 50 (2.00%) 1 | 1 / 6 (16.67%) 1 | 0 / 14 (0.00%) 0 |
| Body tinea subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 1 / 6 (16.67%) 1 | 0 / 14 (0.00%) 0 |
| Bronchitis subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Candida infection subjects affected / exposed occurrences (all) | 1 / 50 (2.00%) 1 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Catheter site cellulitis subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 1 / 6 (16.67%) 1 | 0 / 14 (0.00%) 0 |
| Cellulitis subjects affected / exposed occurrences (all) | 2 / 50 (4.00%) 4 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 2 |
| Conjunctivitis subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Diverticulitis subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |

| | | | |
|-----------------------------|----------------|----------------|-----------------|
| Ear infection | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye infection | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastroenteritis viral | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Herpes ophthalmic | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Herpes simplex | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nail infection | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 1 | 0 | 1 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral candidiasis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Oral herpes | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Paronychia | | | |
| subjects affected / exposed | 2 / 50 (4.00%) | 2 / 6 (33.33%) | 2 / 14 (14.29%) |
| occurrences (all) | 2 | 2 | 4 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|------------------------------------|----------------|----------------|-----------------|
| Pneumonia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinusitis | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 1 | 0 | 1 |
| Skin infection | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tinea pedis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Tinea versicolour | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Tooth infection | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 2 / 50 (4.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 2 / 14 (14.29%) |
| occurrences (all) | 1 | 0 | 3 |
| Urinary tract infection bacterial | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vaginal infection | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metabolism and nutrition disorders | | | |
| Cachexia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Decreased appetite | | | |

| | | | |
|-----------------------------|------------------|----------------|-----------------|
| subjects affected / exposed | 12 / 50 (24.00%) | 1 / 6 (16.67%) | 1 / 14 (7.14%) |
| occurrences (all) | 12 | 1 | 1 |
| Dehydration | | | |
| subjects affected / exposed | 6 / 50 (12.00%) | 1 / 6 (16.67%) | 1 / 14 (7.14%) |
| occurrences (all) | 7 | 2 | 1 |
| Fluid overload | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fluid retention | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glucose tolerance impaired | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 5 / 50 (10.00%) | 0 / 6 (0.00%) | 2 / 14 (14.29%) |
| occurrences (all) | 8 | 0 | 2 |
| Hypercholesterolaemia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 2 / 50 (4.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Hyperkalaemia | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 1 | 0 | 1 |
| Hyperphosphataemia | | | |
| subjects affected / exposed | 39 / 50 (78.00%) | 4 / 6 (66.67%) | 8 / 14 (57.14%) |
| occurrences (all) | 78 | 6 | 12 |
| Hypertriglyceridaemia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperuricaemia | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypoalbuminaemia | | | |

| | | | |
|-----------------------------|------------------|----------------|-----------------|
| subjects affected / exposed | 3 / 50 (6.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Hypocalcaemia | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypoglycaemia | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypokalaemia | | | |
| subjects affected / exposed | 3 / 50 (6.00%) | 0 / 6 (0.00%) | 2 / 14 (14.29%) |
| occurrences (all) | 3 | 0 | 2 |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 2 / 50 (4.00%) | 1 / 6 (16.67%) | 2 / 14 (14.29%) |
| occurrences (all) | 3 | 1 | 2 |
| Hyponatraemia | | | |
| subjects affected / exposed | 3 / 50 (6.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 5 | 1 | 0 |
| Hypophosphataemia | | | |
| subjects affected / exposed | 10 / 50 (20.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 17 | 1 | 0 |
| Malnutrition | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metabolic acidosis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitamin D deficiency | | | |
| subjects affected / exposed | 3 / 50 (6.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |

| Non-serious adverse events | Parts 1 and 2: Continuous pemigatinib 13.5 mg QD | Parts 1 and 2: Continuous pemigatinib 20 mg QD | Part 1: Continuous pemigatinib 7.5 mg BID |
|--|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 30 / 30 (100.00%) | 15 / 15 (100.00%) | 4 / 4 (100.00%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |

| | | | |
|---|----------------------|---------------------|---------------------|
| Benign neoplasm of thyroid gland subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Cancer pain subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | 1 / 15 (6.67%) 1 | 0 / 4 (0.00%) 0 |
| Melanocytic naevus subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Metastases to central nervous system subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Pyogenic granuloma subjects affected / exposed occurrences (all) | 2 / 30 (6.67%) 2 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Seborrhoeic keratosis subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Skin papilloma subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Vascular disorders | | | |
| Diastolic hypertension subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Hot flush subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Hypertension subjects affected / exposed occurrences (all) | 2 / 30 (6.67%) 4 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Hypotension subjects affected / exposed occurrences (all) | 6 / 30 (20.00%) 6 | 1 / 15 (6.67%) 1 | 1 / 4 (25.00%) 1 |
| Systolic hypertension | | | |

| | | | |
|--|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thrombophlebitis | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Venous thrombosis | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Catheter site pain | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chest discomfort | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chills | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Fatigue | | | |
| subjects affected / exposed | 8 / 30 (26.67%) | 4 / 15 (26.67%) | 2 / 4 (50.00%) |
| occurrences (all) | 8 | 5 | 3 |
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Generalised oedema | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza like illness | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Mucosal inflammation | | | |

| | | | |
|------------------------------|-----------------|-----------------|---------------|
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 4 / 30 (13.33%) | 2 / 15 (13.33%) | 0 / 4 (0.00%) |
| occurrences (all) | 4 | 3 | 0 |
| Pain | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Performance status decreased | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Peripheral swelling | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pyrexia | | | |
| subjects affected / exposed | 3 / 30 (10.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 6 | 0 | 0 |
| Swelling face | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Tenderness | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Immune system disorders | | | |
| Allergy to animal | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Drug hypersensitivity | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypersensitivity | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|---|-----------------|-----------------|---------------|
| Reproductive system and breast disorders | | | |
| Breast fibrosis | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Postmenopausal haemorrhage | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Aspiration | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Cough | | | |
| subjects affected / exposed | 6 / 30 (20.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 6 | 0 | 0 |
| Dysphonia | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 3 / 30 (10.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 5 | 0 | 0 |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Epistaxis | | | |
| subjects affected / exposed | 4 / 30 (13.33%) | 2 / 15 (13.33%) | 0 / 4 (0.00%) |
| occurrences (all) | 4 | 2 | 0 |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hiccups | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoxia | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Nasal congestion | | | |

| | | | |
|------------------------------|-----------------|-----------------|----------------|
| subjects affected / exposed | 1 / 30 (3.33%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Nasal discomfort | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 1 / 4 (25.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Nasal dryness | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nasal septum deviation | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 4 / 30 (13.33%) | 3 / 15 (20.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 6 | 3 | 0 |
| Paranasal sinus discomfort | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pharyngeal inflammation | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Productive cough | | | |
| subjects affected / exposed | 3 / 30 (10.00%) | 0 / 15 (0.00%) | 1 / 4 (25.00%) |
| occurrences (all) | 3 | 0 | 1 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rales | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory tract congestion | | | |

| | | | |
|---|-----------------|----------------|----------------|
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rhinitis allergic | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinorrhoea | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rhonchi | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus disorder | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Sinus pain | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sneezing | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper-airway cough syndrome | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Wheezing | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Psychiatric disorders | | | |
| Adjustment disorder with depressed mood | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Anxiety | | | |
| subjects affected / exposed | 4 / 30 (13.33%) | 1 / 15 (6.67%) | 1 / 4 (25.00%) |
| occurrences (all) | 4 | 1 | 1 |
| Confusional state | | | |

| | | | |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed | 1 / 30 (3.33%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Depression | | | |
| subjects affected / exposed | 3 / 30 (10.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Disorientation | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Insomnia | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Restlessness | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Investigations | | | |
| Activated partial thromboplastin time prolonged | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 7 / 30 (23.33%) | 2 / 15 (13.33%) | 0 / 4 (0.00%) |
| occurrences (all) | 11 | 2 | 0 |
| Amylase increased | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 1 / 4 (25.00%) |
| occurrences (all) | 1 | 0 | 1 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 7 / 30 (23.33%) | 3 / 15 (20.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 10 | 4 | 0 |
| Blood 1,25-dihydroxycholecalciferol decreased | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood 1,25-dihydroxycholecalciferol increased | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood 25-hydroxycholecalciferol decreased | | | |

| | | | |
|---|------------------|-----------------|----------------|
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 1 / 4 (25.00%) |
| occurrences (all) | 1 | 0 | 2 |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine increased | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 1 / 4 (25.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 11 / 30 (36.67%) | 4 / 15 (26.67%) | 1 / 4 (25.00%) |
| occurrences (all) | 18 | 4 | 4 |
| Blood folate decreased | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood glucose increased | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood phosphorus increased | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood thyroid stimulating hormone decreased | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood uric acid increased | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Computerised tomogram abnormal | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gamma-glutamyltransferase increased | | | |

| | | | |
|----------------------------------|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lipase increased | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 1 / 4 (25.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Liver function test increased | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count increased | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Platelet count decreased | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Urine analysis abnormal | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitamin B12 decreased | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitamin D decreased | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitamin D increased | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Weight decreased | | | |
| subjects affected / exposed | 3 / 30 (10.00%) | 5 / 15 (33.33%) | 3 / 4 (75.00%) |
| occurrences (all) | 3 | 7 | 3 |
| Weight increased | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| White blood cell count decreased | | | |

| | | | |
|--|----------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 2 / 30 (6.67%) 2 | 1 / 15 (6.67%) 1 | 0 / 4 (0.00%) 0 |
| White blood cell count increased subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Injury, poisoning and procedural complications | | | |
| Contusion | | | |
| subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Fall | | | |
| subjects affected / exposed occurrences (all) | 5 / 30 (16.67%) 8 | 0 / 15 (0.00%) 0 | 1 / 4 (25.00%) 1 |
| Infusion related reaction | | | |
| subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Limb injury | | | |
| subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Lip injury | | | |
| subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 1 / 15 (6.67%) 1 | 0 / 4 (0.00%) 0 |
| Nail avulsion | | | |
| subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | 1 / 15 (6.67%) 1 | 0 / 4 (0.00%) 0 |
| Procedural pain | | | |
| subjects affected / exposed occurrences (all) | 2 / 30 (6.67%) 2 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Skin abrasion | | | |
| subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Tooth fracture | | | |
| subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Wound complication | | | |

| | | | |
|---|----------------------|----------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 1 / 15 (6.67%) 1 | 0 / 4 (0.00%) 0 |
| Congenital, familial and genetic disorders | | | |
| Corneal dystrophy subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 1 / 15 (6.67%) 1 | 0 / 4 (0.00%) 0 |
| Cardiac disorders | | | |
| Atrial thrombosis subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Bradycardia subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Nodal rhythm subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Palpitations subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 1 / 15 (6.67%) 1 | 0 / 4 (0.00%) 0 |
| Sinus tachycardia subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 2 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Tachycardia subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | 2 / 15 (13.33%) 2 | 0 / 4 (0.00%) 0 |
| Nervous system disorders | | | |
| Ataxia subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 1 / 4 (25.00%) 1 |
| Dizziness subjects affected / exposed occurrences (all) | 4 / 30 (13.33%) 6 | 1 / 15 (6.67%) 1 | 0 / 4 (0.00%) 0 |
| Dysarthria subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Dysgeusia | | | |

| | | | |
|-----------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 9 / 30 (30.00%) | 4 / 15 (26.67%) | 4 / 4 (100.00%) |
| occurrences (all) | 9 | 5 | 4 |
| Headache | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Hyperaesthesia | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hypoaesthesia | | | |
| subjects affected / exposed | 3 / 30 (10.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Memory impairment | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Presyncope | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Restless legs syndrome | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Seizure | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Somnolence | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Taste disorder | | | |

| | | | |
|---|----------------------|----------------------|---------------------|
| subjects affected / exposed occurrences (all) | 2 / 30 (6.67%) 2 | 2 / 15 (13.33%) 2 | 0 / 4 (0.00%) 0 |
| Tremor subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Vocal cord paralysis subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia subjects affected / exposed occurrences (all) | 6 / 30 (20.00%) 9 | 4 / 15 (26.67%) 5 | 2 / 4 (50.00%) 3 |
| Iron deficiency anaemia subjects affected / exposed occurrences (all) | 2 / 30 (6.67%) 2 | 1 / 15 (6.67%) 1 | 0 / 4 (0.00%) 0 |
| Leukopenia subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Lymph node pain subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Lymphadenopathy subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Lymphopenia subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | 2 / 15 (13.33%) 3 | 0 / 4 (0.00%) 0 |
| Microcytic anaemia subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Neutropenia subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Thrombocytopenia subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 2 / 15 (13.33%) 2 | 0 / 4 (0.00%) 0 |

| | | | |
|------------------------------|----------------|----------------|----------------|
| Ear and labyrinth disorders | | | |
| Cerumen impaction | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Deafness | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Ear congestion | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear pain | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Excessive cerumen production | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 1 / 4 (25.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Tinnitus | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vertigo | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye disorders | | | |
| Blepharitis | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blepharospasm | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 1 / 4 (25.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Cataract | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 1 / 4 (25.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Cataract cortical | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Cataract nuclear | | | |

| | | | |
|--|------------------|-----------------|----------------|
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Cataract subcapsular | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Chorioretinopathy | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctival haemorrhage | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Corneal epithelium defect | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Detachment of macular retinal pigment epithelium | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diplopia | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 1 / 4 (25.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Dry age-related macular degeneration | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 1 / 4 (25.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Dry eye | | | |
| subjects affected / exposed | 10 / 30 (33.33%) | 4 / 15 (26.67%) | 1 / 4 (25.00%) |
| occurrences (all) | 11 | 4 | 1 |
| Entropion | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 1 / 4 (25.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Eye discharge | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eye irritation | | | |

| | | | |
|-----------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 2 / 30 (6.67%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Eye pain | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eye pruritus | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Eyelid function disorder | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Eyelid pain | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eyelid ptosis | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Growth of eyelashes | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Iridocyclitis | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Keratitis | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Keratopathy | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lacrimation decreased | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lacrimation increased | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Macular fibrosis | | | |

| | | | |
|-----------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Meibomian gland dysfunction | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 1 / 4 (25.00%) |
| occurrences (all) | 1 | 0 | 1 |
| Ocular discomfort | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ocular hyperaemia | | | |
| subjects affected / exposed | 3 / 30 (10.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Ocular hypertension | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ocular surface disease | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Periorbital oedema | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Photophobia | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Photopsia | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pterygium | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Punctate keratitis | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Retinal degeneration | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Retinal detachment | | | |

| | | | |
|---------------------------------|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Retinal disorder | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Retinal fovea disorder | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Retinal oedema | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Scleral discolouration | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Scleral hyperaemia | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Subretinal fluid | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Trichiasis | | | |
| subjects affected / exposed | 6 / 30 (20.00%) | 1 / 15 (6.67%) | 2 / 4 (50.00%) |
| occurrences (all) | 6 | 1 | 2 |
| Ulcerative keratitis | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Vision blurred | | | |
| subjects affected / exposed | 5 / 30 (16.67%) | 3 / 15 (20.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 5 | 5 | 0 |
| Visual acuity reduced | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Visual impairment | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitreoretinal traction syndrome | | | |

| | | | |
|--|----------------------|----------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Vitreous detachment subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | 0 / 15 (0.00%) 0 | 1 / 4 (25.00%) 1 |
| Vitreous floaters subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Gastrointestinal disorders | | | |
| Abdominal discomfort subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Abdominal distension subjects affected / exposed occurrences (all) | 2 / 30 (6.67%) 2 | 3 / 15 (20.00%) 3 | 0 / 4 (0.00%) 0 |
| Abdominal pain subjects affected / exposed occurrences (all) | 6 / 30 (20.00%) 6 | 2 / 15 (13.33%) 2 | 0 / 4 (0.00%) 0 |
| Abdominal pain lower subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Abdominal pain upper subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 1 / 15 (6.67%) 1 | 0 / 4 (0.00%) 0 |
| Abdominal tenderness subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Angular cheilitis subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 1 / 15 (6.67%) 1 | 0 / 4 (0.00%) 0 |
| Ascites subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 2 / 15 (13.33%) 3 | 0 / 4 (0.00%) 0 |
| Chapped lips subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 1 / 15 (6.67%) 1 | 0 / 4 (0.00%) 0 |

| | | | |
|----------------------------------|------------------|-----------------|----------------|
| Colitis | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Constipation | | | |
| subjects affected / exposed | 12 / 30 (40.00%) | 4 / 15 (26.67%) | 1 / 4 (25.00%) |
| occurrences (all) | 13 | 6 | 2 |
| Diarrhoea | | | |
| subjects affected / exposed | 15 / 30 (50.00%) | 9 / 15 (60.00%) | 1 / 4 (25.00%) |
| occurrences (all) | 18 | 12 | 2 |
| Diarrhoea haemorrhagic | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Dry mouth | | | |
| subjects affected / exposed | 13 / 30 (43.33%) | 8 / 15 (53.33%) | 2 / 4 (50.00%) |
| occurrences (all) | 13 | 8 | 2 |
| Dyspepsia | | | |
| subjects affected / exposed | 5 / 30 (16.67%) | 0 / 15 (0.00%) | 1 / 4 (25.00%) |
| occurrences (all) | 5 | 0 | 1 |
| Dysphagia | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Eructation | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flatulence | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 1 / 4 (25.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 3 / 15 (20.00%) | 1 / 4 (25.00%) |
| occurrences (all) | 1 | 3 | 1 |
| Gingival pain | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|------------------|-----------------|----------------|
| Glossodynia | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haematochezia | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemorrhoidal haemorrhage | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemorrhoids | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hiatus hernia | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperaesthesia teeth | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoaesthesia oral | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lip ulceration | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Loose tooth | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mouth ulceration | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Nausea | | | |
| subjects affected / exposed | 13 / 30 (43.33%) | 5 / 15 (33.33%) | 3 / 4 (75.00%) |
| occurrences (all) | 15 | 5 | 3 |
| Oesophageal hypomotility | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|------------------|-----------------|----------------|
| Oesophageal stenosis | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oesophageal ulcer | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral dysaesthesia | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 1 / 4 (25.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Oral pain | | | |
| subjects affected / exposed | 7 / 30 (23.33%) | 2 / 15 (13.33%) | 0 / 4 (0.00%) |
| occurrences (all) | 8 | 2 | 0 |
| Paraesthesia oral | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rectal tenesmus | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Stomatitis | | | |
| subjects affected / exposed | 15 / 30 (50.00%) | 7 / 15 (46.67%) | 2 / 4 (50.00%) |
| occurrences (all) | 18 | 11 | 2 |
| Tongue erythema | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth disorder | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vomiting | | | |
| subjects affected / exposed | 9 / 30 (30.00%) | 3 / 15 (20.00%) | 2 / 4 (50.00%) |
| occurrences (all) | 12 | 6 | 4 |
| Hepatobiliary disorders | | | |
| Hyperbilirubinaemia | | | |

| | | | |
|--|------------------------|----------------------|---------------------|
| subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 3 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Portal vein thrombosis subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Skin and subcutaneous tissue disorders | | | |
| Actinic keratosis subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Alopecia subjects affected / exposed occurrences (all) | 11 / 30 (36.67%) 12 | 5 / 15 (33.33%) 5 | 1 / 4 (25.00%) 1 |
| Decubitus ulcer subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Dry skin subjects affected / exposed occurrences (all) | 7 / 30 (23.33%) 7 | 1 / 15 (6.67%) 1 | 1 / 4 (25.00%) 1 |
| Ecchymosis subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Eczema subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Eczema asteatotic subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Erythema subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Hyperhidrosis subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Hyperkeratosis subjects affected / exposed occurrences (all) | 2 / 30 (6.67%) 2 | 1 / 15 (6.67%) 1 | 0 / 4 (0.00%) 0 |

| | | | |
|-----------------------------|-----------------|-----------------|----------------|
| Hypertrichosis | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Lichenoid keratosis | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Madarosis | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nail bed bleeding | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nail bed tenderness | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nail discolouration | | | |
| subjects affected / exposed | 7 / 30 (23.33%) | 3 / 15 (20.00%) | 1 / 4 (25.00%) |
| occurrences (all) | 7 | 3 | 1 |
| Nail hypertrophy | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nail ridging | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 1 / 4 (25.00%) |
| occurrences (all) | 1 | 0 | 1 |
| Onychoclasia | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Onycholysis | | | |
| subjects affected / exposed | 9 / 30 (30.00%) | 3 / 15 (20.00%) | 1 / 4 (25.00%) |
| occurrences (all) | 11 | 3 | 1 |
| Onychomadesis | | | |
| subjects affected / exposed | 6 / 30 (20.00%) | 0 / 15 (0.00%) | 2 / 4 (50.00%) |
| occurrences (all) | 7 | 0 | 3 |
| Pain of skin | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|--|-----------------|-----------------|----------------|
| Palmar-plantar erythrodysesthesia syndrome | | | |
| subjects affected / exposed | 8 / 30 (26.67%) | 3 / 15 (20.00%) | 2 / 4 (50.00%) |
| occurrences (all) | 9 | 5 | 2 |
| Paraneoplastic pemphigus | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 3 / 30 (10.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Psoriasis | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash | | | |
| subjects affected / exposed | 5 / 30 (16.67%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 8 | 0 | 0 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Rash papular | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash pruritic | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin fissures | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Skin induration | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin irritation | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Skin lesion | | | |

| | | | |
|--|----------------------|---------------------|--------------------|
| subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 1 / 15 (6.67%) 1 | 0 / 4 (0.00%) 0 |
| Skin ulcer subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Urticaria subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Vitiligo subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury subjects affected / exposed occurrences (all) | 3 / 30 (10.00%) 3 | 1 / 15 (6.67%) 1 | 0 / 4 (0.00%) 0 |
| Autoimmune nephritis subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Bladder pain subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 1 / 15 (6.67%) 1 | 0 / 4 (0.00%) 0 |
| Bladder spasm subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Dysuria subjects affected / exposed occurrences (all) | 2 / 30 (6.67%) 4 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Haematuria subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Hydronephrosis subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Lower urinary tract symptoms subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |

| | | | |
|-------------------------------|-----------------|----------------|----------------|
| Micturition urgency | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Nephrolithiasis | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nocturia | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pollakiuria | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary retention | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 1 / 4 (25.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Urinary tract obstruction | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Urinary tract pain | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Endocrine disorders | | | |
| Adrenal insufficiency | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperparathyroidism | | | |
| subjects affected / exposed | 3 / 30 (10.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Hyperparathyroidism secondary | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperthyroidism | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoparathyroidism | | | |

| | | | |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypothyroidism | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 1 / 4 (25.00%) |
| occurrences (all) | 1 | 0 | 1 |
| Steroid withdrawal syndrome | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thyroiditis | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 4 / 30 (13.33%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 6 | 1 | 0 |
| Arthritis | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Back pain | | | |
| subjects affected / exposed | 3 / 30 (10.00%) | 0 / 15 (0.00%) | 1 / 4 (25.00%) |
| occurrences (all) | 4 | 0 | 1 |
| Bone pain | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flank pain | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | 2 / 15 (13.33%) | 1 / 4 (25.00%) |
| occurrences (all) | 2 | 2 | 1 |
| Joint swelling | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscle spasms | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Muscle tightness | | | |

| | | | |
|-----------------------------|-----------------|-----------------|---------------|
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscular weakness | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Myalgia | | | |
| subjects affected / exposed | 5 / 30 (16.67%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 5 | 0 | 0 |
| Neck pain | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Osteoarthritis | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Osteonecrosis of jaw | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain in extremity | | | |
| subjects affected / exposed | 5 / 30 (16.67%) | 3 / 15 (20.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 6 | 3 | 0 |
| Trismus | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infections and infestations | | | |
| Acute sinusitis | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Body tinea | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| Bronchitis | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Candida infection | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 1 / 4 (25.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Catheter site cellulitis | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cellulitis | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Conjunctivitis | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Diverticulitis | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear infection | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye infection | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 1 / 4 (25.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Gastroenteritis viral | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Herpes ophthalmic | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Herpes simplex | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Influenza | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |

| | | | |
|-----------------------------|-----------------|-----------------|----------------|
| Nail infection | | | |
| subjects affected / exposed | 3 / 30 (10.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Oral candidiasis | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 2 / 15 (13.33%) | 0 / 4 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Oral herpes | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Paronychia | | | |
| subjects affected / exposed | 4 / 30 (13.33%) | 2 / 15 (13.33%) | 0 / 4 (0.00%) |
| occurrences (all) | 6 | 2 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumonia | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Sinusitis | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Skin infection | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 1 / 4 (25.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Tinea pedis | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Tinea versicolour | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth infection | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|------------------------|----------------------|----------------------|
| Upper respiratory tract infection subjects affected / exposed occurrences (all) | 4 / 30 (13.33%) 4 | 1 / 15 (6.67%) 1 | 0 / 4 (0.00%) 0 |
| Urinary tract infection subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | 5 / 15 (33.33%) 5 | 2 / 4 (50.00%) 2 |
| Urinary tract infection bacterial subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Vaginal infection subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Metabolism and nutrition disorders | | | |
| Cachexia subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Decreased appetite subjects affected / exposed occurrences (all) | 11 / 30 (36.67%) 11 | 5 / 15 (33.33%) 5 | 2 / 4 (50.00%) 2 |
| Dehydration subjects affected / exposed occurrences (all) | 4 / 30 (13.33%) 4 | 4 / 15 (26.67%) 4 | 4 / 4 (100.00%) 6 |
| Fluid overload subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Fluid retention subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Glucose tolerance impaired subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 1 / 15 (6.67%) 1 | 0 / 4 (0.00%) 0 |
| Hypercalcaemia subjects affected / exposed occurrences (all) | 8 / 30 (26.67%) 9 | 3 / 15 (20.00%) 3 | 1 / 4 (25.00%) 1 |
| Hypercholesterolaemia | | | |

| | | | |
|-----------------------------|------------------|------------------|-----------------|
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | 2 / 15 (13.33%) | 0 / 4 (0.00%) |
| occurrences (all) | 3 | 2 | 0 |
| Hyperkalaemia | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hyperphosphataemia | | | |
| subjects affected / exposed | 28 / 30 (93.33%) | 13 / 15 (86.67%) | 4 / 4 (100.00%) |
| occurrences (all) | 49 | 19 | 5 |
| Hypertriglyceridaemia | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Hyperuricaemia | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Hypoalbuminaemia | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 4 | 1 | 0 |
| Hypocalcaemia | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypoglycaemia | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 15 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypokalaemia | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 2 / 15 (13.33%) | 1 / 4 (25.00%) |
| occurrences (all) | 1 | 3 | 1 |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 1 / 15 (6.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 8 / 30 (26.67%) | 4 / 15 (26.67%) | 0 / 4 (0.00%) |
| occurrences (all) | 14 | 5 | 0 |
| Hypophosphataemia | | | |

| | | | |
|--|----------------------|----------------------|---------------------|
| subjects affected / exposed occurrences (all) | 5 / 30 (16.67%) 7 | 2 / 15 (13.33%) 2 | 2 / 4 (50.00%) 2 |
| Malnutrition subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Metabolic acidosis subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 15 (0.00%) 0 | 1 / 4 (25.00%) 1 |
| Vitamin D deficiency subjects affected / exposed occurrences (all) | 4 / 30 (13.33%) 4 | 1 / 15 (6.67%) 1 | 0 / 4 (0.00%) 0 |

| Non-serious adverse events | Part 1: Continuous pemigatinib 10 mg BID | Part 3: Gem/Cis/intermittent pemigatinib 9 mg | Part 3: Gem/Cis/intermittent pemigatinib 13.5 mg |
|--|--|---|---|
| Total subjects affected by non-serious adverse events subjects affected / exposed | 3 / 3 (100.00%) | 1 / 1 (100.00%) | 7 / 7 (100.00%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) Benign neoplasm of thyroid gland subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Cancer pain subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Melanocytic naevus subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Metastases to central nervous system subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Pyogenic granuloma subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Seborrhoeic keratosis subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |

| | | | |
|--|---------------------|--------------------|---------------------|
| Skin papilloma subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Vascular disorders | | | |
| Diastolic hypertension subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Hot flush subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Hypertension subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Hypotension subjects affected / exposed occurrences (all) | 1 / 3 (33.33%) 1 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Systolic hypertension subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Thrombophlebitis subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Venous thrombosis subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 1 / 7 (14.29%) 1 |
| General disorders and administration site conditions | | | |
| Asthenia subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 1 / 7 (14.29%) 1 |
| Catheter site pain subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Chest discomfort subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Chills | | | |

| | | | |
|------------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fatigue | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 5 / 7 (71.43%) |
| occurrences (all) | 0 | 0 | 5 |
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Generalised oedema | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Influenza like illness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mucosal inflammation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 2 / 7 (28.57%) |
| occurrences (all) | 0 | 0 | 2 |
| Oedema peripheral | | | |
| subjects affected / exposed | 2 / 3 (66.67%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 2 | 0 | 1 |
| Pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Performance status decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Peripheral swelling | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Swelling face | | | |

| | | | |
|---|--------------------|--------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Tenderness subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Immune system disorders Allergy to animal subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Drug hypersensitivity subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Hypersensitivity subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Reproductive system and breast disorders Breast fibrosis subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Postmenopausal haemorrhage subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Respiratory, thoracic and mediastinal disorders Aspiration subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Cough subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 1 / 7 (14.29%) 1 |
| Dysphonia subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Dyspnoea subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 2 / 7 (28.57%) 2 |
| Dyspnoea exertional | | | |

| | | | |
|-----------------------------|---------------|---------------|---------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Epistaxis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hiccups | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoxia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal congestion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal discomfort | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal dryness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal septum deviation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paranasal sinus discomfort | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pharyngeal inflammation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pleural effusion | | | |

| | | | |
|-------------------------------------|----------------|---------------|---------------|
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Productive cough | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rales | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory tract congestion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinitis allergic | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinorrhoea | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhonchi | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus disorder | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sneezing | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper-airway cough syndrome | | | |

| | | | |
|---|--------------------|--------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Wheezing subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Psychiatric disorders | | | |
| Adjustment disorder with depressed mood subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Anxiety subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Confusional state subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Depression subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Disorientation subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Insomnia subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 1 / 7 (14.29%) 1 |
| Restlessness subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Investigations | | | |
| Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Alanine aminotransferase increased subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 4 / 7 (57.14%) 10 |
| Amylase increased | | | |

| | | | |
|---|---------------|-----------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 4 / 7 (57.14%) |
| occurrences (all) | 0 | 0 | 9 |
| Blood 1,25-dihydroxycholecalciferol decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood 1,25-dihydroxycholecalciferol increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood 25-hydroxycholecalciferol decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 2 |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 1 (100.00%) | 4 / 7 (57.14%) |
| occurrences (all) | 0 | 1 | 6 |
| Blood folate decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood glucose increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 2 / 7 (28.57%) |
| occurrences (all) | 0 | 0 | 4 |
| Blood phosphorus increased | | | |

| | | | |
|---|---------------|-----------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 2 |
| Blood thyroid stimulating hormone decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood uric acid increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Computerised tomogram abnormal | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gamma-glutamyltransferase increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lipase increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Liver function test increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 1 (100.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 2 | 4 |
| Neutrophil count increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Platelet count decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 1 (100.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 1 | 3 |
| Urine analysis abnormal | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitamin B12 decreased | | | |

| | | | |
|--|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitamin D decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitamin D increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 1 (100.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Weight decreased | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 1 | 0 | 1 |
| Weight increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| White blood cell count decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 1 (100.00%) | 3 / 7 (42.86%) |
| occurrences (all) | 0 | 2 | 5 |
| White blood cell count increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Injury, poisoning and procedural complications | | | |
| Contusion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fall | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infusion related reaction | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Limb injury | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lip injury | | | |

| | | | |
|---|--------------------|--------------------|--------------------|
| subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Nail avulsion subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Procedural pain subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Skin abrasion subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Tooth fracture subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Wound complication subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Congenital, familial and genetic disorders Corneal dystrophy subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Cardiac disorders Atrial thrombosis subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Bradycardia subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Nodal rhythm subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Palpitations subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Sinus tachycardia | | | |

| | | | |
|-----------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tachycardia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nervous system disorders | | | |
| Ataxia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dizziness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 3 / 7 (42.86%) |
| occurrences (all) | 0 | 0 | 3 |
| Dysarthria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Dysgeusia | | | |
| subjects affected / exposed | 2 / 3 (66.67%) | 0 / 1 (0.00%) | 2 / 7 (28.57%) |
| occurrences (all) | 2 | 0 | 2 |
| Headache | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Hyperaesthesia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoaesthesia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Memory impairment | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 2 / 7 (28.57%) |
| occurrences (all) | 0 | 0 | 2 |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |

| | | | |
|---|----------------|-----------------|-----------------|
| Presyncope | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Restless legs syndrome | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Seizure | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Somnolence | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Taste disorder | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Tremor | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Vocal cord paralysis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 1 / 1 (100.00%) | 7 / 7 (100.00%) |
| occurrences (all) | 1 | 1 | 8 |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Leukopenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 2 / 7 (28.57%) |
| occurrences (all) | 0 | 0 | 3 |
| Lymph node pain | | | |

| | | | |
|------------------------------|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphadenopathy | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Lymphopenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Microcytic anaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutropenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 4 / 7 (57.14%) |
| occurrences (all) | 0 | 0 | 9 |
| Thrombocytopenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 1 (100.00%) | 4 / 7 (57.14%) |
| occurrences (all) | 0 | 1 | 9 |
| Ear and labyrinth disorders | | | |
| Cerumen impaction | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Deafness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear congestion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Excessive cerumen production | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tinnitus | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |

| | | | |
|--|---------------|---------------|---------------|
| Vertigo | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye disorders | | | |
| Blepharitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blepharospasm | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cataract | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cataract cortical | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cataract nuclear | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cataract subcapsular | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chorioretinopathy | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctival haemorrhage | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Corneal epithelium defect | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Detachment of macular retinal pigment epithelium | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diplopia | | | |

| | | | |
|--------------------------------------|----------------|---------------|---------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry age-related macular degeneration | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry eye | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Entropion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye discharge | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eye irritation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye pruritus | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eyelid function disorder | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eyelid pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eyelid ptosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Growth of eyelashes | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|----------------|---------------|---------------|
| Iridocyclitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Keratitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Keratopathy | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lacrimation decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lacrimation increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Macular fibrosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Meibomian gland dysfunction | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ocular discomfort | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ocular hyperaemia | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Ocular hypertension | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Ocular surface disease | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Periorbital oedema | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|---------------|---------------|----------------|
| Photophobia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Photopsia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pterygium | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Punctate keratitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Retinal degeneration | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Retinal detachment | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Retinal disorder | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Retinal fovea disorder | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Retinal oedema | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Scleral discolouration | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Scleral hyperaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Subretinal fluid | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---------------------------------|---------------|-----------------|----------------|
| Trichiasis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ulcerative keratitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vision blurred | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Visual acuity reduced | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Visual impairment | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitreoretinal traction syndrome | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitreous detachment | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitreous floaters | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal disorders | | | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Abdominal distension | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 1 (100.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 1 | 1 |
| Abdominal pain lower | | | |

| | | | |
|-----------------------------|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Abdominal tenderness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Angular cheilitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ascites | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chapped lips | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Colitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Constipation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 4 / 7 (57.14%) |
| occurrences (all) | 0 | 0 | 4 |
| Diarrhoea | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | 4 / 7 (57.14%) |
| occurrences (all) | 2 | 0 | 7 |
| Diarrhoea haemorrhagic | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry mouth | | | |
| subjects affected / exposed | 3 / 3 (100.00%) | 1 / 1 (100.00%) | 2 / 7 (28.57%) |
| occurrences (all) | 3 | 1 | 2 |
| Dyspepsia | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 1 | 0 | 1 |
| Dysphagia | | | |

| | | | |
|----------------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eructation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flatulence | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 2 / 7 (28.57%) |
| occurrences (all) | 0 | 0 | 2 |
| Gingival pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glossodynia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haematochezia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Haemorrhoidal haemorrhage | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemorrhoids | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hiatus hernia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperaesthesia teeth | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoaesthesia oral | | | |

| | | | |
|-----------------------------|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lip ulceration | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Loose tooth | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mouth ulceration | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Nausea | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 1 (100.00%) | 4 / 7 (57.14%) |
| occurrences (all) | 0 | 1 | 4 |
| Oesophageal hypomotility | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oesophageal stenosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oesophageal ulcer | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral dysaesthesia | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Oral pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paraesthesia oral | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rectal tenesmus | | | |

| | | | |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Stomatitis | | | |
| subjects affected / exposed | 3 / 3 (100.00%) | 1 / 1 (100.00%) | 2 / 7 (28.57%) |
| occurrences (all) | 5 | 1 | 2 |
| Tongue erythema | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth disorder | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 3 / 7 (42.86%) |
| occurrences (all) | 0 | 0 | 5 |
| Hepatobiliary disorders | | | |
| Hyperbilirubinaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Portal vein thrombosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| Actinic keratosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Alopecia | | | |
| subjects affected / exposed | 2 / 3 (66.67%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 2 | 0 | 1 |
| Decubitus ulcer | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry skin | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ecchymosis | | | |

| | | | |
|-----------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eczema | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eczema asteatotic | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erythema | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Hyperhidrosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperkeratosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypertrichosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lichenoid keratosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Madarosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nail bed bleeding | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nail bed tenderness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nail discolouration | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nail hypertrophy | | | |

| | | | |
|--|----------------|---------------|---------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nail ridging | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Onychoclasia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Onycholysis | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Onychomadesis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain of skin | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Palmar-plantar erythrodysesthesia syndrome | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paraneoplastic pemphigus | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Psoriasis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|---------------|---------------|----------------|
| Rash papular | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash pruritic | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin fissures | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin induration | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Skin irritation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin lesion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin ulcer | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urticaria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitiligo | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Autoimmune nephritis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bladder pain | | | |

| | | | |
|------------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bladder spasm | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysuria | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Haematuria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 2 |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lower urinary tract symptoms | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Micturition urgency | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nephrolithiasis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nocturia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pollakiuria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary retention | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 2 / 7 (28.57%) |
| occurrences (all) | 0 | 0 | 2 |
| Urinary tract obstruction | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary tract pain | | | |

| | | | |
|---|---------------------|--------------------|--------------------|
| subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Endocrine disorders | | | |
| Adrenal insufficiency subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Hyperparathyroidism subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Hyperparathyroidism secondary subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Hyperthyroidism subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Hypoparathyroidism subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Hypothyroidism subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Steroid withdrawal syndrome subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Thyroiditis subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia subjects affected / exposed occurrences (all) | 1 / 3 (33.33%) 2 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Arthritis subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Back pain | | | |

| | | | |
|-----------------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bone pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flank pain | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Joint swelling | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscle spasms | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscle tightness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscular weakness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Myalgia | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Neck pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Osteoarthritis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Osteonecrosis of jaw | | | |

| | | | |
|--|---------------------|--------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Pain in extremity subjects affected / exposed occurrences (all) | 1 / 3 (33.33%) 1 | 0 / 1 (0.00%) 0 | 1 / 7 (14.29%) 1 |
| Trismus subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 1 / 7 (14.29%) 1 |
| Infections and infestations | | | |
| Acute sinusitis subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Body tinea subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Bronchitis subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Candida infection subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Catheter site cellulitis subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Cellulitis subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Conjunctivitis subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Diverticulitis subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Ear infection subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 7 (0.00%) 0 |

| | | | |
|-----------------------------|----------------|---------------|----------------|
| Eye infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastroenteritis viral | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Herpes ophthalmic | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Herpes simplex | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nail infection | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 2 |
| Oral candidiasis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral herpes | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paronychia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |

| | | | |
|------------------------------------|----------------|---------------|----------------|
| Sinusitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tinea pedis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tinea versicolour | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Urinary tract infection bacterial | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vaginal infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metabolism and nutrition disorders | | | |
| Cachexia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Decreased appetite | | | |
| subjects affected / exposed | 2 / 3 (66.67%) | 0 / 1 (0.00%) | 2 / 7 (28.57%) |
| occurrences (all) | 2 | 0 | 2 |
| Dehydration | | | |

| | | | |
|-----------------------------|-----------------|-----------------|----------------|
| subjects affected / exposed | 1 / 3 (33.33%) | 1 / 1 (100.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 1 | 1 | 1 |
| Fluid overload | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fluid retention | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Glucose tolerance impaired | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypercholesterolaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Hyperkalaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 2 |
| Hyperphosphataemia | | | |
| subjects affected / exposed | 3 / 3 (100.00%) | 1 / 1 (100.00%) | 3 / 7 (42.86%) |
| occurrences (all) | 5 | 1 | 6 |
| Hypertriglyceridaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperuricaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Hypoalbuminaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 1 (100.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hypocalcaemia | | | |

| | | | |
|-----------------------------|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoglycaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypokalaemia | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 1 / 1 (100.00%) | 2 / 7 (28.57%) |
| occurrences (all) | 2 | 2 | 3 |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 1 / 1 (100.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 1 | 1 | 1 |
| Hyponatraemia | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 1 / 1 (100.00%) | 3 / 7 (42.86%) |
| occurrences (all) | 2 | 1 | 3 |
| Hypophosphataemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Malnutrition | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metabolic acidosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitamin D deficiency | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| Non-serious adverse events | Part 3: Tras/intermittent pemigatinib 13.5 mg | Part 3: Doc/intermittent pemigatinib 13.5 mg | Part 3: Pem/intermittent pemigatinib 9 mg |
|---|---|--|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 6 / 6 (100.00%) | 7 / 7 (100.00%) | 3 / 3 (100.00%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Benign neoplasm of thyroid gland | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cancer pain | | | |

| | | | |
|--------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Melanocytic naevus | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metastases to central nervous system | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pyogenic granuloma | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Seborrhoeic keratosis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin papilloma | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vascular disorders | | | |
| Diastolic hypertension | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hot flush | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypertension | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypotension | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 2 / 7 (28.57%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 2 | 1 |
| Systolic hypertension | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Thrombophlebitis | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Venous thrombosis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Catheter site pain | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chest discomfort | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chills | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Fatigue | | | |
| subjects affected / exposed | 2 / 6 (33.33%) | 5 / 7 (71.43%) | 1 / 3 (33.33%) |
| occurrences (all) | 2 | 6 | 1 |
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Generalised oedema | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza like illness | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Mucosal inflammation | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Non-cardiac chest pain | | | |

| | | | |
|--|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 2 / 7 (28.57%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Pain | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Performance status decreased | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Peripheral swelling | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pyrexia | | | |
| subjects affected / exposed | 2 / 6 (33.33%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Swelling face | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tenderness | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Immune system disorders | | | |
| Allergy to animal | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Drug hypersensitivity | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypersensitivity | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Reproductive system and breast disorders | | | |

| | | | |
|---|----------------|----------------|----------------|
| Breast fibrosis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Postmenopausal haemorrhage | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Aspiration | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cough | | | |
| subjects affected / exposed | 4 / 6 (66.67%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 4 | 1 | 0 |
| Dysphonia | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 2 / 6 (33.33%) | 0 / 7 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 2 | 0 | 1 |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Epistaxis | | | |
| subjects affected / exposed | 2 / 6 (33.33%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hiccups | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoxia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal congestion | | | |

| | | | |
|------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal discomfort | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal dryness | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nasal septum deviation | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Paranasal sinus discomfort | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pharyngeal inflammation | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Productive cough | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rales | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory tract congestion | | | |

| | | | |
|---|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinitis allergic | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinorrhoea | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhonchi | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus disorder | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus pain | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sneezing | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Upper-airway cough syndrome | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Wheezing | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Psychiatric disorders | | | |
| Adjustment disorder with depressed mood | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anxiety | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Confusional state | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Depression | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Disorientation | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Insomnia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Restlessness | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Investigations | | | |
| Activated partial thromboplastin time prolonged | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Amylase increased | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood 1,25-dihydroxycholecalciferol decreased | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Blood 1,25-dihydroxycholecalciferol increased | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Blood 25-hydroxycholecalciferol decreased | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 6 (16.67%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 1 / 7 (14.29%) | 1 / 3 (33.33%) |
| occurrences (all) | 1 | 1 | 1 |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine increased | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 1 / 7 (14.29%) | 1 / 3 (33.33%) |
| occurrences (all) | 1 | 1 | 1 |
| Blood folate decreased | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood glucose increased | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood phosphorus increased | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood thyroid stimulating hormone decreased | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood uric acid increased | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Computerised tomogram abnormal | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gamma-glutamyltransferase increased | | | |

| | | | |
|----------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lipase increased | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Liver function test increased | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count increased | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Platelet count decreased | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urine analysis abnormal | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitamin B12 decreased | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitamin D decreased | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitamin D increased | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Weight decreased | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 3 / 7 (42.86%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 4 | 0 |
| Weight increased | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| White blood cell count decreased | | | |

| | | | |
|--|---------------|----------------|----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| White blood cell count increased | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Injury, poisoning and procedural complications | | | |
| Contusion | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fall | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Infusion related reaction | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Limb injury | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Lip injury | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nail avulsion | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Procedural pain | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Skin abrasion | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth fracture | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Wound complication | | | |

| | | | |
|---|--------------------|---------------------|--------------------|
| subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Congenital, familial and genetic disorders | | | |
| Corneal dystrophy subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Cardiac disorders | | | |
| Atrial thrombosis subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Bradycardia subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Nodal rhythm subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Palpitations subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Sinus tachycardia subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Tachycardia subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Nervous system disorders | | | |
| Ataxia subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Dizziness subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 1 / 7 (14.29%) 1 | 0 / 3 (0.00%) 0 |
| Dysarthria subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Dysgeusia | | | |

| | | | |
|-----------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 3 / 7 (42.86%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Headache | | | |
| subjects affected / exposed | 2 / 6 (33.33%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Hyperaesthesia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoaesthesia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Memory impairment | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Presyncope | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Restless legs syndrome | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Seizure | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Somnolence | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Taste disorder | | | |

| | | | |
|--|---------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 2 / 6 (33.33%) 2 | 3 / 7 (42.86%) 3 | 0 / 3 (0.00%) 0 |
| Tremor | | | |
| subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Vocal cord paralysis | | | |
| subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed occurrences (all) | 2 / 6 (33.33%) 2 | 3 / 7 (42.86%) 3 | 1 / 3 (33.33%) 1 |
| Iron deficiency anaemia | | | |
| subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Leukopenia | | | |
| subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Lymph node pain | | | |
| subjects affected / exposed occurrences (all) | 1 / 6 (16.67%) 1 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Lymphadenopathy | | | |
| subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Lymphopenia | | | |
| subjects affected / exposed occurrences (all) | 1 / 6 (16.67%) 1 | 1 / 7 (14.29%) 1 | 0 / 3 (0.00%) 0 |
| Microcytic anaemia | | | |
| subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Neutropenia | | | |
| subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 3 / 7 (42.86%) 6 | 0 / 3 (0.00%) 0 |
| Thrombocytopenia | | | |
| subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |

| | | | |
|------------------------------|---------------|----------------|---------------|
| Ear and labyrinth disorders | | | |
| Cerumen impaction | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Deafness | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear congestion | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear pain | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Excessive cerumen production | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tinnitus | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vertigo | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Eye disorders | | | |
| Blepharitis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blepharospasm | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cataract | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cataract cortical | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cataract nuclear | | | |

| | | | |
|--|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Cataract subcapsular | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Chorioretinopathy | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctival haemorrhage | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Corneal epithelium defect | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Detachment of macular retinal pigment epithelium | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Diplopia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry age-related macular degeneration | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry eye | | | |
| subjects affected / exposed | 2 / 6 (33.33%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Entropion | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye discharge | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye irritation | | | |

| | | | |
|-----------------------------|---------------|----------------|---------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye pain | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Eye pruritus | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eyelid function disorder | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eyelid pain | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eyelid ptosis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Growth of eyelashes | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Iridocyclitis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Keratitis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Keratopathy | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Lacrimation decreased | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lacrimation increased | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Macular fibrosis | | | |

| | | | |
|-----------------------------|----------------|---------------|---------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Meibomian gland dysfunction | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ocular discomfort | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ocular hyperaemia | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Ocular hypertension | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ocular surface disease | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Periorbital oedema | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Photophobia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Photopsia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pterygium | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Punctate keratitis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Retinal degeneration | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Retinal detachment | | | |

| | | | |
|---------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Retinal disorder | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Retinal fovea disorder | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Retinal oedema | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Scleral discolouration | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Scleral hyperaemia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Subretinal fluid | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Trichiasis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ulcerative keratitis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vision blurred | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 2 / 7 (28.57%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Visual acuity reduced | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Visual impairment | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Vitreoretinal traction syndrome | | | |

| | | | |
|--|--------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Vitreous detachment subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Vitreous floaters subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Gastrointestinal disorders | | | |
| Abdominal discomfort subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Abdominal distension subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Abdominal pain subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 1 / 7 (14.29%) 1 | 0 / 3 (0.00%) 0 |
| Abdominal pain lower subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Abdominal pain upper subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Abdominal tenderness subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Angular cheilitis subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Ascites subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 1 / 3 (33.33%) 1 |
| Chapped lips subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |

| | | | |
|----------------------------------|----------------|----------------|----------------|
| Colitis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Constipation | | | |
| subjects affected / exposed | 2 / 6 (33.33%) | 3 / 7 (42.86%) | 0 / 3 (0.00%) |
| occurrences (all) | 2 | 4 | 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 3 / 6 (50.00%) | 6 / 7 (85.71%) | 1 / 3 (33.33%) |
| occurrences (all) | 3 | 13 | 1 |
| Diarrhoea haemorrhagic | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry mouth | | | |
| subjects affected / exposed | 4 / 6 (66.67%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 4 | 1 | 0 |
| Dyspepsia | | | |
| subjects affected / exposed | 2 / 6 (33.33%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Dysphagia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eructation | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flatulence | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gingival pain | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|----------------|----------------|---------------|
| Glossodynia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haematochezia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemorrhoidal haemorrhage | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Haemorrhoids | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hiatus hernia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperaesthesia teeth | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypoaesthesia oral | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lip ulceration | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Loose tooth | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mouth ulceration | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nausea | | | |
| subjects affected / exposed | 2 / 6 (33.33%) | 4 / 7 (57.14%) | 0 / 3 (0.00%) |
| occurrences (all) | 2 | 6 | 0 |
| Oesophageal hypomotility | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| Oesophageal stenosis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oesophageal ulcer | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral dysaesthesia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral pain | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Paraesthesia oral | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rectal tenesmus | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Stomatitis | | | |
| subjects affected / exposed | 2 / 6 (33.33%) | 2 / 7 (28.57%) | 1 / 3 (33.33%) |
| occurrences (all) | 2 | 2 | 1 |
| Tongue erythema | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth disorder | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 3 / 7 (42.86%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 5 | 1 |
| Hepatobiliary disorders | | | |
| Hyperbilirubinaemia | | | |

| | | | |
|--|---------------------|---------------------|--------------------|
| subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Portal vein thrombosis subjects affected / exposed occurrences (all) | 1 / 6 (16.67%) 1 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Skin and subcutaneous tissue disorders | | | |
| Actinic keratosis subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Alopecia subjects affected / exposed occurrences (all) | 5 / 6 (83.33%) 5 | 3 / 7 (42.86%) 4 | 0 / 3 (0.00%) 0 |
| Decubitus ulcer subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Dry skin subjects affected / exposed occurrences (all) | 1 / 6 (16.67%) 1 | 1 / 7 (14.29%) 1 | 0 / 3 (0.00%) 0 |
| Ecchymosis subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Eczema subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 1 / 7 (14.29%) 1 | 0 / 3 (0.00%) 0 |
| Eczema asteatotic subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 1 / 7 (14.29%) 1 | 0 / 3 (0.00%) 0 |
| Erythema subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 1 / 7 (14.29%) 1 | 0 / 3 (0.00%) 0 |
| Hyperhidrosis subjects affected / exposed occurrences (all) | 1 / 6 (16.67%) 1 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Hyperkeratosis subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 1 / 7 (14.29%) 1 | 0 / 3 (0.00%) 0 |

| | | | |
|-----------------------------|---------------|----------------|---------------|
| Hypertrichosis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lichenoid keratosis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Madarosis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nail bed bleeding | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nail bed tenderness | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nail discolouration | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nail hypertrophy | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nail ridging | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Onychoclasia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Onycholysis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Onychomadesis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain of skin | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|--|----------------|---------------|---------------|
| Palmar-plantar erythrodysesthesia syndrome | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Paraneoplastic pemphigus | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Psoriasis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash papular | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rash pruritic | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin fissures | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin induration | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin irritation | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin lesion | | | |

| | | | |
|------------------------------|---------------|----------------|---------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin ulcer | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urticaria | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitiligo | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Autoimmune nephritis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bladder pain | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bladder spasm | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysuria | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Haematuria | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Lower urinary tract symptoms | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-------------------------------|---------------|----------------|---------------|
| Micturition urgency | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nephrolithiasis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nocturia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pollakiuria | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary retention | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary tract obstruction | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary tract pain | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Endocrine disorders | | | |
| Adrenal insufficiency | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hyperparathyroidism | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperparathyroidism secondary | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperthyroidism | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoparathyroidism | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 6 (16.67%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypothyroidism | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Steroid withdrawal syndrome | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thyroiditis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 1 | 1 |
| Arthritis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Back pain | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 1 / 7 (14.29%) | 1 / 3 (33.33%) |
| occurrences (all) | 1 | 1 | 1 |
| Bone pain | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flank pain | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Joint swelling | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Muscle spasms | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Muscle tightness | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscular weakness | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Myalgia | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Neck pain | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Osteoarthritis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Osteonecrosis of jaw | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Trismus | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infections and infestations | | | |
| Acute sinusitis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Body tinea | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|---------------|----------------|---------------|
| Bronchitis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Candida infection | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Catheter site cellulitis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Diverticulitis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear infection | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye infection | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastroenteritis viral | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Herpes ophthalmic | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Herpes simplex | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|----------------|----------------|---------------|
| Nail infection | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral candidiasis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral herpes | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paronychia | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 2 / 7 (28.57%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinusitis | | | |
| subjects affected / exposed | 3 / 6 (50.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Skin infection | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Tinea pedis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tinea versicolour | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth infection | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---------------------|---------------------|---------------------|
| Upper respiratory tract infection subjects affected / exposed occurrences (all) | 2 / 6 (33.33%) 2 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Urinary tract infection subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 1 / 7 (14.29%) 2 | 0 / 3 (0.00%) 0 |
| Urinary tract infection bacterial subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 1 / 7 (14.29%) 1 | 0 / 3 (0.00%) 0 |
| Vaginal infection subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Metabolism and nutrition disorders | | | |
| Cachexia subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Decreased appetite subjects affected / exposed occurrences (all) | 3 / 6 (50.00%) 3 | 1 / 7 (14.29%) 2 | 0 / 3 (0.00%) 0 |
| Dehydration subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 4 / 7 (57.14%) 7 | 1 / 3 (33.33%) 1 |
| Fluid overload subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Fluid retention subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Glucose tolerance impaired subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Hypercalcaemia subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 1 / 7 (14.29%) 1 | 1 / 3 (33.33%) 1 |
| Hypercholesterolaemia | | | |

| | | | |
|------------------------------|----------------|----------------|-----------------|
| subjects affected / exposed | 1 / 6 (16.67%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 2 | 1 |
| Hyperkalaemia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Hyperphosphataemia | | | |
| subjects affected / exposed | 5 / 6 (83.33%) | 6 / 7 (85.71%) | 3 / 3 (100.00%) |
| occurrences (all) | 9 | 7 | 4 |
| Hypertriglyceridaemia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperuricaemia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoalbuminaemia | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 1 / 7 (14.29%) | 1 / 3 (33.33%) |
| occurrences (all) | 1 | 2 | 1 |
| Hypocalcaemia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hypoglycaemia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Hypokalaemia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 7 (14.29%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 1 | 1 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 2 / 7 (28.57%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 3 | 2 |
| Hypophosphataemia | | | |

| | | | |
|-----------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 1 / 6 (16.67%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Malnutrition | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metabolic acidosis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitamin D deficiency | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 7 (0.00%) | 2 / 3 (66.67%) |
| occurrences (all) | 0 | 0 | 2 |

| Non-serious adverse events | Part 3: Pem/intermittent pemigatinib 13.5 mg | Part 3: Pem/continuous pemigatinib 13.5 mg | Part 3: Ref/continuous pemigatinib 9 mg |
|--|--|--|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 14 / 14 (100.00%) | 9 / 9 (100.00%) | 7 / 7 (100.00%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Benign neoplasm of thyroid gland | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Cancer pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Melanocytic naevus | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Metastases to central nervous system | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Pyogenic granuloma | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Seborrhoeic keratosis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin papilloma | | | |

| | | | |
|--|----------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Vascular disorders | | | |
| Diastolic hypertension subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Hot flush subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 1 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Hypertension subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Hypotension subjects affected / exposed occurrences (all) | 2 / 14 (14.29%) 2 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Systolic hypertension subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Thrombophlebitis subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Venous thrombosis subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| General disorders and administration site conditions | | | |
| Asthenia subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 1 / 9 (11.11%) 1 | 2 / 7 (28.57%) 2 |
| Catheter site pain subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Chest discomfort subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 1 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Chills | | | |

| | | | |
|------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 1 / 14 (7.14%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Fatigue | | | |
| subjects affected / exposed | 5 / 14 (35.71%) | 1 / 9 (11.11%) | 3 / 7 (42.86%) |
| occurrences (all) | 5 | 1 | 3 |
| Gait disturbance | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Generalised oedema | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza like illness | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mucosal inflammation | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Performance status decreased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 2 |
| Peripheral swelling | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pyrexia | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 3 / 9 (33.33%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 3 | 0 |
| Swelling face | | | |

| | | | |
|--|----------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 1 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Tenderness subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 1 / 9 (11.11%) 1 | 0 / 7 (0.00%) 0 |
| Immune system disorders Allergy to animal subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Drug hypersensitivity subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Hypersensitivity subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Reproductive system and breast disorders Breast fibrosis subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Postmenopausal haemorrhage subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 1 / 7 (14.29%) 1 |
| Respiratory, thoracic and mediastinal disorders Aspiration subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 1 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Cough subjects affected / exposed occurrences (all) | 4 / 14 (28.57%) 4 | 2 / 9 (22.22%) 2 | 0 / 7 (0.00%) 0 |
| Dysphonia subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Dyspnoea subjects affected / exposed occurrences (all) | 3 / 14 (21.43%) 3 | 1 / 9 (11.11%) 1 | 2 / 7 (28.57%) 2 |
| Dyspnoea exertional | | | |

| | | | |
|-----------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Epistaxis | | | |
| subjects affected / exposed | 2 / 14 (14.29%) | 0 / 9 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 2 | 0 | 1 |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hiccups | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hypoxia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal congestion | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal discomfort | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal dryness | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nasal septum deviation | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Paranasal sinus discomfort | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pharyngeal inflammation | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pleural effusion | | | |

| | | | |
|------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Productive cough | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rales | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory tract congestion | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinitis allergic | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Rhinorrhoea | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhonchi | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Sinus disorder | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sneezing | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper-airway cough syndrome | | | |

| | | | |
|---|----------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Wheezing subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 1 / 7 (14.29%) 1 |
| Psychiatric disorders | | | |
| Adjustment disorder with depressed mood subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Anxiety subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Confusional state subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 1 / 9 (11.11%) 1 | 0 / 7 (0.00%) 0 |
| Depression subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 1 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Disorientation subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 1 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Insomnia subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 1 | 0 / 9 (0.00%) 0 | 2 / 7 (28.57%) 2 |
| Restlessness subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 1 / 9 (11.11%) 1 | 0 / 7 (0.00%) 0 |
| Investigations | | | |
| Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Alanine aminotransferase increased subjects affected / exposed occurrences (all) | 5 / 14 (35.71%) 9 | 3 / 9 (33.33%) 4 | 0 / 7 (0.00%) 0 |
| Amylase increased | | | |

| | | | |
|---|-----------------|----------------|----------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 5 / 14 (35.71%) | 3 / 9 (33.33%) | 0 / 7 (0.00%) |
| occurrences (all) | 10 | 4 | 0 |
| Blood 1,25-dihydroxycholecalciferol decreased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood 1,25-dihydroxycholecalciferol increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood 25-hydroxycholecalciferol decreased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 2 / 14 (14.29%) | 3 / 9 (33.33%) | 0 / 7 (0.00%) |
| occurrences (all) | 5 | 4 | 0 |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood creatine increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 4 / 14 (28.57%) | 1 / 9 (11.11%) | 1 / 7 (14.29%) |
| occurrences (all) | 7 | 1 | 2 |
| Blood folate decreased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood glucose increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood phosphorus increased | | | |

| | | | |
|---|-----------------|---------------|---------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood thyroid stimulating hormone decreased | | | |
| subjects affected / exposed | 2 / 14 (14.29%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Blood uric acid increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Computerised tomogram abnormal | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gamma-glutamyltransferase increased | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Lipase increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Liver function test increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Platelet count decreased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urine analysis abnormal | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Vitamin B12 decreased | | | |

| | | | |
|--|----------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 1 / 7 (14.29%) 1 |
| Vitamin D decreased subjects affected / exposed occurrences (all) | 2 / 14 (14.29%) 2 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Vitamin D increased subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 1 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Weight decreased subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 2 | 1 / 9 (11.11%) 1 | 1 / 7 (14.29%) 1 |
| Weight increased subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| White blood cell count decreased subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 1 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| White blood cell count increased subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Injury, poisoning and procedural complications | | | |
| Contusion subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Fall subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 1 | 1 / 9 (11.11%) 1 | 1 / 7 (14.29%) 1 |
| Infusion related reaction subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 1 / 9 (11.11%) 1 | 0 / 7 (0.00%) 0 |
| Limb injury subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 1 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Lip injury | | | |

| | | | |
|---|---------------------|--------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Nail avulsion subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Procedural pain subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Skin abrasion subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 1 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Tooth fracture subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Wound complication subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Congenital, familial and genetic disorders Corneal dystrophy subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Cardiac disorders Atrial thrombosis subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Bradycardia subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Nodal rhythm subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 1 / 7 (14.29%) 1 |
| Palpitations subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Sinus tachycardia | | | |

| | | | |
|-----------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Tachycardia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nervous system disorders | | | |
| Ataxia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dizziness | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 2 / 9 (22.22%) | 2 / 7 (28.57%) |
| occurrences (all) | 1 | 2 | 2 |
| Dysarthria | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysgeusia | | | |
| subjects affected / exposed | 2 / 14 (14.29%) | 1 / 9 (11.11%) | 1 / 7 (14.29%) |
| occurrences (all) | 2 | 1 | 1 |
| Headache | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 2 / 7 (28.57%) |
| occurrences (all) | 1 | 0 | 3 |
| Hyperaesthesia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoaesthesia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Memory impairment | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|-----------------|----------------|----------------|
| Presyncope | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Restless legs syndrome | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Seizure | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Somnolence | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Taste disorder | | | |
| subjects affected / exposed | 2 / 14 (14.29%) | 3 / 9 (33.33%) | 2 / 7 (28.57%) |
| occurrences (all) | 3 | 3 | 2 |
| Tremor | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vocal cord paralysis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 7 / 14 (50.00%) | 3 / 9 (33.33%) | 2 / 7 (28.57%) |
| occurrences (all) | 10 | 4 | 2 |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Leukopenia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymph node pain | | | |

| | | | |
|------------------------------|-----------------|---------------|---------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphadenopathy | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphopenia | | | |
| subjects affected / exposed | 2 / 14 (14.29%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Microcytic anaemia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutropenia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thrombocytopenia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear and labyrinth disorders | | | |
| Cerumen impaction | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Deafness | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear congestion | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Excessive cerumen production | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tinnitus | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|--|----------------|---------------|----------------|
| Vertigo | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye disorders | | | |
| Blepharitis | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blepharospasm | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cataract | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cataract cortical | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 2 |
| Cataract nuclear | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Cataract subcapsular | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chorioretinopathy | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Conjunctival haemorrhage | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Corneal epithelium defect | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Detachment of macular retinal pigment epithelium | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diplopia | | | |

| | | | |
|--------------------------------------|-----------------|----------------|---------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry age-related macular degeneration | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry eye | | | |
| subjects affected / exposed | 4 / 14 (28.57%) | 4 / 9 (44.44%) | 0 / 7 (0.00%) |
| occurrences (all) | 4 | 4 | 0 |
| Entropion | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye discharge | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye irritation | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye pruritus | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eyelid function disorder | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eyelid pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eyelid ptosis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Growth of eyelashes | | | |
| subjects affected / exposed | 2 / 14 (14.29%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| Iridocyclitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Keratitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Keratopathy | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lacrimation decreased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lacrimation increased | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 1 / 9 (11.11%) | 1 / 7 (14.29%) |
| occurrences (all) | 2 | 1 | 1 |
| Macular fibrosis | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Meibomian gland dysfunction | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ocular discomfort | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Ocular hyperaemia | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Ocular hypertension | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Ocular surface disease | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Periorbital oedema | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| Photophobia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Photopsia | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pterygium | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Punctate keratitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Retinal degeneration | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Retinal detachment | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Retinal disorder | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Retinal fovea disorder | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Retinal oedema | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Scleral discolouration | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Scleral hyperaemia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Subretinal fluid | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---------------------------------|-----------------|----------------|----------------|
| Trichiasis | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 1 | 0 | 1 |
| Ulcerative keratitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vision blurred | | | |
| subjects affected / exposed | 3 / 14 (21.43%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Visual acuity reduced | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Visual impairment | | | |
| subjects affected / exposed | 2 / 14 (14.29%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Vitreoretinal traction syndrome | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitreous detachment | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitreous floaters | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Gastrointestinal disorders | | | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal distension | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Abdominal pain | | | |
| subjects affected / exposed | 2 / 14 (14.29%) | 2 / 9 (22.22%) | 0 / 7 (0.00%) |
| occurrences (all) | 7 | 2 | 0 |
| Abdominal pain lower | | | |

| | | | |
|-----------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 2 |
| Abdominal tenderness | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Angular cheilitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ascites | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 2 |
| Chapped lips | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Colitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Constipation | | | |
| subjects affected / exposed | 5 / 14 (35.71%) | 1 / 9 (11.11%) | 1 / 7 (14.29%) |
| occurrences (all) | 7 | 1 | 1 |
| Diarrhoea | | | |
| subjects affected / exposed | 7 / 14 (50.00%) | 3 / 9 (33.33%) | 3 / 7 (42.86%) |
| occurrences (all) | 17 | 7 | 6 |
| Diarrhoea haemorrhagic | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry mouth | | | |
| subjects affected / exposed | 4 / 14 (28.57%) | 5 / 9 (55.56%) | 4 / 7 (57.14%) |
| occurrences (all) | 5 | 5 | 4 |
| Dyspepsia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Dysphagia | | | |

| | | | |
|----------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 3 / 14 (21.43%) | 1 / 9 (11.11%) | 3 / 7 (42.86%) |
| occurrences (all) | 3 | 1 | 4 |
| Eructation | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flatulence | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Gingival pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glossodynia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haematochezia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Haemorrhoidal haemorrhage | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemorrhoids | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hiatus hernia | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hyperaesthesia teeth | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoaesthesia oral | | | |

| | | | |
|-----------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lip ulceration | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Loose tooth | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mouth ulceration | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nausea | | | |
| subjects affected / exposed | 3 / 14 (21.43%) | 3 / 9 (33.33%) | 2 / 7 (28.57%) |
| occurrences (all) | 8 | 3 | 4 |
| Oesophageal hypomotility | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Oesophageal stenosis | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Oesophageal ulcer | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Oral dysaesthesia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Paraesthesia oral | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rectal tenesmus | | | |

| | | | |
|--|----------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Stomatitis | | | |
| subjects affected / exposed occurrences (all) | 5 / 14 (35.71%) 7 | 3 / 9 (33.33%) 4 | 4 / 7 (57.14%) 5 |
| Tongue erythema | | | |
| subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Tooth disorder | | | |
| subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 1 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Vomiting | | | |
| subjects affected / exposed occurrences (all) | 3 / 14 (21.43%) 5 | 3 / 9 (33.33%) 3 | 2 / 7 (28.57%) 4 |
| Hepatobiliary disorders | | | |
| Hyperbilirubinaemia | | | |
| subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Portal vein thrombosis | | | |
| subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Skin and subcutaneous tissue disorders | | | |
| Actinic keratosis | | | |
| subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Alopecia | | | |
| subjects affected / exposed occurrences (all) | 6 / 14 (42.86%) 6 | 5 / 9 (55.56%) 5 | 1 / 7 (14.29%) 1 |
| Decubitus ulcer | | | |
| subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 1 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Dry skin | | | |
| subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 1 / 9 (11.11%) 1 | 0 / 7 (0.00%) 0 |
| Ecchymosis | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eczema | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eczema asteatotic | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erythema | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hyperhidrosis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperkeratosis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypertrichosis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lichenoid keratosis | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Madarosis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Nail bed bleeding | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nail bed tenderness | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 2 / 9 (22.22%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Nail discolouration | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nail hypertrophy | | | |

| | | | |
|--|-----------------|----------------|---------------|
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nail ridging | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Onychoclasia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Onycholysis | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 2 / 9 (22.22%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 3 | 0 |
| Onychomadesis | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Pain of skin | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Palmar-plantar erythrodysesthesia syndrome | | | |
| subjects affected / exposed | 2 / 14 (14.29%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 3 | 0 |
| Paraneoplastic pemphigus | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Psoriasis | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Rash | | | |
| subjects affected / exposed | 3 / 14 (21.43%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|----------------|----------------|---------------|
| Rash papular | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash pruritic | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Skin fissures | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin induration | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin irritation | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin lesion | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin ulcer | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urticaria | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitiligo | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Autoimmune nephritis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bladder pain | | | |

| | | | |
|------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bladder spasm | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Dysuria | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haematuria | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Lower urinary tract symptoms | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Micturition urgency | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nephrolithiasis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Nocturia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pollakiuria | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary retention | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Urinary tract obstruction | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary tract pain | | | |

| | | | |
|---|----------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Endocrine disorders | | | |
| Adrenal insufficiency subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Hyperparathyroidism subjects affected / exposed occurrences (all) | 2 / 14 (14.29%) 2 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Hyperparathyroidism secondary subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Hyperthyroidism subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 1 / 7 (14.29%) 1 |
| Hypoparathyroidism subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 1 | 1 / 9 (11.11%) 1 | 0 / 7 (0.00%) 0 |
| Hypothyroidism subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Steroid withdrawal syndrome subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 1 / 7 (14.29%) 1 |
| Thyroiditis subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 1 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia subjects affected / exposed occurrences (all) | 4 / 14 (28.57%) 7 | 2 / 9 (22.22%) 2 | 0 / 7 (0.00%) 0 |
| Arthritis subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 1 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Back pain | | | |

| | | | |
|-----------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 2 / 14 (14.29%) | 1 / 9 (11.11%) | 1 / 7 (14.29%) |
| occurrences (all) | 2 | 1 | 1 |
| Bone pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flank pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Joint swelling | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Muscle spasms | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 1 | 0 | 1 |
| Muscle tightness | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscular weakness | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Myalgia | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Neck pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Osteoarthritis | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Osteonecrosis of jaw | | | |

| | | | |
|--|---------------------|---------------------|--------------------|
| subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Pain in extremity subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 1 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Trismus subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Infections and infestations | | | |
| Acute sinusitis subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Body tinea subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Bronchitis subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 1 / 9 (11.11%) 2 | 0 / 7 (0.00%) 0 |
| Candida infection subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Catheter site cellulitis subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Cellulitis subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 1 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Conjunctivitis subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 2 / 9 (22.22%) 2 | 0 / 7 (0.00%) 0 |
| Diverticulitis subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 9 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Ear infection subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 1 / 9 (11.11%) 1 | 0 / 7 (0.00%) 0 |

| | | | |
|-----------------------------|-----------------|----------------|----------------|
| Eye infection | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastroenteritis viral | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Herpes ophthalmic | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Herpes simplex | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nail infection | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral candidiasis | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 2 | 0 | 3 |
| Oral herpes | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paronychia | | | |
| subjects affected / exposed | 2 / 14 (14.29%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pneumonia | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|------------------------------------|-----------------|----------------|----------------|
| Sinusitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin infection | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tinea pedis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tinea versicolour | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth infection | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 1 | 0 | 1 |
| Urinary tract infection | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 3 / 9 (33.33%) | 2 / 7 (28.57%) |
| occurrences (all) | 1 | 5 | 4 |
| Urinary tract infection bacterial | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vaginal infection | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metabolism and nutrition disorders | | | |
| Cachexia | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Decreased appetite | | | |
| subjects affected / exposed | 9 / 14 (64.29%) | 2 / 9 (22.22%) | 1 / 7 (14.29%) |
| occurrences (all) | 11 | 2 | 1 |
| Dehydration | | | |

| | | | |
|-----------------------------|------------------|----------------|----------------|
| subjects affected / exposed | 2 / 14 (14.29%) | 1 / 9 (11.11%) | 3 / 7 (42.86%) |
| occurrences (all) | 3 | 1 | 3 |
| Fluid overload | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Fluid retention | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glucose tolerance impaired | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 4 / 14 (28.57%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 6 | 0 | 0 |
| Hypercholesterolaemia | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 3 / 14 (21.43%) | 0 / 9 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 4 | 0 | 1 |
| Hyperkalaemia | | | |
| subjects affected / exposed | 2 / 14 (14.29%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Hyperphosphataemia | | | |
| subjects affected / exposed | 11 / 14 (78.57%) | 5 / 9 (55.56%) | 4 / 7 (57.14%) |
| occurrences (all) | 41 | 7 | 4 |
| Hypertriglyceridaemia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperuricaemia | | | |
| subjects affected / exposed | 2 / 14 (14.29%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Hypoalbuminaemia | | | |
| subjects affected / exposed | 2 / 14 (14.29%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Hypocalcaemia | | | |

| | | | |
|-----------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 2 / 14 (14.29%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Hypoglycaemia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypokalaemia | | | |
| subjects affected / exposed | 3 / 14 (21.43%) | 0 / 9 (0.00%) | 2 / 7 (28.57%) |
| occurrences (all) | 4 | 0 | 2 |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 5 / 14 (35.71%) | 0 / 9 (0.00%) | 3 / 7 (42.86%) |
| occurrences (all) | 5 | 0 | 3 |
| Hyponatraemia | | | |
| subjects affected / exposed | 2 / 14 (14.29%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Hypophosphataemia | | | |
| subjects affected / exposed | 3 / 14 (21.43%) | 1 / 9 (11.11%) | 0 / 7 (0.00%) |
| occurrences (all) | 4 | 1 | 0 |
| Malnutrition | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Metabolic acidosis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitamin D deficiency | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 9 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| Non-serious adverse events | Part 3: Ref/continuous pemigatinib 13.5 mg | Part 3: Ref/continuous pemigatinib 20 mg | |
|---|--|--|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 9 / 9 (100.00%) | 2 / 2 (100.00%) | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Benign neoplasm of thyroid gland | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Cancer pain | | | |

| | | | |
|--------------------------------------|----------------|----------------|--|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Melanocytic naevus | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Metastases to central nervous system | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Pyogenic granuloma | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Seborrhoeic keratosis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Skin papilloma | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Vascular disorders | | | |
| Diastolic hypertension | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Hot flush | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Hypertension | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Hypotension | | | |
| subjects affected / exposed | 2 / 9 (22.22%) | 1 / 2 (50.00%) | |
| occurrences (all) | 2 | 1 | |
| Systolic hypertension | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Thrombophlebitis | | | |

| | | | |
|---|----------------|----------------|--|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Venous thrombosis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 2 (50.00%) | |
| occurrences (all) | 0 | 2 | |
| Catheter site pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Chest discomfort | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Chills | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 2 (50.00%) | |
| occurrences (all) | 0 | 2 | |
| Fatigue | | | |
| subjects affected / exposed | 6 / 9 (66.67%) | 0 / 2 (0.00%) | |
| occurrences (all) | 10 | 0 | |
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Generalised oedema | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Influenza like illness | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 2 (50.00%) | |
| occurrences (all) | 0 | 1 | |
| Mucosal inflammation | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Non-cardiac chest pain | | | |

| | | | |
|--|----------------|----------------|--|
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 2 (50.00%) | |
| occurrences (all) | 0 | 1 | |
| Oedema peripheral | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 1 / 2 (50.00%) | |
| occurrences (all) | 1 | 1 | |
| Pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Performance status decreased | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) | |
| occurrences (all) | 3 | 0 | |
| Peripheral swelling | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 2 (50.00%) | |
| occurrences (all) | 0 | 2 | |
| Swelling face | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Tenderness | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Immune system disorders | | | |
| Allergy to animal | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Drug hypersensitivity | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Hypersensitivity | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Reproductive system and breast disorders | | | |

| | | | |
|---|----------------|----------------|--|
| Breast fibrosis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Postmenopausal haemorrhage | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Aspiration | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Cough | | | |
| subjects affected / exposed | 2 / 9 (22.22%) | 0 / 2 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Dysphonia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Dyspnoea | | | |
| subjects affected / exposed | 2 / 9 (22.22%) | 0 / 2 (0.00%) | |
| occurrences (all) | 3 | 0 | |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 2 (50.00%) | |
| occurrences (all) | 0 | 1 | |
| Epistaxis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Hiccups | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Hypoxia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Nasal congestion | | | |

| | | |
|------------------------------|----------------|---------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Nasal discomfort | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Nasal dryness | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Nasal septum deviation | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Oropharyngeal pain | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Paranasal sinus discomfort | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Pharyngeal inflammation | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Pleural effusion | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 |
| Pneumonitis | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Productive cough | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Pulmonary embolism | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 |
| Rales | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Respiratory tract congestion | | |

| | | | |
|---|---------------------|---------------------|--|
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Rhinitis allergic subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Rhinorrhoea subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 1 / 2 (50.00%) 1 | |
| Rhonchi subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Sinus disorder subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Sinus pain subjects affected / exposed occurrences (all) | 1 / 9 (11.11%) 1 | 0 / 2 (0.00%) 0 | |
| Sneezing subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 1 / 2 (50.00%) 1 | |
| Upper-airway cough syndrome subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Wheezing subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Psychiatric disorders | | | |
| Adjustment disorder with depressed mood subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Anxiety subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Confusional state | | | |

| | | | |
|---|----------------|----------------|--|
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 2 (50.00%) | |
| occurrences (all) | 0 | 1 | |
| Depression | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Disorientation | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Insomnia | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Restlessness | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Investigations | | | |
| Activated partial thromboplastin time prolonged | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Amylase increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 2 / 9 (22.22%) | 0 / 2 (0.00%) | |
| occurrences (all) | 4 | 0 | |
| Blood 1,25-dihydroxycholecalciferol decreased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Blood 1,25-dihydroxycholecalciferol increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Blood 25-hydroxycholecalciferol decreased | | | |

| | | |
|---|----------------|-----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Blood alkaline phosphatase increased | | |
| subjects affected / exposed | 2 / 9 (22.22%) | 0 / 2 (0.00%) |
| occurrences (all) | 2 | 0 |
| Blood bilirubin increased | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 |
| Blood creatine increased | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Blood creatinine increased | | |
| subjects affected / exposed | 2 / 9 (22.22%) | 2 / 2 (100.00%) |
| occurrences (all) | 5 | 4 |
| Blood folate decreased | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Blood glucose increased | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Blood phosphorus increased | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Blood thyroid stimulating hormone decreased | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Blood uric acid increased | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 2 (50.00%) |
| occurrences (all) | 0 | 1 |
| Computerised tomogram abnormal | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Gamma-glutamyltransferase increased | | |

| | | |
|----------------------------------|----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Lipase increased | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Liver function test increased | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Neutrophil count decreased | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Neutrophil count increased | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Platelet count decreased | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Urine analysis abnormal | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Vitamin B12 decreased | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Vitamin D decreased | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Vitamin D increased | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Weight decreased | | |
| subjects affected / exposed | 2 / 9 (22.22%) | 1 / 2 (50.00%) |
| occurrences (all) | 2 | 1 |
| Weight increased | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 |
| White blood cell count decreased | | |

| | | | |
|--|----------------|---------------|--|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| White blood cell count increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Injury, poisoning and procedural complications | | | |
| Contusion | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Fall | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Infusion related reaction | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Limb injury | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Lip injury | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Nail avulsion | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Procedural pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Skin abrasion | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Tooth fracture | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Wound complication | | | |

| | | | |
|---|---------------------|---------------------|--|
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Congenital, familial and genetic disorders | | | |
| Corneal dystrophy subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Cardiac disorders | | | |
| Atrial thrombosis subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 1 / 2 (50.00%) 1 | |
| Bradycardia subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Nodal rhythm subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Palpitations subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Sinus tachycardia subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Tachycardia subjects affected / exposed occurrences (all) | 1 / 9 (11.11%) 1 | 1 / 2 (50.00%) 1 | |
| Nervous system disorders | | | |
| Ataxia subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Dizziness subjects affected / exposed occurrences (all) | 1 / 9 (11.11%) 1 | 0 / 2 (0.00%) 0 | |
| Dysarthria subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Dysgeusia | | | |

| | | |
|-----------------------------|----------------|----------------|
| subjects affected / exposed | 2 / 9 (22.22%) | 0 / 2 (0.00%) |
| occurrences (all) | 3 | 0 |
| Headache | | |
| subjects affected / exposed | 2 / 9 (22.22%) | 1 / 2 (50.00%) |
| occurrences (all) | 2 | 1 |
| Hyperaesthesia | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Hypoaesthesia | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Memory impairment | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Neuropathy peripheral | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Paraesthesia | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Presyncope | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Restless legs syndrome | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Seizure | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Somnolence | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 2 (50.00%) |
| occurrences (all) | 0 | 1 |
| Syncope | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Taste disorder | | |

| | | | |
|--|--------------------|---------------------|--|
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Tremor | | | |
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Vocal cord paralysis | | | |
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 1 / 2 (50.00%) 1 | |
| Iron deficiency anaemia | | | |
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 1 / 2 (50.00%) 1 | |
| Leukopenia | | | |
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Lymph node pain | | | |
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Lymphadenopathy | | | |
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Lymphopenia | | | |
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Microcytic anaemia | | | |
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 1 / 2 (50.00%) 1 | |
| Neutropenia | | | |
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Thrombocytopenia | | | |
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |

| | | | |
|------------------------------|----------------|---------------|--|
| Ear and labyrinth disorders | | | |
| Cerumen impaction | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Deafness | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Ear congestion | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Ear pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Excessive cerumen production | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Tinnitus | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Vertigo | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Eye disorders | | | |
| Blepharitis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Blepharospasm | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Cataract | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Cataract cortical | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Cataract nuclear | | | |

| | | |
|--|----------------|---------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Cataract subcapsular | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Chorioretinopathy | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Conjunctival haemorrhage | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Corneal epithelium defect | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Detachment of macular retinal pigment epithelium | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Diplopia | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Dry age-related macular degeneration | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Dry eye | | |
| subjects affected / exposed | 3 / 9 (33.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 3 | 0 |
| Entropion | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Eye discharge | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Eye irritation | | |

| | | |
|-----------------------------|----------------|---------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Eye pain | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 |
| Eye pruritus | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Eyelid function disorder | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Eyelid pain | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Eyelid ptosis | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Growth of eyelashes | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Iridocyclitis | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Keratitis | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 |
| Keratopathy | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Lacrimation decreased | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Lacrimation increased | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 |
| Macular fibrosis | | |

| | | |
|-----------------------------|---------------|---------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Meibomian gland dysfunction | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Ocular discomfort | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Ocular hyperaemia | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Ocular hypertension | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Ocular surface disease | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Periorbital oedema | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Photophobia | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Photopsia | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Pterygium | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Punctate keratitis | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Retinal degeneration | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Retinal detachment | | |

| | | |
|---------------------------------|----------------|---------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Retinal disorder | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Retinal fovea disorder | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 |
| Retinal oedema | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Scleral discolouration | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Scleral hyperaemia | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Subretinal fluid | | |
| subjects affected / exposed | 2 / 9 (22.22%) | 0 / 2 (0.00%) |
| occurrences (all) | 2 | 0 |
| Trichiasis | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Ulcerative keratitis | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Vision blurred | | |
| subjects affected / exposed | 3 / 9 (33.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 3 | 0 |
| Visual acuity reduced | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Visual impairment | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Vitreoretinal traction syndrome | | |

| | | | |
|--|---------------------|---------------------|--|
| subjects affected / exposed occurrences (all) | 1 / 9 (11.11%) 1 | 0 / 2 (0.00%) 0 | |
| Vitreous detachment subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Vitreous floaters subjects affected / exposed occurrences (all) | 3 / 9 (33.33%) 3 | 0 / 2 (0.00%) 0 | |
| Gastrointestinal disorders | | | |
| Abdominal discomfort subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Abdominal distension subjects affected / exposed occurrences (all) | 1 / 9 (11.11%) 1 | 0 / 2 (0.00%) 0 | |
| Abdominal pain subjects affected / exposed occurrences (all) | 1 / 9 (11.11%) 1 | 0 / 2 (0.00%) 0 | |
| Abdominal pain lower subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 1 / 2 (50.00%) 1 | |
| Abdominal pain upper subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Abdominal tenderness subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Angular cheilitis subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Ascites subjects affected / exposed occurrences (all) | 1 / 9 (11.11%) 1 | 0 / 2 (0.00%) 0 | |
| Chapped lips subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |

| | | |
|----------------------------------|----------------|-----------------|
| Colitis | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Constipation | | |
| subjects affected / exposed | 3 / 9 (33.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 4 | 0 |
| Diarrhoea | | |
| subjects affected / exposed | 3 / 9 (33.33%) | 1 / 2 (50.00%) |
| occurrences (all) | 6 | 1 |
| Diarrhoea haemorrhagic | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Dry mouth | | |
| subjects affected / exposed | 3 / 9 (33.33%) | 2 / 2 (100.00%) |
| occurrences (all) | 3 | 2 |
| Dyspepsia | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 |
| Dysphagia | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 1 / 2 (50.00%) |
| occurrences (all) | 1 | 1 |
| Eructation | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 |
| Flatulence | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 |
| Gastrointestinal haemorrhage | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Gastrooesophageal reflux disease | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Gingival pain | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 |

| | | |
|-----------------------------|----------------|---------------|
| Glossodynia | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Haematochezia | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Haemorrhoidal haemorrhage | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Haemorrhoids | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Hiatus hernia | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Hyperaesthesia teeth | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Hypoaesthesia oral | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Lip ulceration | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Loose tooth | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Mouth ulceration | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Nausea | | |
| subjects affected / exposed | 3 / 9 (33.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 3 | 0 |
| Oesophageal hypomotility | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |

| | | | |
|-----------------------------|----------------|----------------|--|
| Oesophageal stenosis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Oesophageal ulcer | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Oral dysaesthesia | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Oral pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Paraesthesia oral | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Rectal tenesmus | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Stomatitis | | | |
| subjects affected / exposed | 7 / 9 (77.78%) | 1 / 2 (50.00%) | |
| occurrences (all) | 10 | 1 | |
| Tongue erythema | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Tooth disorder | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Vomiting | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 1 / 2 (50.00%) | |
| occurrences (all) | 1 | 1 | |
| Hepatobiliary disorders | | | |
| Hyperbilirubinaemia | | | |

| | | | |
|--|---------------------|----------------------|--|
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Portal vein thrombosis subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Skin and subcutaneous tissue disorders | | | |
| Actinic keratosis subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Alopecia subjects affected / exposed occurrences (all) | 3 / 9 (33.33%) 3 | 2 / 2 (100.00%) 2 | |
| Decubitus ulcer subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 1 / 2 (50.00%) 1 | |
| Dry skin subjects affected / exposed occurrences (all) | 2 / 9 (22.22%) 2 | 0 / 2 (0.00%) 0 | |
| Ecchymosis subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Eczema subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Eczema asteatotic subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Erythema subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Hyperhidrosis subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Hyperkeratosis subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |

| | | |
|-----------------------------|----------------|----------------|
| Hypertrichosis | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Lichenoid keratosis | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Madarosis | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Nail bed bleeding | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Nail bed tenderness | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Nail discolouration | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Nail hypertrophy | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Nail ridging | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 |
| Onychoclasia | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Onycholysis | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 |
| Onychomadesis | | |
| subjects affected / exposed | 2 / 9 (22.22%) | 0 / 2 (0.00%) |
| occurrences (all) | 2 | 0 |
| Pain of skin | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 2 (50.00%) |
| occurrences (all) | 0 | 1 |

| | | |
|--|----------------|---------------|
| Palmar-plantar erythrodysesthesia syndrome | | |
| subjects affected / exposed | 2 / 9 (22.22%) | 0 / 2 (0.00%) |
| occurrences (all) | 3 | 0 |
| Paraneoplastic pemphigus | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Pruritus | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 |
| Psoriasis | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Rash | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 |
| Rash maculo-papular | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Rash papular | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Rash pruritic | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Skin fissures | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 |
| Skin induration | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Skin irritation | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Skin lesion | | |

| | | | |
|--|---------------------|---------------------|--|
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Skin ulcer subjects affected / exposed occurrences (all) | 1 / 9 (11.11%) 1 | 0 / 2 (0.00%) 0 | |
| Urticaria subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Vitiligo subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Renal and urinary disorders | | | |
| Acute kidney injury subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Autoimmune nephritis subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 1 / 2 (50.00%) 1 | |
| Bladder pain subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Bladder spasm subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Dysuria subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Haematuria subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Hydronephrosis subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Lower urinary tract symptoms subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |

| | | | |
|---|---------------------|--------------------|--|
| Micturition urgency subjects affected / exposed occurrences (all) | 1 / 9 (11.11%) 1 | 0 / 2 (0.00%) 0 | |
| Nephrolithiasis subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Nocturia subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Pollakiuria subjects affected / exposed occurrences (all) | 1 / 9 (11.11%) 1 | 0 / 2 (0.00%) 0 | |
| Urinary retention subjects affected / exposed occurrences (all) | 1 / 9 (11.11%) 1 | 0 / 2 (0.00%) 0 | |
| Urinary tract obstruction subjects affected / exposed occurrences (all) | 1 / 9 (11.11%) 1 | 0 / 2 (0.00%) 0 | |
| Urinary tract pain subjects affected / exposed occurrences (all) | 1 / 9 (11.11%) 1 | 0 / 2 (0.00%) 0 | |
| Endocrine disorders | | | |
| Adrenal insufficiency subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Hyperparathyroidism subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Hyperparathyroidism secondary subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Hyperthyroidism subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Hypoparathyroidism | | | |

| | | | |
|---|----------------|----------------|--|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Hypothyroidism | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Steroid withdrawal syndrome | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Thyroiditis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 2 / 9 (22.22%) | 1 / 2 (50.00%) | |
| occurrences (all) | 3 | 1 | |
| Arthritis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Back pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Bone pain | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Flank pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Joint swelling | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Muscle spasms | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Muscle tightness | | | |

| | | | |
|------------------------------------|----------------|----------------|--|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Muscular weakness | | | |
| subjects affected / exposed | 2 / 9 (22.22%) | 0 / 2 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Myalgia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Neck pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Osteoarthritis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Osteonecrosis of jaw | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Pain in extremity | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 1 / 2 (50.00%) | |
| occurrences (all) | 1 | 1 | |
| Trismus | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Infections and infestations | | | |
| Acute sinusitis | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Body tinea | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |

| | | |
|-----------------------------|----------------|---------------|
| Bronchitis | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 |
| Candida infection | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Catheter site cellulitis | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Cellulitis | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Conjunctivitis | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Diverticulitis | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Ear infection | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Eye infection | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Gastroenteritis viral | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Herpes ophthalmic | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Herpes simplex | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Influenza | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |

| | | |
|-----------------------------|----------------|----------------|
| Nail infection | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Nasopharyngitis | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Oral candidiasis | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Oral herpes | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Paronychia | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 |
| Pharyngitis | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Pneumonia | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Sinusitis | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 1 / 2 (50.00%) |
| occurrences (all) | 1 | 1 |
| Skin infection | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Tinea pedis | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Tinea versicolour | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Tooth infection | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 |

| | | | |
|---|---------------------|---------------------|--|
| Upper respiratory tract infection subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Urinary tract infection subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Urinary tract infection bacterial subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Vaginal infection subjects affected / exposed occurrences (all) | 1 / 9 (11.11%) 1 | 0 / 2 (0.00%) 0 | |
| Metabolism and nutrition disorders | | | |
| Cachexia subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Decreased appetite subjects affected / exposed occurrences (all) | 3 / 9 (33.33%) 6 | 1 / 2 (50.00%) 1 | |
| Dehydration subjects affected / exposed occurrences (all) | 3 / 9 (33.33%) 6 | 1 / 2 (50.00%) 1 | |
| Fluid overload subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Fluid retention subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Glucose tolerance impaired subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Hypercalcaemia subjects affected / exposed occurrences (all) | 2 / 9 (22.22%) 2 | 0 / 2 (0.00%) 0 | |
| Hypercholesterolaemia | | | |

| | | |
|-----------------------------|----------------|-----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Hyperglycaemia | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Hyperkalaemia | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Hyperphosphataemia | | |
| subjects affected / exposed | 5 / 9 (55.56%) | 2 / 2 (100.00%) |
| occurrences (all) | 9 | 4 |
| Hypertriglyceridaemia | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 |
| Hyperuricaemia | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 2 (50.00%) |
| occurrences (all) | 0 | 1 |
| Hypoalbuminaemia | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Hypocalcaemia | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Hypoglycaemia | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Hypokalaemia | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 |
| Hypomagnesaemia | | |
| subjects affected / exposed | 2 / 9 (22.22%) | 1 / 2 (50.00%) |
| occurrences (all) | 2 | 1 |
| Hyponatraemia | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 |
| Hypophosphataemia | | |

| | | | |
|-----------------------------|----------------|---------------|--|
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 2 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Malnutrition | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Metabolic acidosis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Vitamin D deficiency | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|-------------------|--|
| 19 November 2014 | The objective of this amendment was to address the Food and Drug Administration's (FDA's) November 17, 2014, clinical deficiencies. |
| 11 June 2015 | The objective of this amendment was to refine procedural language regarding pharmacokinetics (PK) and food effect, ophthalmologic examination frequency, electrocardiogram (ECG) monitoring, and biopsy requirements. |
| 02 November 2015 | The primary purpose of this amendment was to add Part 3, Combination Therapy. In Part 3, INCB054828 was paired with 3 different treatment regimens that were already being used for cancer treatment. The amendment also contained changes to the inclusion/exclusion criteria and corrections to the Schedule of Assessment tables. |
| 09 March 2016 | The primary purpose of this amendment was to adjust language in the protocol to allow more flexibility for enrollment based on accumulated safety data. The secondary purpose was to adjust the management guidelines for hyperphosphatemia (HP). |
| 27 September 2016 | The primary purpose of this amendment was to revise the study design in order to add a continuous dosing cohort, a trastuzumab combination cohort in Part 3, and a lower dose level cohort in Part 1 and Part 3 with mandatory biopsies, and to increase the number of participants in the study. |
| 26 June 2017 | The primary purpose of this amendment was to increase the number of participants in Part 2 and make changes to clarify and/or simplify the study design. |
| 10 August 2018 | The protocol was updated to include 1) a new combination treatment arm, 2) a renally impaired treatment arm, and 3) mandatory biopsies. |
| 11 December 2018 | Changes were made to the protocol based on FDA feedback after review of Amendment 7. Additional changes included the modification of ECG sampling times and the addition of a 4.5-milligram (mg) tablet across all sites/countries. |
| 02 July 2019 | The amendment added a twice daily (BID) dosing regimen and updated the clinical experience section. |
| 27 March 2020 | The amendment incorporated administrative changes and included updated language for comprehensive eye examination, per FDA feedback. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported